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SUMMARY
Changes in hepatic drug metabolism during pregnancy have been characterised 
and the role of steroids and other hormonal factors investigated. Studies 
with human placental lactogen and rat placental homogenate suggest that 
during gestation elevated levels of circulating placental lactogen cause a 
significant decrease in maternal hepatic mixed-function oxidase activity 
when expressed per gram liver. Drug enzyme activity, determined with the 
substrates aniline (£-hydroxylation), ethylmorphine (N-demethylation) and 
jD-nitrobenzoic acid (reduction), decreased progressively during gestation 
to 53-73% of non-pregnant control levels by day 20 of gestation. Enzyme 
activity remained low 1 day post-partum but had returned to control 
non-pregnant levels by 5 days post-partum. The total capacity of the liver 
to metabolise drugs remained unchanged or increased because liver weight 
was elevated by up to 40% during pregnancy.
Alterations in hepatic drug metabolism are possibly mediated via changes in 
microsomal phospholipids and/or the cytochrome P450 spin state equilibrium, 
since pregnancy was associated with a significant decrease in (i) 
microsomal total phospholipids, (ii) the phosphatidylcholine to 
phosphatidylethanolamine ratio and (iii) the high-spin form of 
ferricytochrome P450.
Changes in drug metabolism were not related to alterations in the 
concentration, substrate induced binding affinity (Ks) or maximal spectral 
change (AAMax) of cytochrome P450 or to the activity of NADPH-cytochrome c 
reductase. The rise in circulating steroids, particularly progesterone, 
during gestation does not appear to be an important modulator of 
mixed-function oxidase activity.
The effect of phenobarbitone and 3-methylcholanthrene and of a choline 
supplemented diet on mixed-function oxidase activity during gestation has 
been investigated.
The significance of changes in the haemoprotein spin state and microsomal 
phospholipids to hepatic drug metabolism has been discussed. Possible 
mechanisms of action of placental lactogen have been discussed with respect 
to the related polypeptide, growth hormone.
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CHAPTER ONE GENERAL INTRODUCTION
1.1 DRUG METABOLISM AND THE MICROSOMAL MONOOXYGENASE SYSTEM
1.1.1 The importance of the hepatic microsomal monooxygenase system
Drugs form only a relatively small percentage of the organic chemicals 
to which living organisms in our biosphere are increasingly exposed. The 
U.S. Environmental Protection Agency has estimated that there may be as 
many as 50,000 commonly used chemicals, not including pesticides, 
pharmaceuticals and food additives and as many as 1,500 different active 
ingredients in pesticides (Blumberg,1978). The U.S. Food and Drug 
Administration estimates that there are about 4,000 active ingredients in 
drugs and about 2,000 other ancillary compounds used in the drug industry. 
In addition there are in the order or 2,500 additives used for nutritional 
value and flavouring and 3,000 chemicals used to preserve food. All these 
compounds, collectively called "xenobiotics", do not enter normal metabolic 
routes and must be excreted. Numerous xenobiotics, including many chemical 
carcinogens, are so hydrophobic that they would remain in the body 
indefinitely were it not for their metabolism to more polar compounds.
Drugs are metabolised in two phases; 'Phase 1' metabolism in which 
one or more polar groups (such as hydroxyl) are introduced into the parent 
molecule, thereby presenting the 'Phase 2' conjugating enzymes (eg. UDP
glucuronyl-transferase) with a substrate. The conjugates are sufficiently 
polar to be excreted from the cell and the body. During 'Phase 1' 
metabolism drugs generally lose their pharmacological activity, though 
examples of drug activation are well documented.
The hepatic microsomal cytochrome P450 mediated monooxygenase system 
is the most important example of 'Phase 1' enzymes. In addition to its 
role in xenobiotic metabolism the monooxygenase (or mixed-function oxidase) 
system also metabolises endogenous substrates such as steroids, fatty 
acids, and prostaglandins (Brenner,1977)•
A discussion of 'Phase 1' and 'Phase 2' metabolism is presented by 
Goldstein et al.(1974).
1.1.2 Cytochrome P450: Historical Aspects and Distribution
Oxygen is a ubiquitous and essential commodity of life and plays a 
central role in metabolism and energy generation in all aerobic organisms. 
The most familiar role of oxygen is as a terminal oxidant in the 
respiratory chain where a four-electron reduction generates two molecules 
of water. An equally important role for oxygen in metabolism was 
demonstrated in 1953 when Mason and Hayaishi independently demonstrated 
that oxygen atoms from atmospheric 0^ could be enzymatically incorporated 
into the carbon chains of intermediate metabolites without equilibration 
with water (Mason et al.,1953; Hayaishi et al., 1953). Enzymes of this class 
were designated monooxygenases or dioxygenases depending on whether one or 
both atoms of oxygen were inserted.
• In 1955 it was reported that a rabbit liver microsomal fraction 
contained an enzyme system which could hydroxylate aromatic compounds in 
the presence of NADPH and molecular oxygen (Brodie et aL,1955) and in 1957 
Mason proposed that certain biological oxidations were catalysed by a class 
of enzyme he called 'mixed-function oxidases' (Mason,1957)• The 
mixed-function oxidase system performs a monooxygenation in which one atom 
of atmospheric oxygen is inserted into the substrate while the second atom 
is reduced to form water.
Klingenberg (1958) and Garfinkel (1958) discovered a carbon monoxide 
binding pigment in liver microsomes. Omura and Sato (1963) called this 
pigment 'P450' because it had an optical absorption peak in the Soret 
region,at about 450nm, when it was poisoned by carbon monoxide in the
reduced state. They determined that it was a type of cytochrome or haem
containing protein which they called cytochrome P450.
The subsequent involvement of cytochrome P450 with enzymic 
hydroxylation was demonstrated when it was shown that light of 450nm was - 
optimal for the reversal of carbon monoxide inhibition of steroid C-21
hydroxylation (Estabrook et aL,1963)«
Much of the early work was hampered by the difficulty experienced in 
purifying the mammalian membrane-bound cytochrome P450 system. Initial 
attempts to solubilize mammalian cytochrome P450 resulted in its conversion 
to inactive cytochrome P420 (Omura and Sato,1964a). The properties of 
cytochrome P450 were therefore studied in the NADH-dependent soluble 
cytochrome P-450cam isolated from Pseudomonas putida (Katagiri et aL, 1968). 
Mammalian cytochrome P450 was finally solubilized in 1967 with the use of 
glycerol (Ichikawa and Yamano,1967). Shortly thereafter Lu and Coon (1968)
successfully solubilized rabbit liver microsomes with deoxycholate in the 
presence of glycerol and obtained cytochrome P450, NADPH-cytochrome P450 
reductase and phosphatidylcholine fractions using DEAE-cellulose 
chromatography. When these three fractions were recombined under certain 
conditions, laurate hydroxylase activity could be reconstituted. 
Subsequently the mixed-function oxidase activity of such reconstituted 
systems was demonstrated using steroids, drugs and alkanes as substrates 
(Lu et aL, 1969a,b; Lu,1976; Lu and West,1978).
The mixed-function oxidase system is now recognised to be a complex
multi- component system comprising NADPH, a
phospholipid-protohaem-sulphide-protein complex known as cytochrome P450 
and a linking electron transport system of NADPH-cytochrome P450 reductase 
and possibly cytochrome b5 (Coon et aL, 1973; Estabrook et__aL, 1973). Among
the reactions catalysed by this system are N-dealkylations
(eg.aminopyrine), O-dealkylations (eg.codeine),side chain oxidations 
(eg.barbiturates), aromatic ring hydroxylations (eg.aniline) and 
sulfoxidation (eg.chlorpromazine).
Cytochrome P450 is widely distributed in nature. It has been found in 
a large number of mammals, various birds, fish, insects, plants, yeasts and 
bacteria. In mammals cytochrome P450 has been found in liver, kidney, 
lung, placenta, testis, adrenal gland, skin, brain, corpus luteum, 
intestinal mucosa, spleen, heart, aorta, lymphocytes and platelets. It is 
mainly found in the endoplasmic reticulum but it is also found in 
mitochondria of steroidogenic tissues such as the adrenal gland and corpus 
luteum.- A review of the distribution of cytochrome P450 has been written 
by Wickramasinghe (1975).
1.1.3 The structure of cytochrome P450
In 1930 Keilin classified cytochromes into three spectroscopically 
distinct groups which he called 'a', 'b', and 'c' in order of their 
absorption maxima: 'a' absorbing at the longest wavelength and 'c' at the
shortest. Cytochrome P450 is classified as a 'b' cytochrome (systematic, 
name cytochrome B420)and contains an iron protoporphyrin IX group (Figure 
1) Cytochrome P450 differs from other 'b' type cytochromes in that it can 
react with oxygen, cyanide and carbon monoxide. One of the most 
characteristic and distinguishing optical features of cytochrome P450 is 
that the Soret maximum of the reduced haemoprotein when complexed with CO 
occurs at a wavelength 30nm longer than the usual CO-haem complex. This 
unusual property is highly dependent on the nature of the protein structure 
and lipid environment. Treatment of microsomes with agents that alter the 
lipid structure of the membrane, such as detergents and lipases, and with 
agents that denature the haemoprotein, such as urea and proteases, cause a 
conversion of cytochrome P450 to cytochrome P420 (Omura and Sato,1964a;
Imai and Sato, 1967b; Mason et al., 1965). Cytochrome P420 is an inactive 
form of cytochrome P450 and has a spectrum typical of a type 'b' cytochrome 
with a Soret maximum at 420nm.
The iron atom of cytochrome P450 haem has four planar ligand 
interactions with the four nitrogen atoms of the protoporphyrin ring system 
and has two ligand positions available for further binding. The nature of 
the two axial ligands has been the subject of intense investigation. Based 
on model compound studies, it was first suggested by Stem and Peisach 
(1974) and subsequently confirmed by others (Collman and Sorell,1975;
Chang and Dolphin,1975), that the red shifted Soret maximum of cytochrome
Figure 1 Iron Protoporphyrin IX
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P450 arose from a chromophore which consisted of haem, carbon monoxide and 
a mercaptide (RS-) sulphur atom believed to be bound to the haem trans to 
the CO. It was thought that the presence of this axial sulphur ligand 
differentiated cytochrome P450 from other CO binding haemoproteins which 
absorbed at or near 420nm when CO bound. Furthermore, model compounds 
containing the mercaptan (RSH) in place of the mercaptide showed Soret . 
bands at "normal" wavelengths (413-422nm).
When isolated or in situ, cytochrome P450 rests in the ferric 
oxidation state and is thus amenable to study by electron spin 
(paramagnetic) resonance (EPR) which detects unpaired electrons. The 
ferric form of cytochrome P450 has 5 electrons in the iron d-orbital and 
depending on the spin pairing of these electrons the haemoprotein can exist 
in the high-spin (S=5/2, 5 unpaired electrons) or low-spin configuration 
(S=l/2, 1 unpaired electron). Cytochrome P450 has been shown to exist in 
both high-spin and low-spin states (Jefcoate and Gaylor,1969; Hill et 
aL, 1970)» In the absence of substrates, the EPR spectrum of cytochrome 
P450 is that of a low-spin ferric haem compound (Mason et_aL, 1965;
Blumberg and Peisach,1971; Tsai et aL, 1970)» Studies using model systems 
with thiol agents and haemoglobin or metmyoglobin showed similar low-spin 
EPR spectra (Jefcoate and Gaylor,1969; Peisach et aL, 1973; Hill et 
aL, 1970; Blumberg and Peisach, 1971; Tang et al., 1976) to those obtained 
with cytochrome P450 from mammalian (Jefcoate and Gaylor,1969; Peisach et 
aL, 1973; Stern et al., 1973) and bacterial (Tsai et_aL, 1970) sources.
The nature of the sixth ligand to haem is still equivocal, though 
cytochrome P450 has been shown to have a heterogenous ligand field in the 
vicinity of haem (Peisach et al., 1973). Various proposals have been made
which include water (Peterson and Griffin,1973; Griffin and 
Peterson,1975), the imidazole nitrogen of a histidine residue (Jefcoate and 
Gaylor,1969; Tang et al., 1976; Chevion et al., 1977; Peisach et aL, 1979) 
and a hydroxyl group (Nebert et al. 1976; Kumaki and Nebert,1978).
1.1.4 The mechanism of cytochrome P450 mediated monooxygenations
Estabrook et al. (1971) proposed the following mechanism for the 
cytochrome P450 mediated mixed-function oxidation of xenobiotics and 
endogenous substrates (Figure 2)
(a) Association of substrate to oxidised cytochrome P450.
(b) Reduction of NADPH-cytochrome P450 reductase by NADPH.
(c) Reduction of cytochrome P450-substrate complex by reduced 
NADPH-cytochrome P450 reductase.
(d) Addition of oxygen to reduced cytochrome P450-substrate complex.
(e) Reduction of oxygenated reduced cytochrome P450-substrate complex by 
another electron probably from reduced NADPH-cytochrome P450 reductase.
(f) Decomposition of oxygenated reduced cytochrome P450-substrate complex 
to yield hydroxylated substrate, oxidised cytochrome P450 and water.
The nature of the rate limiting step in this scheme has been the
subject of intense research in recent years. It has been complicated by a
number of factors such as the heterogeneity of the system with respect to 
cytochrome P450, the presence of significant amounts of endogenous 
substrates even in partially purified systems and the broad substrate
specificity of the system whereby the rate limiting step may be different
for different substrates. Each of the reaction steps outlined above will
Figure 2 The mechanism of microsomal cytochrome P450 mediated
monooxygenations (after Estabrook et al.,1970
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be discussed in greater detail.
(1) Association of substrate to oxidised cytochrome P450
The association of substrate with oxidised cytochrome P450 can be 
followed spectrophotometrically (Remmer et aL, 1966; Imai and Sato,1966; 
Schenkman et aL, 1967)• These changes, monitored by difference 
spectroscopy, are of three types (Schenkman et al., 1972). Type '1' spectral 
changes are characterised by an absorption maximum at 385-390nm and a 
minimum at 415-425nm. Type '2' changes show an absorption maximum at 
425-435nm and minimum at 390-400nm. The third type, known as 'reverse type 
1' (type Rl) is essentially a mirror image of the type '1' change 
(absorption maximum of 415-425nm, minimum 385-390nm).
The spectral dissociation constant (Ks), analogous to the Michaelis 
constant (Km), and the maximum absorbance change (AAmax), analogous to the 
maximal velocity (Vmax) of an enzyme reaction, can be determined by 
plotting the spectral change against substrate concentration as a double 
reciprocal Lineweaver-Burk plot. The constant Ks is defined as the 
concentration of substrate giving a half maximal spectral change and is 
independent of protein concentration. The AAmax is dependent on substrate 
and cytochrome P450 concentration (Estabrook et aL, 1972b).
The type '1' spectral change is the most common substrate-cytochrome 
P450 interaction and is produced by a wide range' of endogenous and 
exogenous compounds such as steroids, fatty acids, barbiturates and 
polycyclic aromatic hydrocarbons. The type '1' spectral change is 
elicited, in general, by lipophilic compounds and a correlation between Ks
values and lipid solubility for some type '1' compounds has been 
demonstrated (Kitigawa et aL, 1972; Al-Gailany et al„1975). The 
interaction of a type '1' compound with cytochrome P450 has been shown to 
cause an increase in the polarity of the sixth haem ligand though type '1' 
compounds interact with the apoprotein and not the haem portion of 
cytochrome P450 (Schenkman,1968). This interaction is associated with the 
conversion of the haemoprotein from low-spin to high-spin (Whysner et 
aL, 1970; Waterman et aL, 1973; Tsai et aL, 1970). The increase in 
high-spin form of cytochrome P450 shifts the redox potential of the 
cytochrome to a less negative value which results in an increased rate of 
electron flow from NADPH-cytochrome P450 reductase to cytochrome P450 
(Sligar et aL, 1979; Ristau et al., 1979; Sligar, 1976). Thus a common 
characteristic of type '1' compounds is that they accelerate the reduction 
of cytochrome P450 and it seems that the haem iron spin equilibrium could 
be of importance in the regulation of monooxygenase activity. In some 
cases the rate of metabolism has been shown to be proportional to the 
binding of the substrate to microsomes (Schenkman,1970) and with many type 
'1' compounds, similarity between the spectral dissociation constant and 
the Km of the hydroxylation has been found (Schenkman et aL, 1967; Jansson 
et aL, 1972; Schenkman et aL, 1973; Ulrich,1969; Orrenius et aL, 1970).
The type '2' spectral change is caused by the interaction of amines or 
compounds containing nitrogen, with a lone pair of electrons (eg. pyridine 
and imidazole) with cytochrome P450 producing a ferrihaemochrome (Schenkman 
et aL,1967; Jefcoate et aL, 1969; Schenkman,1970; Temple,1971)• This 
involves an electron transfer between the nitrogen atom of the added 
compound and the sixth ligand position of the haem iron (Schenkman et 
aL, 1967)♦ Few' compounds which cause a type '2' spectrum are metabolised by 
cytochrome P450; aniline, however, is an exception. Schenkman (1970)
showed that the interaction of aniline with cytochrome P450 has a type '1' 
component and it is this that is related to aniline metabolism. The type 
'2' spectrum of aniline is due to an interaction at the haem iron since it 
competes with CO for reduced cytochrome P450 ( Schenkman et aL, 1967). This 
is associated with the production of a low-spin iron which has an 
absorbance peak with a longer wavelength (red shift). This is thought to 
be due to an increase in ligand field strength.
The reverse type '1' (type Rl) spectral change is produced by a wide
range of compounds, including acetanilide, short chain monohydric alcohols 
and Warfarin. It is associated with a high-spin to low-spin conversion of 
cytochrome P450 in which the sixth ligand position of the iron becomes 
occupied by a weak ligand (Estabrook et al., 1973). The nature of the type*R 
1' spectrum has yet to be elucidated. There are three current hypotheses.
(a) It has been suggested that the type Rl spectrum is similar to the 
type '2' interaction (Whysner et al., 1970). This appears to be unlikely 
since type Rl compounds cannot displace CO or alter the binding of aniline
to the oxidised haemoprotein (Schenkman et al., 1973).
(b) The type Rl spectrum is possibly caused by a reversal of the type 
'1' spectrum due to a displacement of endogenous substrates already bound 
to cytochrome P450 (Schenkman et al., 1973; Diehl et aL,1970). When butanol 
was added to microsomes in which the type '1' binding sites had been 
saturated with cyclohexane, a type Rl spectrum was produced (Diehl et
aL,1970). Furthermore Schenkman et al. (1973) found that solvent extraction 
of microsomes reduced the type Rl spectrum induced by phenacetin. Vore et 
al.(1974) found similar results using microsomes from 3-methylcholanthrene 
treated rats and Powis et- al. (1977) found that the addition of bovine serum
albumin to microsomal suspensions caused a type Rl spectrum which the 
authors concluded was due to the displacement of endogenous substrates from 
cytochrome P450. In contrast to these results it has been suggested that 
the type Rl spectrum is due to substrate binding at a specific site of 
cytochrome P450 rather than the displacement of endogenous substrates. In 
addition type '1', type '2' and type Rl binding sites were contrasted to be 
in different environments depending on the interaction of cytochrome P450 
with phospholipids in the endoplasmic reticulum (Al-Gailany,1975).
(c) Since many of the compounds causing a type Rl spectrum contain 
oxygen it has been suggested that the oxygen atoms interact with the haem 
to displace the sixth ligand in a similar way to the nitrogen atoms that 
cause type '2' spectral changes (Mailman et aL, 1974). The lower 
nucleophilicity of the type Rl groups is responsible for the hypsochromic 
shift from the type '2' spectrum. Furthermore it has been suggested that 
type Rl binding is due to interaction between the type Rl compound and 
high-spin cytochrome P450 (Yoshida and Kumaoka,1975; Kumaki et_aL,1978).
(2) Reduction of NADPH-cytochrome P450 Reductase with NADPH
The mechanism of reduction in microsomal hydroxylations can be 
understood more clearly after considering the properties of the 
NADPH-dependent flavoprtoein: NADPH-cytochrome P450 reductase.
NADPH-cytochrome P450 reductase has been purified to apparent homogeneity 
and consists of a single polypeptide chain of molecular weight 78,000 as 
determined by sodium dodecylsulphate gel electrophoresis (Dignan and 
Strobel,1975,1977; Yasukochi and Masters,1976; Vermilion and Coon,1978). 
It is unusual among flavoproteins in that it contains two different flavin 
groups, FAD and FMN, per molecule (Iyanagi and Mason,1973; Yasukochi and
Masters,1976). It has been suggested that one flavin group may be 
specifically concerned with electron transfer from NADPH and the other with 
electron transfer to the terminal acceptor cytochrome P450 (Iyanagi and 
Mason,1973; Iyanagi et al., 1974). Masters and colleagues have proposed 
that the aerobically stable form of the enzyme obtained by reduction with 
NADPH contains two electron equivalents (Masters et aL, 1965a.b.; Yasukochi 
and Masters,1976), in which both flavin groups are probably in the 
semiquinone form. Other workers (Iyanagi and Mason,1973; Iyanagi et 
aL, 1974; Vermilion and Coon,1978) have suggested that the air stable form 
of the enzyme is in a one electron reduced state in which one of the two 
flavins exist in the semiquinone form and the other in the oxidised form.
From the finding that the reduction of cytochrome c by microsomal 
NADPH-cytochrome P450 reductase is at least one order of magnitude more 
rapid than the reduction of cytochrome P450 in the microsomal fraction the 
conclusion has been drawn that penetration of the microsomes by NADPH and 
subsequent reduction of the flavoproten is not the rate limiting step 
(Holtzman,1970). This has been confirmed by Bjorkhem (1972) using 
deuterated NADPH.
(3) Reduction of cytochrome P450-substrate complex by reduced 
cytochrome P450 reductase
NADPH-cytochrome P450 reductase can transfer electrons directly to 
three types of acceptor, cytochrome c and P450 (Masters et aL, 1971; Glazer 
et al., 1971), oxygen (Aust et aL, 1972), and artificial acceptors such as 
f erricy-anide, dichlorophenolindophenol, azo compounds and a variety of 
quinones (Masters et al., 1971; Iyanagi and Yamazaki, 1969; Nishibayashi et 
aL, 1967). It appears that the enzyme functions as a single electron
transferring system and all of the artificial acceptors undergo single 
electron reduction. Molecular oxygen similarly undergoes a one electron 
reduction to form superoxide. Cytochrome c is a single electron acceptor 
and by analogy it might be expected that the natural acceptor cytochrome 
P450 would also undergo single electron reduction by NADPH-cytochrome P450 
reductase. This has subsequently been confirmed by an anaerobic titration 
of purified and microsomal cytochrome P450 (Ullrich et al., 1968; Peterson 
et aL, 1977; Cooper et aL, 1977) and potentiometric studies (Waterman and 
Mason,1970; Guengerich et aL, 1975).
Gigon et al. (1969) have shown that ethylmorphine, hexobarbital, 
aminopyrine and imipramine, all of which cause type 'lr spectral changes, 
markedly enhance the rate of reduction of cytochrome P450 by 
NADPH-cytochrome P450 reductase. In contrast, type '2' compounds such as 
aniline and nicotinamide decreased the rate of reduction. This substrate 
induced enhancement of cytochrome P450 reduction was found to be closely 
related to the rate of hydroxylation and a number of subsequent studies 
have confirmed it to be rate limiting for a number of type '1' compounds 
(Diehl et al., 1970; Holtzman and Rumack,1973; Gillette and Sasame,1970; 
Gillette,1971). Substrate binding to cytochrome P450 is associated with an 
increase in the high-spin character; this shifts the redox potential of 
the cytochrome by 70mv to a less negative value (Sligar,1976; Sligar et 
aL, 1979)» This enables the terminal cytochrome acceptor of the mixed 
function oxidase to be more readily reduced by NADPH-cytochrome P450 
reductase. The nature of the endoplasmic reticulum and its lipid content 
has been shown to be important in the rate of drug metabolism via an effect 
on the spin state of cytochrome P450 (Gibson et aL, 1980a.b)
Thus it appears that formation of the enzyme-substrate complex 
'triggers' the hydroxylation of the substrate providing an efficient 
regulation mechanism for the monooxygenase system. Diehl et al.(1970) 
pointed out that this mechanism prevents a futile cycle that reduces oxygen 
by NADPH without subsequent substrate hydroxylation.
(4) Addition of oxygen to the reduced cytochrome P450-substrate 
complex.
The addition of oxygen to reduced cytochrome P450 or reduced 
cytochrome P450-substrate complex is a very fast reaction and can only be 
rate limiting in the overall reaction under specific conditions. Gunsalus 
and Lipscomb (1972) reported that in a purified bacterial cytochrome P450 
system the rate of binding of oxygen to cytochrome P450cam was more than 20 
times faster than the rate limiting step. Carbon monoxide, however, was 
competitive with oxygen for the terminal oxidase and was thus able to 
inhibit hydroxylation. In the case of aniline hydroxylation, it has been 
suggested that the addition of oxygen to the reduced cytochrome 
P450-substrate complex is the rate limiting step (Schenkman,1971,1972). 
Addition of aniline decreases both NADPH oxidation and oxygen consumption 
by the microsomal fraction and it appeared that aniline interfered with 
oxygen activation, thereby slowing down its own hydroxylation.
(5) Reduction of the oxygenated reduced cytochrome P450-substrate 
complex
The reduced cytochrome P450-substrate complex undergoes one further 
electron reduction. This can be donated by NADPH-cytochrome P450 
reductase, however a number of studies have shown that cytochrome b5 and
NADH-cytochrome b5 reductase can also mediate in the reduction 
(Hilderbrandt and Estabrook,1971; Estabrook et aL, 1971; Sasame et 
aL, 1973). This observation explains the synergistic effect of NADH on 
microsomal monooxygenation (Conney et aL, 1957; Cohen and Estabrook,1971a) 
in which, in the presence of high concentrations of NADPH, NAD had a 
greater than additive effect on microsomal drug metabolism.
Estabrook and his colleagues (Cohen and Estabrook,1971b; Hildebrandt 
and Estabrook,1971) suggested that the ferrous cytochrome P450-substrate 
complex can be reduced by an electron supplied by either NADPH via 
NADPH-cytochrome P450 reductase or NADH via cytochrome b5. Staudt et al. 
(1974) have proposed that cytochrome b5 exerts a sparing effect on the 
mixed-function oxidase. This was based on the observation that the extent 
of NADH synergism was higher with compounds such as hexane which produced 
uncoupling of the microsomal mixed-function oxidase. They suggested that 
cytochrome b5 discharged activated oxygen which would otherwise be released 
to the medium from cytochrome P450. This was developed by Schenkman et al. 
(1976) who envisaged uncoupling as being due to a slower reaction between 
substrate and activated oxygen than between activated oxygen and oxygenated 
cytochrome P450 with release of H^O^. Electrons from cytochrome b5 were 
suggested to reduce the uncoupled cytochrome P450 bound active oxygen at a 
rate faster than it could be released to the medium to react with another 
cytochrome P450 bound active oxygen. Estabrook et al.(1971,1973) found 
that the effect of phenobarbital induction was to shift the rate limiting 
step from the conversion of ferric cytochrome P450 to ferrous cytochrome 
P450 to the transfer of the second electron to o'xycytochrome P450.
(6) The decomposition of the oxygenated reduced cytochrome 
P45Q-substrate complex
The oxygenated-reduced cytochrome P450-substrate complex dissociates 
to give oxidised cytochrome P450, water and hydroxylated substrate. A 
variety of reactive oxygen or oxygen-containing species have been reported 
to be formed at this stage. These include hydrogen peroxide (Hilderbrandt 
et aL, 1973; Schenkman et aL, 1979), the superoxide anion radical (Aust et 
al., 1972; Bartoli et aL, 1977; Schenkmann et al,1979) and singlet oxygen 
(Sugioka and Nakano,1976)•
Hamilton (1964) suggested the involvement of an oxene mechanism 
involving an active oxygen species analogous to a carbene or nitrene. 
Support for this mechanism has been provided by Guroff et al. (1967) who 
observed the 'NIH' shift in which an existing ring substituent was 
displaced to an adjacent group by the incoming hydroxyl group. Rahimtula 
and O'Brien (1974,1975) showed that cumene hydroperoxide and other 
hydroperoxides could sustain the hydroxylation and O-dealkylation of a 
variety of substrates in rabbit liver microsomes in the absence of NADPH 
and molecular oxygen. Similarly other 'active oxygen' containing compounds 
such as sodium chlorite and sodium periodite have been shown to support 
hydroxylation of steroids and fatty acids in the absence of NADPH and 
molecular oxygen (Hrycay et aL, 1975a, 1976).
Studies with model systems by Ullrich et al. (1972) led them to the
conclusion that the active oxygen species might be an iron bound oxygen in 
• «
the oxene formOO ) which electrophilically attacks the substrate. The 
ferryl complex Fe 0 (in resonance with a ferric oxene complex Fe —  
cT.5=£f/—  0) has been suggested as the most likfely candidate for the 
'active-oxygen' of the mixed-function oxidase (Rahimtula et aL,1974; 
Gustafsson et al., 1976).
The microsomal reactions of oxygen have been reviewed by O'Brien.
1.1.5 Cytochrome P450 dependent reductions
The hepatic microsomal fraction can catalyse the reductive metabolism 
of a variety of compounds (Gillette,1966,1969; Mitchard,1971)• Many of 
these reactions are catalysed by microsomal flavoproteins; cytochrome 
P450, however, appears to be involved in the NADPH-dependent reduction of 
azo- and nitro-compounds and these reactions can be partially inhibited by
carbon monoxide (Gillette et al., 1968; Hernandez et aL, 1967). More recent
studies have shown that cytochrome P450 catalyses the reduction of tertiary 
amine N-oxides under anaerobic conditions (Sugiura et aL,1976; Iwasaki et 
aL, 1977; Kato et aL,1978) and it has been suggested that the N-oxide 
coordinates at the sixth position of the haem iron in the same position as 
oxygen and carbon monoxide. The mechanism for the NADPH dependent 
reduction of tertiary amine oxides is thought to involve a two electron
reduction of cytochrome P450 in a similar manner to cytochrome P450's
action as a terminal oxidase (Sigiura et aL, 1976). Cytochrome b5 has also 
been found to be involved in N-hydroxylamine reduction in an NADH dependent 
reaction (Kadlubar and Ziegler,1974)•
1.1.6 The structure of the endoplasmic reticulum and the molecular
organisation of the mixed-function oxidase system.
The hepatic endoplasmic reticulum consists of a complex membrane 
network comprising tubules, vesicles and lamellae, on which are located a 
large number of enzymes and enzyme systems. The endoplasmic reticulum is 
divided into rough and smooth components; the former (60%) is associated 
with ribosomes on the cytoplasmic surface. Compositional studies of 
isolated rat liver microsomes revealed that the membrane is about 70% 
protein and 30% lipid (of which 85% is phospholipid) by weight (Glaumann 
and Dallner,1968; Eriksson,1973). This represents approximately 23 
molecules of phospholipid per protein molecule. The phospholipid 
composition is 55-60% phosphatidylcholine, 20-25% phosphatidylethanolamine, 
5-10% phosphatidylserine, 5-10% phosphatidylinositol and 4-7% 
sphingomyelin. The fatty acid moieties of the phospholipids consist mainly 
of 16-22 carbon atoms. The relative amount and degree of unsaturation 
depends to some extent on the diet of the animal. The structure of the 
endoplasmic reticulum has been reviewed by Depierre and Dallner (1975).
The organisation of the mixed-function oxidase within the endoplasmic 
reticulum has been the subject of much research in recent years. 
Consideration of the molecular arrangement of this enzyme system must bear 
in mind the following points:
(1) The microsomal membrane is a single membrane 70-80& thick 
(Claude,1969)• This suggests a limit of 2 or 3 protein molecules, of 
molecular weight 50,000, spanning the membrane.
(2) Cytochrome P450 can account for as much .as 15% of liver microsomal 
protein and the number of molecules of the haemoprotein can be 20-30 times
greater than that of NADPH-cytochrome P450 reductase in the membrane 
(Estabrook et aL, 1976)
(3) The reductase has a molecular weight of about 78,000 daltons and is 
bound to the membrane through its hydrophobic portion (Vermilion and 
Coon,1974; Dignum and Strobel,1975; Yasukochi and Masters,1976). The 
hydrophilic and catalytic portion of the reductase probably protrudes from 
the membrane since it can be cleaved by trypsin digestion (Estabrook et 
aL, 1976).
(4) Cytochrome P450 is relatively resistant to proteolytic digestion, in 
particular in the presence of a substrate to be hydroxylated, suggesting 
that it is deeply buried in the membrane.
Two organisational models have been developed to account for these and 
other observations: the "rigid" and "non rigid" system (Franklin and
Estabrook,1971)• In the "rigid" system the reductase molecule is 
surrounded by many cytochrome P450 molecules in a complex; the structural 
organisation precludes any interaction between electron carriers from 
diferent complexes. According to this model, only 50% of cytochrome P450 
can be reduced enzymatically when 50% of the reductase is inactivated. 
Mersalyl has been used to inactivate the reductase and the results were
reported to be consistent with the rigid system (Franklin and
Estabrook,1971). Yang (1975) however, observed that when the reductase 
activity in the microsomes was inactivated to different extents (up to 80% 
inhibition) by mersalyl almost all of the cytochrome P450 could still, be 
reduced enzymatically, although the rate of reduction was significantly 
retarded. These results suggested that cytochrome P450 and the reductase 
were not rigidly associated and that these enzymes possessed lateral 
mobility in the membrane. These observations are consistent with the "non
rigid" model. This model does not imply that the monooxygenase enzymes are
randomly distributed in the membrane. Certain domains of the membrane may 
have high local concentrations of these enzymes (Depierre and Dallner,1975; 
Schultz and Staudinger,1971; Winquist and Dallner,1976). Matsubara et al. 
(1976) and Peterson et al.(1976) have studied the rate of NADPH-dependent 
reduction of cytochrome P450 in microsomes. Biphasic reduction kinetics 
have been observed. Upon studying the effect of temperature on the 
reaction a break in the Arrhenius plot was observed for the slow phase but 
not for the fast phase of the reaction. In the light of this finding 
Peterson et al.(1976) have suggested that the monooxygenase system exists 
as "clusters" with 8-12 cytochrome P450 molecules arranged around a central 
reductase molecule. This central reductase is able to reduce randomly the 
cytochrome P450 molecules within the "cluster", in the fast phase of the 
reduction, without transitional motion. The slow phase of reduction 
represents the reduction of molecules not directly associated with the 
cluster. The "non rigid" model has been further supported by experiments 
in which partially purified cytochrome P448 has been incorporated into the 
membrane leading to an enhanced (up to 5 fold) microsomal benzo(c*)pyrene 
hydroxylase activity, showing that added cytochrome P448 can become a 
functional part of the monooxygenase system (Yang and Strickhart,1975).
The enhancement was not instantaneous and a temperature dependent 
incorporation of cytochrome P448 into the microsomal membrane was observed.
1.1.7 The role of microsomal lipids in cytochrome P450 mediated
monooxyg enat ion
Lu and Coon (1968) resolved the microsomal cytochrome P450 system into 
three components, each necessary for maximal fatty acid hydroxylating 
activity in a reconstituted system: cytochrome P450, NADPH-cytochrome P450
reductase and a heat stable factor extractable into organic solvents which 
was subsequently shown to be phosphatidylcholine (Strobel,1970). Since 
then phosphatidylcholine has been shown to be essential for the achievement 
of maximal rates of fatty acid (laurate), hydrocarbon (hexane, cyclohexane, 
octane) drug (benzphetamine, hexobarbital, ethylmorphine) carcinogen 
(benzpyrene) and aniline metabolism by reconstituted cytochrome P450 
systems (Strobel et aL, 1970; Lu et aL,1972a,b; Lu and West,1972;
Bjorkhem et_aL, 1973; Lu et aL, 1973; Guengerich and Coon,1975; van der 
Hoevan et aL, 1974).
Strobel et al. (1970) proposed that the lipid component in 
reconstituted systems was essential for electron transfer from NADPH to 
cytochrome P450 via NADPH-cytochrome P450 reductase but phosphatidylcholine 
is not an electron carrier so its mode of action remains unknown. More 
recently Guengerich and Coon (1975) showed that phosphatidylcholine lowered 
the apparent binding constant and Km for benzphetamine, increased the 
magnitude of the spectral change seen upon interaction of this substrate 
with cytochrome P450 and increased Vmax for benzphetamine metabolism. Lu 
et al.(1974) showed that certain non-ionic detergents at appropriate 
concentrations substitute for lipid in supporting benzphetamine 
N-demethylation. Lu et al.(1974) concluded that lipids play a physical 
rather than a chemical role in maintaining monooxygenase activity. A
similar conclusion was reached by Eletr et al.(1973) who found that an
o o
abrupt change in microsomal membrane fluidity occured at 19 C and 32 C.
This was detected by following the electron spin resonance of lipophilic 
nitroxide radicals. These results have been correlated with the apparent
O O
breaks at 19 C and 32 C in the Arrhenius plot of the
UDP-glucuronyltransferase reaction. Stier and Sackmann (1973) studied the 
effect of temperature on the NADPH-dependent reduction of a lipophilic 
nitroxide spin labelled substrate with liver microsomes from phenobarbital
o
treated rabbits. A break in the Arrhenius plot was observed at 32 C and
this led to the suggestion that NADPH-cytochrome P450 reductase was
surrounded by a halo of phospholipids which, unlike the bulk of microsomal
o
lipids, underwent a phase transition at 32 C. NMR and ESR studies by Stier 
(1976) suggested that the binding of cytochrome P450 to lipids imposed a 
high degree of order on the lipids and that the liproprotein complex
O
changed its conformation at about 36 C.
Cinti et al. (1979) reported that, in the absence of added substrate, 
rat liver microsomes contain large amounts of high-spin cytochrome P450.
In contrast the spin equilibrium of the purified soluble haemoprotein was 
predominantly in the low- spin configuration. It was suggested that 
membrane components might modulate the spin equilibrium of cytochrome P450 
and thus change the spin state. A subsequent study by the same group 
(Gibson et aL, 1980a) revealed that the whole lipid extract of rat liver 
microsomes, when added to purified cytochrome P450, resulted in a shift in 
the high-spin form from 17% to 53% at 20°C. Furthermore, they attributed 
this change largely to the free fatty acid fraction in the lipid extract 
which may behave as endogenous substrates.
1.1.8 Induction and multiple forms of cytochrome P450
The increased activities of the microsomal drug-metabolising enzymes 
following pretreatment with a wide range of drugs, pesticides, food 
additives, steroids, polycyclic hydrocarbons and other xenobiotic compounds 
is now well known and extensively documented (Conney,1967). Stimulation of 
these enzymes occurs when the inducing compounds are administered to the 
living animal, are perfused through the isolated liver or other organs 
(Juchau et aL, 1965) or are added to mammalian cell cultures in vitro 
(Nebert and Gelboin,1968a,b). Enzyme induction acts to increase the rate 
of production and/or decrease the rate of degradation of an enzyme and must 
not be confused with agents such as ethylisocyanide, acetone and metyropone 
which bring about an in vitro activation of monooxygenase reactions 
(Cinti,1978)•
There is increasing evidence that different inducers elevate the 
levels of different forms of cytochrome P450. Treatment with phenobarbital 
causes an increase in cytochrome P450 levels while 3-methylcholanthrene 
pretreatment causes a change in the absorbance maximum of the reduced 
carbon monoxide difference spectrum from 450nm to 446-448nm (Alvares et 
aL, 1967). This altered form has an altered ethyl isocyanide difference 
spectrum (Sladek and Mannering,1966). The haemoproteins induced by 
phenobarbitone and 3-methylcholanthrene exhibit major differences in their 
catalytic properties. Phenobarbitone increases the metabolism of a wide 
range of substrates whereas 3-methylcholanthrene is more specific in its 
action (Conney,1967).
A number of substrates of the monooxygenase system are metabolised, 
after pretreatment with inducing agents, to give different products in 
microsomal suspensions. These include Warfarin (Pohl et aL, 1977; Kaminsky 
et aL, 1980), steroids (Kremers et aL, 1978, Conney et aL, 1973), 
benzo(ot)pyrene (Rasmussen and Wang,1974) and biphenyl (Burke and 
Bridges,1975). Kremers et al. (1978) investigated the effect of inducers on 
the activity of 16fc-hydroxylase using four steroid substrates and concluded 
that there are at least two cytochrome P450 forms in addition to cytochrome 
P448. More recently Kaminsky et al. (1980) reported that, on the basis of 
three criteria (regio- and stereoselectivity of Warfarin metabolism and 
immunological inhibition), there is one distinct form of cytochrome P450 
induced by 3-methylcholanthrene and two to four forms in phenobarbitione 
treated rats. Uninduced rat microsomes contain two distinct cytochrome 
P450 forms, one of which is identical with a phenobarbital induced form.
Sodium dodecylsulphate (SDS) polyacrylamide gel electrophoresis has 
been used to separate microsomal proteins. A preferential induction of 
proteins in the 45,000-60,000 molecular weight region has been observed in 
phenobarbitone and 3-methylcholanthrene pretreated rats (Alvares and 
.Siekevitz,1973; Welton and Aust,1974), mice (Huang et aL, 1976) and rabbits 
(Haugen et aL, 1975). Proteins induced by polycyclic aromatic hydrocarbons 
are in general of a higher molecular weight than those induced by 
phenobarbitone. Other inducers have been shown to induce proteins with a 
molecular weight different to those induced by both 3-methylcholanthrene or 
phenobarbitone, for instance, nitrogen-containing carcinogens (Cameron et 
aL,1976) and isosafrole (Dickins et aL, 1978). A large number of inducing 
agents are now recognised, these include endogenous and contraceptive 
steroids (Selye,1970), pregnenolone 16ot-carbonitrile (PCN) (Lu et 
aJU, 1972a),polyhalogenated compounds such as DDT (Hart and Fouts,1965),
polychlorinated biphenyls (Ryan et aL, 1977;Alvares and Kappas,1977), 
flavones such as jB>-napthoflavone (Boobis et aL, 1977) and ethanol (Joly et 
a_L, 1977).
The investigation of multiple forms of cytochrome P450 is particularly 
important since early work with reconstitituted systems indicated that 
substrate specificity resides within the cytochrome P450 fraction and that 
NADPH-cytochrome P450 reductase and phospholipid fractions could be used 
interchangably (Lu et aL,1971,1973; Nebert et aL,1973). Much of the 
evidence for multiple forms of cytochrome P450 has been obtained from 
studies on purified preparations. This has been reviewed recently by 
Guengerich (1979). A number of techniques are in use to investigate 
purified cytochrome P450 preparations, these include spectral, catalytic, 
electrophoretic, peptide mapping, amino acid analysis and immunochemical 
methods. Guengerich (1979) concluded that there were at least 8-12 forms 
of cytochrome P450 present in rats under varying conditions. At least 20 
different cytochrome P450 types have been found in rabbits, rats and mice.
The molecular basis of induction is thought to involve de novo protein 
synthesis and administration of protein synthesis inhibitors will prevent 
the increase in microsomal monooxygenase activity. The effects of a number 
of inhibitors such as cycloheximide, actinomycin D and o(.-amanitin have been 
studied. These inhibit peptidyl transferase, DNA-dependent RNA synthesis 
and RNA polymerase II respectively and all inhibit induction of cytochrome
P450 (Cutroneo and Bresnick,1973; Gelboin and Blackburn,1963; Jacob et
aL,1974). In addition, induction may be associated with reduced 
degradation or increased stabilization of components involved in protein 
synthesis (Seifert and Vacha,1970; Black et aL,1971; Pousada and
Lechner,1972). It has been suggested that the primary event in induction
is the combination of the inducer with a receptor protein. This mechanism 
has been proposed for polycyclic aromatic hydrocarbons (Poland and 
Kende,1976). Lipid peroxides, produced by an uncoupling of electron flow 
from cytochrome P450 by the binding of poor receptors of active oxygen and 
subsequent release of singlet oxygen, might control the induction of 
cytochrome P450 (Paine,1978).
1.1.9 Denaturation and destruction of cytochrome P450
Cytochrome P450 can be converted into its inactive form (cytochrome 
P420) by a variety of agents which act by blocking or oxidising the 
thiolate haem ligand or disrupting the membrane environment. These agents 
include high concentrations of neutral salts such as potassium thiocyanate 
and sodium iodide (Imai and Sato,1967a), sulphydryl reagents such as 
£ -chloromercuribenzoate (Mason et aL, 1965), cholate (Klingenberg,1958), 
deoxycholate, phospholipase A and steapsin (Cmura and Sato,1964a,b) , 
trypsin and urea (Mason et aL, 1965). NADPH dependent lipid peroxidation is 
thought to cause the destruction of cytochrome P450 haem (Levin et 
aL, 1973a,b; Jacobson et aL, 1973). A number of compounds cause a loss of 
cytochrome P450 on metabolism including allyl substituted barbiturates 
(Levin et aL, 1973a).
A loss of cytochrome P450 occurs after the administration to animals 
of heavy metals such as cobalt (Tephly and Hibbeln,1971), nickel and 
platinum (Maines and Kappas,1977) and cadmium (Hadley et aL, 1974). Heavy 
metals may cause this conversion by reaction with sulphydryl groups and/or 
induction of haem oxygenase (De Matteis,1978).
1.1.10 Sex differences in drug metabolism
Kato (1974) has reviewed the sex related differences in drug 
metabolism. Hepatic microsomes isolated from male rats can hydroxylate 
many drugs more rapidly than those from female rats (Conney,1967;
Gillette,1963; Quinn et aL, 1958; Kato and Onoda,1966) and this is 
paralleled by greater drug induced spectral changes in cytochrome P450 from 
male rats, indicating a higher binding capacity of cytochrome P450 
(Schenkman et aL, 1967; Kato and 0noda,1970).
Hepatic microsomes from newborn animals have little of no ability to 
metabolise drugs (Fouts and Adamson,1959; Jondorf et aL, 1959). During the 
first four weeks after birth there is a similar increase in mixed-function 
oxidase activity in male and female rats (Conney,1967)• Thereafter sex 
differences begin to appear, becoming maximal at about 50 days (Quinn et 
aL, 1958; Kato et aL, 1962; Murphy and Dubois,1958).
In male rats, castration decreases the rate of oxidation of some drugs 
and the binding capacity of cytochrome P450 for these compounds. The 
administration of androgens restores both deficiencies to the level of 
intact male rats whereas oestrogen antagonises these effects. The 
hydroxylation of hexobarbital and the N-demethylation of aminopyrine, as 
well as the binding capacity of cytochrome P450 with hexobarbital and 
aminopyrine, are androgen-dependent. The hydroxylation of aniline.and 
zoxazolamine, as well as the binding capacity, are androgen- independent. 
Thus castration of male rats increased Km and Ks for androgen- dependent 
hydroxylations while comparable values for androgen- independent 
hydroxylations were unaffected (Kato and 0noda,1970; Schenkman et
aL,1967).
The effect of 3-methylcholanthrene treatment on the activity of the 
microsomal drug metabolising enzymes is sex related. The 
androgen-dependent activities are decreased in male rats but not 
significantly affected in female rats whereas androgen-independent 
activities are increased in both sexes (Kato and Takayanagi,1966).
Treatment with thyroxine, morphine and alloxan, adrenalectomy and 
starvation decreased the metabolism of hexobarbital and aminopyrene and the 
binding capacity -of cytochrome P450 in male but not female rats (Kato and 
Gillette,1965a,b). These states do not decrease the metabolism of aniline 
or zoxazolamine or the binding capacity of cytochrome P450 for these drugs 
in rats of either sex. The reduction in binding capacity of cytochrome 
P450 might be responsible for the decrease in drug oxidation seen in male 
rats during these states. These conditions may interfere with the action 
of androgen to increase the binding capacity of cytochrome P450 (Kato et 
aL, 1971; Kato., 1974). Androgen has an action on steroid hydroxylation 
similar to its effect on drug metabolism.
Sex differences in drug metabolism are pronounced in rats, though some 
strains of mice exhibit a difference in the metabolism of type '1' 
substrates (Van den Berg,1978; Noordhoek et aL, 1978). Guinea pigs, 
hamsters, rabbits, dogs and monkeys do. not show a sex mediated difference 
in drug metabolism (Quinn et aL, 1958; Kato et aL, 1962; Kato et aL, 1968).
1.2 DRUG METABOLISM IN PREGNANCY
1.2.1 The extent and character of drug consumption during pregnancy
The necessity for closely monitoring the extent and character of drug 
consumption during pregnancy and relating this to adverse effects on the 
mother and her offspring has been widely recognised following the 
thalidomide tragedy of the early I960's. Drugs administered during 
pregnancy have as their principal target the mother, while, with very few 
exceptions (eg. corticosteroids administered to the mother to enhance 
foetal lung maturation), no therapeutic effect on the foetus is intended.
A number of studies have appeared in which the nature of drug 
consumption during pregnancy has been monitored (Peckham and King,1963; 
Hill,1973; Forfar and Nelson,1973; Forrests1976; Brocklebank et aL, 1978; 
Doering and Stewart,1978). Doering and Stewart (1978) in Florida, reported 
that an average of eleven drug products were consumed in the prenatal 
period and seven in the perinatal period. This finding was based on a 
study of 168 patients. The authors pointed out that the average number of 
drugs consumed does not accurately reflect the number of different chemical 
entities to which the foetus is exposed since many products contain up to 
four or five different ingredients. Aspirin appears to be the most common, 
drug consumed during pregnancy and the maternal and foetal effects of this 
analges-ic have been recently reviewed by Corby (1978).
1.2.2 Factors affecting drug metabolism during pregnancy
During pregnancy there many characteristic alterations in maternal 
physiology that influence the pharmacokinetic properties of drugs (Krauer 
and Krauer,1977)• These are reflected in a variation in the plasma 
concentrations of some drugs in pregnancy compared with the non-pregnant 
state (Eadie et aL, 1977). The influence of pregnancy on drug absorption, 
distribution and elimination will be briefly discussed.
(1) Drug Absorption
Gastrointestinal absorption: The gastrointestinal absorption of drugs
is influenced by several factors such as drug formulation, diet, the 
chemical composition and pH of the intestinal secretions, gastric emptying 
time, intestinal motility and intestinal blood flow. In pregnancy, the 
motility of the stomach and gut and the composition of the intestinal 
secretions change. A reduction in intestinal motility and an increase of 
30-50% in gastric and intestinal emptying time during pregnancy has been 
reported (Davison et al., 1970; Parry et aL, 1970; Prescott,1974)•
Secretions of the stomach have a different biochemical activity (Hunt and 
Murray,1958) and there is a reduction in gastric acid secretion and an 
increase in the secretion of mucus. These alterations result in an 
increased gastric pH and buffer capacity which influences the ionisation of 
weakly acid or basic drugs and hence their pharmacokinetics.
Pulmonary absorption: This is known to be influenced by haemodynamic
and ventilatory factors. Inhalation agents cross the alveolar membrane at 
a higher rate during pregnancy since an increased tidal volume produces a
relative hyperventilation (Templeton and Kelman,1976). Furthermore, 
alveolar drug uptake in also favoured by a higher pulmonary blood flow due 
to an increased cardiac output.
Intramuscular absorption: Measurements of regional blood flow show a
general increase in peripheral tissue perfusion during pregnancy. In late 
pregnancy blood flow is markedly slowed down in the lower limbs due to an 
increased hydrostatic pressure in the venous system (Ginsberg and 
Duncan,1967)•
(2) Drug Distribution
Many factors modify drug distribution in pregnancy, including an 
increased circulating blood (plasma) volume and an increased cardiac output 
due to a raised heart beat and a greater stroke volume (Walters and Leng 
Ling,1975). The plasma volume increases by about 50% during pregnancy and 
cardiac output by about 30%. Renal blood flow is increased by 50% by the 
end of the first trimester of pregnancy, although hepatic blood flow does 
not seem to alter (Munnell and Taylor,1947). There is evidence that the 
plasma or serum protein binding of drugs decreases during pregnancy 
(Crawford and Rooi, 1968; Levy et aL, 1975). This results in an increase in 
the free fraction of a drug in the plasma and usually causes a 
corresponding elevation in total clearance (Levy and Yacobi,1974) combined 
with changes in the intensity and pharmacological effects of drugs 
(Levy,1976). A reduction of the serum protein binding of a number of 
weakly acidic drugs has been reported during pregnancy in the rat (Stock et 
aL, 1980). This was associated with an increase in the unbound form of the 
drug in- the plasma and was due, in part, to the accumulation of endogenous 
displacing agents.
(3) Drug Elimination
Drug elimination is defined as the sum of drug excretion and drug 
metabolism. Distribution and elimination are interrelated and 
simultaneously operating processes and any factor affecting one will also 
affect the other.
Renal drug elimination: Creatine clearance is elevated by 50% during
pregnancy and this suggests an increased clearance for drugs which are 
primarily removed by the kidney (Krauer and Krauer,1977)•
Hepatic drug elimination: This will be dealt with in section 1.2.5.
1.2.3 Foetal drug metabolism
A large number of drugs are now known which have undesirable side 
effects on the developing foetus (Hill and Stem, 1979). A number of 
investigators have found that in laboratory animals the foetal hepatic 
cytochrome P450 mediated mixed-function oxidase system remains undeveloped 
(<5% of adult values) even late in gestation (Dallner et aL, 1966; Jori and 
Briatico, 1973; Hart et al., 1962; Rane et al., 1973; Gillette, 1973; 
Vainio,1975; Th Cresteil et al., 1979). Adult enzyme levels are reached 3-4 
weeks after birth (Gram et al., 1969; Henderson, 1971; McLeod et aL, 1972; 
Bresnick and Stevenson,1968). Microsomal levels of cytochrome P450 and 
NADPH-cytochrome P450 reductase represent less than 14% of adult levels in. 
the full term rat foetus. Drug metabolism in the human foetus, by 
contrast, develops at a much earlier stage, first becoming apparent in late 
organogenesis (12-50 days). In the full term human foetus, the hepatic 
microsomal drug enzyme activity represents 35-40% of adult values (Rane and
Ackeman,1972)
In most mammalian species studied the hepatic microsomal monooxygenase 
system will respond to drugs only during the last few days of gestation 
(Pouts and Devereux, 1972; Hart et al., 1962; Dixon and Willson, 1968;
Pan tuck et a 1., 1968), if at all (Schlede et aL, 1973; Bresnick and 
Stevenson,1968). This is apparently the case for both barbiturate and . 
polycyclic hydrocarbon inducing agents (Conney,1967). Thus Hart et al. 
(1962) found that the metabolism of hexobarbital and aminopyrine could be 
stimulated by phenobarbitone pretreatment only during the last 4 days of 
foetal life in the rabbit. It has been suggested that this is due to the 
relatively small amounts of inducing agent actually reaching the foetal 
liver (Bresnick and Stevenson,1968; Dixon and Willson,1968). Recent work 
in the rat by Th Cresteil et al. (1979) has suggested that
3-methylcholanthrene pretreatment induced a net biosynthesis of cytochrome 
P450 in the near term foetal liver whereas phenobarbitone pretreatment 
produces a premature transformation of rough into smooth endoplasmic 
reticulum thus decreasing ribosomal protein 'contamination' of the 105,000g 
pellet. As a result, the specific microsomal content of cytochrome P450 
appears to be increased although there is no true induction of the 
haemoprotein. The development of the foetal and neonatal microsomal 
monooxygenase system has been reviewed by Short et al.(1976).
1.2.4 Placental drug metabolism
The placenta contains very low levels of cytochrome P450, though it 
does exhibit certain mixed-function oxidase activity, especially that 
concerning the synthesis of estrogens and the aromatization of androgens. 
Treatment of pregnant rats with a variety of polycyclic aromatic 
hydrocarbons known to be present in cigarette smoke produced a large 
increase in placental benzo(oOpyrene hydroxylase activity (Welch et 
aL, 1969,1971). Cigarette smoking also markedly increased the activity of 
benzo(crt.)pyrene and 3-methyl-4-monomethylaminoazobenzene demethylase in the 
human placenta. In the placenta of non-smoking mothers these enzyme 
activities are almost undetectable (Welch et ah, 1969). The rat placenta 
does not show any induction of the drug metabolising enzymes after 
pretreatment with phenobarbitone, and although pretreatment with
3-methylcholanthrene enhances the activity of benzo(oOpyrene hydroxylase 
many other monooxygenase activities such as biphenyl 4-hydroxylase,
4-chloromethylaniline N-demethylase, UDP-glucuronyltransferase and 
p-nitrobenzoic acid reductase remain unaffected (Lake et al., 1973). Similar 
results were found in the rabbit with the exception that phenobarbitone 
caused an increase in UDP-glucuronyltransferase activity (Lake et aL, 1973). 
Juchau et al. (1974) reported that there was a marked increase in 
benzo(c<)pyrene hydroxylation and a decrease in cholesterol metabolism in 
the human term placenta as the number of cigarettes smoked per day 
increased. It was proposed that smoking might, via its effect on 
cholesterol metabolism, cause a decrease in the placental synthesis of 
progestational hormones and oestrogens which are essential for the 
maintenance of pregnancy. The association between smoking in pregnancy and 
deletrious effects on foetal wellbeing is now well established (Hill and
Stern,1979)•
1.2.5 Maternal drug metabolism in pregnancy
In recent years a number of publications have appeared on the subject 
of drug metabolism in pregnancy. These have been concerned primarily with 
hepatic microsomal Phase 1 drug metabolism in the rat and rabbit; studies 
involving the human have dealt with the in vivo pharmacokinetics of a drug.
Pregnancy can influence the activity of certain enzymes not directly 
concerned with drug metabolism, thus /5-glucuronidase activity is increased 
in rat liver and serum (Bernard and Odell,1950) and in human serum 
(Fishman,1947; Pulkkinen and Willman,1968). Other serum enzymes have been 
shown to decrease in activity during pregnancy in women;
acetylcholinesterase, lactate dehydrogenase and succinic dehydrogenase are 
all affected in this way (Visiliu et aL, 1967). The enzyme system 
responsible for conjugating bromosulphthalein with glutathione, which is 
present in the soluble fraction of liver preparations, is decreased in 
activity during the last trimester of pregnancy in rats (Combes and 
Stakehem,1962).
Pharmacokinetic studies in the human have revealed an impairment in
14-
the disappearance of injected 4- C-cortisol from the plasma of pregnant 
women near term and a decreased rate of appearance of cortisol metabolites 
in the urine (Migeon et al., 1957). Crawford and Rudofsky (1966) found that 
the metabolism of pethidine and promazine is reduced during pregnancy in 
the human. This finding was based on a study of the urinary excretion of
these drugs and their metabolites but it has been criticised for the use of 
too few subjects and for not controlling the pH of the urine (Editorial in 
the Lancet,1966). In contrast, Peiker et al.(1979) have found that the 
half life of orally administered methaqualone was significantly decreased 
during the last trimester of pregnancy in the human though there was no 
significant difference in the volume of distribution. Similarly, Ray et al. 
(1979) have found a decrease in the half life of chlorazepate elimination
during pregnancy in the human. The influence of pregnancy on the plasma
levels and clearance of primidone has been studied in the mouse (McElhation 
et al., 1977a,b). On the basis of plasma level determinations following 
orally dosed primidone it was concluded that there may be an increased rate 
of metabolism of primidone in the 14 day pregnant mouse compared with the 
non-pregnant mouse.
The conjugation (Phase 2 metabolism) of drugs and xenobiotics with 
glucuronic acid was first shown to be inhibited during pregnancy by Cessi
(1952) and this has been attributed to inhibition of glucuronyl
transferase(s) by high circulating levels of pregnane-3c(,20<*-diol and other 
progestational and oestrogenic steroids (Lathe and Walker,1958; Hsia et 
al., 1963; Hartiala et aL,1963). Conjugation with sulphate has also been 
shown to be decreased during pregnancy in the rat and is thought to be due 
to high levels of oestrogens (Pulkinnen,1966). Since these early studies 
various workers have reported decreased hepatic glucuronyl transferase 
activity during pregnancy of n-aminophenol (Feuer and Liscio,1969),
4-methylumbelliferone (Neale and Parke,1973), bilirubin and £-nitrophenol 
(Halac and Sicignano, 1969) and oestrone and oestradiol (Vore and 
Soliven-, 1979) • In contrast, Blake et al. (1978) have failed to find a 
change in glucuronyl transferase activity during pregnancy using
5-(j>-hydroxyphenyl)-5-phenylhydantoin as substrate.
Maternal hepatic Phase '1' metabolism during pregnancy has been the 
subject of a number of investigations since the early 1960's when it was 
reported that coumarin and biphenyl hydroxylation were decreased to 50% of 
normal levels during late pregnancy in the rabbit (Creaven and Parke,1965). 
These investigations were concerned primarily with determining the effect 
of pregnancy on hepatic mixed-function oxidase activity rather than a 
characterization of the mechanism involved in these changes. The results 
presented have often been contradictory and confusing and for this reason 
the various studies have been dealt with in some detail in the following 
review. This is followed by a summary of the major findings.
Feuer and Liscio (1969) demonstrated that the duration of sleeping 
induced by phenobarbitone was increased during pregnancy in the rat when 
dosed on a weight basis. This confirmed work by King and Becker (1963).
The authors were also able to show that the hydroxylation of
4-methylcoumarin was reduced during pregnancy and that pretreatment with 
phenobarbitone or 3-methylcholanthrene induced an increase in enzyme 
activity in pregnant rats but not to the level of that in induced 
non-pregnant animals. Induction of the hepatic microsomal mixed-function 
oxidase system in the pregnant rat has been reported previously (Inscoe and 
Axelrod,1969; Pantuck,1968) although a decrease in enzyme activity in 
untreated pregnant rats was not found. Kato et al.(1968a) have reported 
that the effect of phenobarbitone to increase the activities of microsomal 
drug metabolising enzymes is greater in pregnant rats than in non-pregnant 
rats
Guarino et al. (1969a) investigated alterations in the kinetic 
properties of aniline hydroxylase and ethylmorphine N-demethylase 
associated with pregnancy-in the rat. Values for Km and Vmax were
determined in control and pregnant rats 6, 20, and 23 (1 day post pairtum) 
days after mating. It was found that during pregnancy Km did not alter 
significantly while Vmax was significantly reduced on day 20 of pregnancy. 
Cytochrome P450 levels paralleled this change in Vmax, being significantly 
reduced at day 20 of pregnancy. The authors, proposed that high levels of 
circulating steroids present during pregnancy competitively inhibited 
microsomal drug metabolism. Neale and Parke (1973) however, point out that 
it is more likely that the decreased activity of the enzyme system in the 
full term rat is due to a reduction of the enzymic haemoprotein cytochrome 
P450 rather than competitive inhibition from steroids. Studies by Peters 
(1973) using livers from 20 day pregnant rats showed that pregnancy tended 
to decrease Vmax for methadone metabolism while Km remained unchanged. The 
reported decrease was not, however statistically significant. Gabler and 
Falace (1970) found that microsomes prepared from the livers of late 
pregnancy rats hydroxylated aniline at a rate 32% slower than similar 
preparations from non-pregnant females. Furthermore, the clearance of 
5,5'-diphenylhydantoin from several tissues of pregnant rats was markedly 
slower than from non-pregnant rats.
A survey of the effects of pregnancy on the hepatic microsomal Phase
'1' and '2' metabolism of drugs by Neale and Parke (1973) has shown that 
the full term pregnant rat exhibits decreases in the order of 30% in the 
specific activities of biphenyl 4-hydroxylase and 4-methylumbelliferone 
glucuronyltransferase and in the level of cytochrome P450, vrtiile biphenyl
2-hydroxylase, ]D-nitrobenzoic acid reductase and microsomal protein levels 
are unchanged. Liver weight is elevated by up to 40% in pregnancy and when
expressed per whole liver weight there is an increase in both microsomal
protein and nitroreductase levels in the pregnant rat and no change in 
cytochrome P450, glucuronyltransferase or biphenyl hydroxylases when
compared with the non-pregnant rat. The authors suggested that these 
findings could explain the results obtained for hexobarbital sleeping times 
since it was found that hexobarbital, when administered to rats at doses 
related to pregnant weight, significantly increased the sleeping time in 
pregnant animals. At doses related to non-pregnant weight the sleeping 
time remained unchanged. Dean and Stock (1975) have pointed out, however, 
that administering hexobarbital during late pregnancy in a dose based on 
non-pregnant weight will not give plasma levels equivalent to those in the 
non-pregnant rat. Neale and Parke determined the effect of inducing agents 
on the drug enzyme system and found that phenobarbitone and 
3-methylcholanthrene pretreatment increased enzyme activities in pregnant 
and non-pregnant animals to such an extent as to annul the inhibitory 
effect of pregnancy. The authors suggested that the reduction in 
microsomal enzyme activity during pregnancy in the rat was due to a 
parallel decrease in the level of cytochrome P450. A different situation 
was found in the rabbit where there was no increase in liver weight during 
pregnancy. Glucuronyltransferase and coumarin 7-hydroxylase activities 
were significantly decreased during pregnancy while cytochrome P450, 
microsomal protein, nitroreductase and biphenyl 4-hydroxylase were 
unchanged from non-pregnant control levels. Devereux and Fouts (1975) have 
reported that hepatic dimethylaniline demethylation and N-oxidation are 
unchanged during pregnancy in the rabbit.
Schlede and Borowski (1974) reported that Km values for ethylmorphine 
N-demethylase and benzo(cOpyrene hydroxylase did not alter during pregnancy 
compared with non-pregnant control rats. Vmax values for these enzymes 
were found to be significantly decreased during gestation (14 and 21 days) 
when expressed per gram liver weight and unchanged if expressed per total 
liver. Cytochrome.P450 levels were unaltered during pregnancy if expressed
per gram liver and elevated if the total liver weight was taken into 
account. Phenobarbitone pretreatment resulted in a significant increase in 
the Vmax for benzo(t*)pyrene hydroxylase and ethylmorphine N-demethylase in 
both pregnant and non-pregnant rats though this was larger in the latter 
group. Phenobarbitone pretreatment caused an elevation in cytochrome P450 
levels in non-pregnant rats but not in pregnant rats, a finding also 
reported by Neale and Parke (1973). Hexobarbital sleeping time was 
unaffected by pregnancy and decreased after phenobarbital pretreatment.
Dean and Stock (1975) have found a progressive depression in the in 
vitro hepatic microsomal enzyme metabolism of four drug substrates 
(aniline,j^-nitroanisole, aminopyrine and £-nitrobenzoic acid) during 
pregnancy. This decrease was most pronounced on day 20 of pregnancy, being 
greatest with aniline £-hydroxylation and least with £-nitrobenzoic acid 
reduction (45% and 80% of non-pregnant levels respectively). The depressed 
metabolism which correlated with prolonged in vivo hexobarbital sleeping 
times was paralleled by a decrease in hepatic microsomal cytochrome P450 
levels and was significant even when calculated per total liver weight. A 
rapid reversal of this depression was found just prior to parturition. It 
was suggested that the lower levels of hepatic microsomal enzyme activity 
might reflect a biological control mechanism to ensure the elevated levels 
of progesterone required to maintain the pregnant state. At the approach 
of term, when the elevated levels are no longer required, the inhibition of 
metabolism would be released.
Feuer and Kardish (1975) studied the effect' of pregnancy and the in 
vivo administration of a number of progesterone metabolites on the hepatic 
microsomal monooxygenase system in the rat. The authors found that 
pregnancy (18-20 days) resulted in a significant decrease in the activity
of the microsomal drug enzymes aniline jD-hydroxylase, aminopyrine 
N-demethylase and coumarin 3-hydroxylase and a decrease in microsomal total 
phospholipid, phosphatidylcholine and phosphatidylethanolamine together 
with phospholipid synthesis. Microsomal levels of cytochrome P450 and 
cytochrome c reductase were also significantly decreased. The effect of 
pregnancy could be mimicked by the pretreatment of non-pregnant females 
with reduced metabolites of progesterone and it was proposed that increased 
levels of these metabolites occuring in pregnancy were responsible for the 
changes observed in drug metabolism. Pretreatment of non-pregnant rats 
with 5<<-pregnan-3^-ol-20-one or 5<*-pregnan-3p, 20/J-diol produced a decrease 
in microsomal drug hydroxylation and microsomal phospholipids.
Pretreatment with the hydroxylated progesterone metabolite, 
16<rt-hydroxyprogesterone produced an opposite effect. The authors suggested 
that these opposite reactions provided evidence that during pregnancy the 
formation of the endoplasmic reticulum and associated decrease in drug 
metabolism might be regulated by a balance displayed in the production of 
the various progesterone metabolites. The role of the reduced metabolites 
of progesterone in the control of microsomal drug enzyme activity has been 
discussed previously by Kardish and Feuer (1972) who followed progesterone 
metabolism in the liver of pregnant (18-20 day) and non-pregnant rats. 
During pregnancy they found a decrease in 16oC-hydroxylase activity and an 
increase in A*-5rt-hydrogenase activity. The drug enzyme coumarin 
3-hydroxylase showed a significant decrease in activity in the pregnant 
state. More recently, data presented by Feuer and colleagues (Dhami et 
aL, 1979a.b) has shown that pregnancy in the rat is associated with a 
decrease in microsomal and total hepatic phospholipid fatty acids 
paralleling the decrease in phospholipids. The ratio of unsaturated to 
saturated fatty acids did not, however, appear to alter significantly in 
pregnancy. The work of this group has been reviewed recently (Feuer,1979)
The effect of pregnancy on hepatic microsomal drug metabolism in 
rabbits and rats has been investigated by Gut et al. (1976). In pregnant 
Dutch-Belted rabbits on the 29th day of gestation, the rate of 
biotransformation of aminopyrine, benzphetamine and hexobarbital by hepatic 
9000g supernatant fractions were several fold lower than in non-pregnant 
females. The liver to body weight ratio was not changed by pregnancy and 
the optimum pH for in vivo aminopyrine metabolism was between 7.3 and 7.8 
for both groups. A different situation was found in the rat where aniline 
hydroxylase was the only enzyme found to be decreased during pregnancy. 
Cytochrome P450 levels were unchanged during pregnancy. The duration of 
hexobarbital sleeping time in pregnant rats (given a standard dose) was not 
significantly different from that in the non-pregnant rats. The authors 
suggested that the larger volume of distribution of hexobarbital in the 
pregnant rat possibly reflected the ability of the foetus to function as a 
storage compartment since it does not metabolise drugs to any degree.
Tabei and Heinrichs (1976) reported on the effect of pregnancy, in the 
rat and rabbit, cn hepatic dehydroepiandrosterone (DHA) 7a-, 7fS- and 16cC- 
hydroxylase and aminopyrine N-demethylase activity. In the rat aminopyrine 
N-demethylase and DHA 7<*-hydroxylase were significantly elevated early in 
pregnancy but at the end of gestation enzyme activities had fallen to below 
the non-pregnant levels. Cytochrome P450 levels remained unchanged during 
pregnancy. In rabbits cytochrome P450 levels were significantly decreased 
early in pregnancy (8 days) but not at the later stages. Aminopyrine 
N-demethylase activity followed these changes. Mukhtar et al. (1978) failed 
to find a decrease in hepatic cytochrome P450 in’ late pregnancy (19-20 
days) rats compared with non-pregnant controls although a small but 
significant decrease in arylhydrocarbon hydroxylase activity was found.
The kinetic constants for phenytoin metabolism have been determined in 
the pregnant and non-pregnant rat (Blake et aL, 1978). In late pregnancy 
(21-22 days) Vmax for the hydroxylation of phenytoin to
5-(jD-hydroxyphenyl)-5-phenylhydantoin was significnatly decreased while 
Vmax for 5-(3,4,-dihydroxy-1,5-cyclohexadien-l-yl)-5-phenylhydantoin 
formation was unchanged. Michaelis constants (Km) for these reactions were 
unaltered during pregnancy. If the increased liver size in pregnancy was 
accounted for the total phenytoin hydroxylase activity in pregnant rats was 
not significantly different from that of non-pregnant controls.
Some general conclusions concerning the effect of pregnancy on the 
hepatic microsomal mixed-function oxidase system are summarised below:
(1) Hepatic Phase '1' drug metabolism has been determined during 
pregnancy in the rat and rabbit. Pregnancy in the rat is associated with a 
marked increase in liver weight; a similar change is not however found in 
the rabbit.
(2) Hepatic monooxygenase activity, when expressed per unit liver 
weight, has been shown to be decreased during pregnancy in the rat by most 
investigators. This decrease appears to be progressive and Dean and Stock 
(1975) have found it to be rapidly reversible just prior to parturition. 
When expressed per total liver, monooxygenase activity is decreased or 
unchanged in the pregnant rat compared with the activity in the 
non-pregnant controls.
(3-) Microsomal levels of cytochrome P450 have been reported variously 
as increasing, decreasing or remaining unchanged during pregnancy (when 
expressed per unit liver weight).
(4) The kinetic constants Km and Vmax have been measured for a number 
of drug substrates. Vmax is reduced during pregnancy in the rat when 
expressed per unit liver weight while Km is unchanged.
(5) Microsomal phospholipids have been determined during pregnancy in 
the rat by Feuer and colleagues. Pregnancy appears to be associated with a 
decrease in total and component phospholipids. The ratio of saturated to 
unsaturated phospholipid fatty acids is not altered during pregnancy.
(6) Monooxygenase inducing agents such as phenobarbitone and
3-methylcholanthrene elevate drug enzyme activity in both pregnant and 
non-pregnant rats. Some investigators have reported that induction 
abolishes the inhibitory effect of pregnancy while others have found that 
it does not.
(7) In rabbits there appears to be a decrease in mixed-function 
oxidase activity during pregnancy when expressed per unit liver weight or
• per total liver. Cytochrome P450 levels remain unchanged during pregnancy.
(8) A number of authors have discussed the possibility that elevated 
plasma steroids, particularly progesterone, are responsible for the 
observed changes in hepatic monooxygenase activity during pregnancy. 
Steroids could act in a number of ways to mediate this effect, for instance 
via competitive inhibition of drug metabolism, a decrease in cytochrome 
P450 levels or by affecting the microsomal membrane (phospholipid) 
environment of the mixed-function oxidase system. There is a lack of 
information concerning the effect of progesterone and other steroids on 
drug metabolism during pregnancy. Feuer and colleagues have studied the 
effect of the in vivo administration of progesterone metabolites on in
vitro drug metabolism. The effect of progesterone, the predominant steroid 
of pregnancy, was not, however, studied.
1.3 AIMS OF THIS PROJECT
This project is concerned with a detailed investigation of the effect 
of steroids and other hormones, that are found to be elevated during 
pregnancy, on the maternal hepatic mixed-function oxidase system. In 
addition, the role of cytochrome P450 and microsomal phospholipids in 
mediating the pregnancy-induced alterations in drug metabolism will be 
studied. It is hoped that from this a rationalisation of the changes 
occuring in hepatic drug metabolism during pregnancy in the rat can be 
made.
CHAPTER 2. MATERIALS AND METHODS
2.1 Materials 
Cofactors
-Nicotinamide adenine dinucleotide phosphate (NADP sodium salt,98%),
J5-Nicotinamide adenine dinucleotide (NAD,98%), J5-Nicotinamide adenine 
dinucleotide phosphate reduced form (NADPH, Tetrasodium salt,95-97%), 
^-Nicotinamide adenine dinucleotide reduced form (NADH, disodium salt,98%), 
Glucose-6-phosphate (G6P, disodium salt,98%) and Flavin mononucleotide, 
95-97%) were obtained from Sigma London Chemical Co.Ltd.,Poole, Dorset, 
England.
Adenosine-5'-triphosphoric acid disodium dihydrogen salt (ATP,98%) was 
obtained from BDH Chemicals,Ltd., Poole, Dorset, England. '
Steroids
Progesterone, oestradiol, cortisol, testosterone and oestriol were 
obtained from Sigma London Chemical Co.Ltd., Poole, Dorset, England.
Pregnanolone (5$-pregnane-3£>-ol-20-one), pregnanedione 
(5j3-pregnane-3,20-dione) and 17oC-hydroxyprogesterone were obtained from 
Steraloids Ltd., Croydon.
Aniline hydrochloride, j5-aminophenol, NED (N-l-Napthylethylenediamine 
dihydrochloride) and j>-nitrobenzoic acid were obtained from BDH Ltd.,
Poole, Dorset, England,.
£-Aminobenzoic acid was obtained from Sigma London Chemical Co.Ltd., 
Poole, Dorset, England.
PPO (2,5-diphenyloxazole) and DMPOPOP (l,4-di-2- 
(4-methyl-5-phenyloxazolyl) benzene) were obtained from the Packard 
Instrument Co., Switzerland.
Specific reagents are dealt with in the Methods section (2.2). All 
other reagents were of Analar grade.
2.2 Methods
2.2.1 Animals
Female, nulliparous (unless stated) Wistar albino rats (170-250g) were 
obtained from the University of Surrey Animal Breeding Unit. Animals were 
kept in polypropylene cages covered with stainless steel tops (North Kent 
Plastic Cages Ltd.) on sterolite bedding (U.P.Usher Ltd.). Animals were 
allowed food (Spratts Animal Diet No 1) and water ad libitum. A twelve 
hour light/dark cycle was in operation (0700-1900 light) at a temperature 
of 22° and 50% humidity.
2.2.2 Mating of Animals
Mating was carried out on sawdust bedding (Lee and Co., Chertsey, 
Surrey). A proven male breeder was placed into a large cage containing 6 
females (170-190g) during the morning and left for 24 hours. The day of 
removal of the male was considered to be day 1 of gestation. Pregnancy was 
indicated by the presence of a vaginal plug and confirmed by abdominal 
palpation at day 7. Animals were transferred to a sterolite bedding at day 
1 of pregnancy or at least seven days before death.
The rats were killed at various times during pregnancy and 
post-partum. When using post-partum rats the litter was removed from the 
mother within 16 hours of delivery. Non-pregnant rats in the same weight 
range at day 0 of pregnancy (170-190g) were used as controls.
2.2.3 Preparation of liver fractions
Rats were killed by cervical dislocation at 9.00am +/- 1 hour and the 
livers were rapidly excised and placed in ice cold 1.15% (w/v) KC1. The 
livers were washed, blotted dry and weighed. Subsequent operations were 
carried out at 0-4°. The livers were scissor minced and homogenised in 
three volumes (w/v) of ice cold 1.15% (w/v) KC1 (ie. 1ml = 250 mg liver; 
25%) using a motor driven Potter-Elvehjem glass-Teflon homogeniser (3 
return strokes). This was designa ted 'liver homogenate'.
Liver homogenate was centrifuged in 50ml polycarbonate centrifuge  ^
tubes at 10,000gQV (ll,000rpm) for 20 minutes at 4° using an 8x50 aluminium 
angle-head rotor in an M.S.E. "High Speed 18" refrigerated centrifuge.
This removed cellular debris, nuclei, mitochondria and lysosomes. The 
supernatant was decanted and designated the "microsomal supernatant" and 
comprised the microsomal and soluble fraction.
The microsomal supernatant was further centrifuged at 105,000g 
(40,000 rev/min) for 1 hour at 4 using an 8x25ml aluminium angle head 
rotor in an M.S.E. "Superspeed 50" refrigerated centrifuge. The 
supernatant obtained was discarded and the pellet washed carefully in 
homogenising medium. The washed pellet was finally resuspended in 20mM 
Tris-HCL (pH 7.4) buffer containing 250mM sucrose and 5.4mM EDTA to give a 
concentration equivalent to 500mg wet weight of liver per ml. This was 
designated the "microsomal suspension" and was stored in 2.0ml aliquots at. 
-20°.
In the determination of glucose-6-phosphatase, glucose 6-phosphate 
dehydrogenase, malic enzyme, glucokinase, hexokinase, aspartate 
aminotransferase and glutamate dehydrogenase liver fractions were prepared 
as follows.
Liver homogenate was prepared as described above in 1.15% (w/v) KC1 
containing 0.2mM KHCOg adjusted so that lg liver = 3ml homogenate. A 
sample of this homogenate was retained for enzyme assays. The remaining 
homogenate was centrifuged at 105,000gQV (40,000 rev/min) for 1 hour at 4 
using an 8x25 aluminium angle-head rotor in an M.S.E. "Superspeed 50" 
refrigerated centrifuge. The supernatant was carefully decanted to avoid 
contamination from the upper layer of fat and designated the "soluble
fraction".
2.2.4 Serum preparation
/
Blood was obtained from rats under a light ether anaesthetic by 
cardiac puncture. Rats were killed by cervical dislocation immediately 
after blood collection. After clotting in Soveril tubes the blood was 
centrifuged in an M.S.E. bench centrifuge at 2000rpm for 15 minutes. 
Serum was carefully withdrawn from the tube using a pasteur pipette and 
stored in glass vials (Payne 1x5/8" stoppered glass tubes) at -20°.
2.2.5 Animal pretreatment
2.2.5.1 Phenobarbitone
Sodium phenobarbitone (BDH Ltd.) was administered as a solution in
0.9% (w/v) saline. Rats received 80mg/kg phenobarbitone by 
intra-peritoneal (i.p) injection, once daily (at 9am +/- lhour) for three 
consecutive days and were killed 24 hours after the last injection. 
Pregnant rats received phenobarbitone on days 17, 18 and 19 of gestation 
and were killed on day 20. Control rats received saline alone.
2.2.5.2 3-Methylcholanthrene
3-Methylcholanthrene (Sigma Chemical Co.Ltd.) was administered as a 
solution in com oil. Rats received 20mg/kg by i.p injection daily (at 9am 
+/- 1 hour) for three days and were killed 24 hours after the last 
injection. Pregnant rats received 3-methylcholanthrene on days 17, 18 and 
19 of pregnancy and were killed on day 20. Control rats received corn oil 
alone.
2.2.5.3 Progesterone 
Chronic progesterone treatment
Rats were treated chronically with progesterone in two ways:
(a) Chronic progesterone treatment by i.p injection
Progesterone was administered (lOmg/kg) in com oil. Rats were injected
i.p (at 9am +/- 1 hour) for 12 days and killed 24 hours after the last 
injection. Control rats receieved com oil alone.
(b) Progesterone implants
Autoclaved silicone rubber implants (lcmx0.4cm) containing 32mg 
progesterone were obtained from Dr.N.F.Cunningham (M.A.F.F. Central
er
Vetinary Laboratory, Surrey). The implants were placed intradermally on 
the flank of the right leg of rats under a light ether anaesthetic. The 
wound was closed with Michel clips (Holborn Surgical, London). Control 
rats were sham operated. Rats were killed 7, 14 and 21 days after 
insertion of the implant.
Acute progesterone treatment
Rats received progesterone (40mg/kg) i.p in corn oil (at 9am +/- 1 
hour) and were killed 60 minutes later. Control rats received com oil 
alone.
2.2.5.4 Oestradiol
Oestradiol -170 was administered by i.p injection in c o m  oil. Rats 
received lOmg/kg oestradiol for 10 days and were killed 24 hours after the 
last injection. Control rats received com oil alone.
2.2.5.5 Increased dietary choline 
Diet Preparation
Spratts No.l powdered animal diet was mixed thoroughly with choline 
chloride (Sigma Chemical Co.Ltd.). The final diet contained lg choline 
chloride per lOOg diet (1% choline diet).
Diet administration
Pregnant and non-pregnant animals (170-190g) received a 1% choline 
diet ad libitum for 20 days. Body weight gain was monitored throughout the 
period of feeding. Control animals received a normal diet (Spratts No.l 
powdered diet) containing 45mg choline chloride / lOOg. Pregnant animals 
were killed on day 20 of gestation.
2.2.5.6 Human placental lactogen
Source
Human placental lactogen (Ref.No. 70/144) was obtained from the 
National Institute for Biological Standards and Control (NIBSAC), London. 
Adminis tration
Non-pregnant rats received daily (9am +/- 1 hour) i.p injections of 
0«22mg human placental lactogen in 0.9% saline (containing 0.22% (w/v) 
lactose) for six days and were killed on the morning of the seventh day. 
Control rats received 0.9% saline (containing 0.22% (w/v) lactose) alone.
2.2.5.7 Rat placental homogenate
Preparation of placental homogenate
Placental homogenate was prepared according to the method of Linkie
and Niswender (1973). Pregnant rats (13 days) were killed by cervical .
dislocation and the placentae (5-14 per donor rat) removed. Placentae were
dissected free of uterine atta chments and embryos and were placed in ice
cold saline (0.9% (w/v) NaCl). Combined placentae were homogenised in
saline (3.5 placentae per ml) and centrifuged (Beckman J6) at lOOOg for 20
minutes at 4°. The supernatant was stored in 3.0 ml aliquots in glass 
o
vials at -20 until the morning of administration.
Administration
Non-pregnant rats received daily (9am +/- 1 hour) i.p injections of 
placental homogenate (2.0 placental equivalents per rat) for 6 days and 
were killed on the seventh day. Control rats received saline alone.
2.2.6 Drug enzyme assays
Three drug enzyme activities were measured in the hepatic microsomal 
supernatant (10,000g supernatant). These were ethylmorphine N-demethylase, 
aniline ]D-hydroxylase and jD-nitrobenzoic acid reductase.
2.2.6.1 N-demethylation of ethylmorphine
The N-demethylation of ethylmorphine is followed by measuring the 
formaldehyde formed from the methyl group. Formaldehyde is trapped by 
semicarbazide. Trapped formaldehyde is then heated with the Nash reagent 
to form a yellow complex (Nash,1953) The incubation mixture was essentially 
that of Holtzman et al. (1968), developed in our laboratory by Ioannides 
(1973).
Reagents
(1) 0.3M Tris-HCl pH 7.6
(2) 60mM Ethylmorphine in 0.3M Tris-HCl pH 7.6
(3) 1.2mM Formaldehyde
(4) lOOmM MgCl2
(5) 2% (w/v) Semicarbazide HC1 pH 7.0 in 0.3M Tris-HCl
(6) 30mM Glucose 6-phosphate in 0.3M Tris-HCl (prepared fresh)
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(7) 2.5mM NADP in 0.3M Tris-HCl (prepared fresh)
(8) 15% (w/v) ZnSO^
(9) Saturated Ba(OH)2 solution
(10) Saturated Na2B^ 0^ . solution
(11) Nash reagent: 4M Ammonium acetate containing 4ml/1 acetylacetone
(Prepared fresh)
Method
The incubation was carried out in soveril tubes (8.0ml). The 
incubation contained:
0.3M Tris-HCl pH 7.6 0.50ml
lOOmM MgCl2 0.10ml
60mM Ethylmorphine 0.25ml
2% (w/v) semicarbazide HC1 0.20ml
30mM Glucose-6-phosphate 0.50ml
2.5mM NADP 0.50ml
Microsomal supernatant (25%) 0.50ml
Total Volume 2.55ml
The reaction mixture, excluding microsomal supernatant, was preheated 
to 37° and the reaction initiated by the addition of microsomal
supernatant. Incubation was carried out for 10 minutes at 37 in a Mickle 
shaking water bath. The rate of shaking was kept constant at 60 cycles per 
minute. The reaction was terminated by addition of 15% ZnSO^ (1.0ml) 
followed by a mixture (2:1) of saturated solutions of Ba(0H )2 and Na2B^0^ 
(1.0ml). The tubes were centrifuged to remove protein at 2,500rpm for 10 
minutes in a Beckman J6 centrifuge. Aliquots of supernatant (2.0ml) were 
added to Nash reagent (2.0ml) in clean test tubes. The mixture was 
incubated for 40 minutes at 37° in a Mickle shaking water bath (60 cycles 
per minute).
The yellow colour was measured at 412nm in a Gilford 250 
spectrophotometer. Suitable blanks and standards (0.3^umoles) were carried 
through the same procedure.
2.2.6.2 Aniline p-hydroxylation
Aniline, a type 2 substrate, is metabolised by rat liver microsomes to 
jD-aminophenol. The method is essentially that of Guarino et al.(1969b), 
developed in our laboratory by Ioannides (1973).
n h 2
OH
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Reagents
(1) 0.3M Tris-HCl buffer pH 7.6
(2) 40mM Aniline hydrochloride pH 7.6 in 0.3M Tris-HCl
(3) lOOmM MgCl2
(4) lOmM NADP + lOOmM Glucose-6-phosphate in 0.3M Tris-HCl (prepared fresh)
(5) Solid sodium chloride
(6) Peroxide free ether containing 1.5% (w/v) isoamylalcohol
(7) ImM j>-Aminophenol in 0.1M HC1
(8) Alkali phenol: 0.5M Tripotassium orthophosphate + 1% (w/v) phenol
(prepared daily)
Method
The incubation was carried out in soveril tubes (15ml). The incubation 
contained:
0.3M Tris-HCl ph 7.6 0.5ml
40mM Aniline hydrochloride 0.5ml
lOOmM MgCl2 0.1ml
lOmM NADP + lOOmM Glucose-6-phosphate 0.2ml
Microsomal supernatant (25%) 0.5ml
Total Volume= 1.8ml
The reaction mixture, excluding microsomal supernatant, was preheated 
to 37°. The reaction was initiated by the addition of microsomal 
supernatant and incubation was carried out for 15 minutes at 37° in a 
Mickle shaking bath. The rate of shaking was kept constant at 60 cycles 
per minute. Longer incubation times have been shown to result in 
jd-aminophenol disappearance (Mazel,1972)J
The reaction was stopped by the addition of solid NaCl (approx.lg) and 
peroxide free ether containing 1.5% (w/v) isoamylalcohol (12ml). 
jd-Aminophenol was extracted into ether on a rotary shaker for 20 minutes. 
Ether aliquots (10.0ml) were subsequently added to alkali phenol (4.0ml) in 
clean soveril tubes and extracted for a further 5 minutes.
The ether layer was removed using a glass pipette attached to a vacuum 
pump. The blue phenol-indophenol complex was measured at 620nm, 30 minutes 
after addition of phenol in a Gilford 250 spectrophotometer. Suitable 
blanks and standards (0. lyumoles js-aminophenol) were carried through the 
same procedure.
2*2.6.3 Reduction of p-nitrobenzoic acid
Microsomal nitroreductase activity can be determined by measuring the 
quantity of jv-aminobenzoic acid formed from the reduction of 
£-nitrobenzoic acid, probably through the formation of nitroso- and 
hydroxylamine intermediates.
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The j>-aminobenzoic acid formed is diazotised and then coupled to 
N-l-napjthylenediamine (NED) to yield a coloured complex (Bratton and Marshall 
1939).
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Incubation was carried out using the method of Fouts and Brodie (1957), 
developed in our laboratory by Ioannides (1973).
Reagents
(1) 0.05M Tris-HCl pH7.6
(2) lOmM ]D-Nitrobenzoic acid in 0.05M Tris-HCl pH7.6
(3) 125yuM ^-Aminobenzoic acid in 0.05M Tris-HCl pH 7.6
(4) 50mM MgCl2
(5) 6.6mM NADP in 0.05M Tris-HCl (prepared fresh)
(6) 250pM FMN in 0.05M Tris-HCl (prepared fresh)
(7) 50mM Glucose-6-phosphate in 0.05M Tris-HCl (prepared fresh)
(8) 12.5% (w/v) Trichloroacetic acid
(9) 0.1% (w/v) NaN02
(10) 0.5% (w/v) Ammonium sulphamate
fcln
(11) 0.1% (w/v) NED (N-l-naphylenediamine)
Method
The incubation was carried out in soveril tubes (8.0ml). The incubation 
contained:
lOmM jD-Nitrobenzoic acid 2.0ml
50mM MgCl2 0.5ml
6.6mM NADP 0.5ml
250^ »M FMN 0.5ml
50mM Glucose-6-phosphate 0.5ml
Microsomal supernatant (25%) 0.5ml
Total Volume= 4.5ml
Tubes containing the reaction mixture were kept on ice while N2 was flushed 
through (1-2 lb/in^) for 10 minutes to maintain anaerobic conditions.
Tubes were transferred to a Mickle shaking water bath at 37° and the 
incubation was carried out under N 2 for 30 minutes. The rate of shaking 
was kept constant at 60 cycles per minute. The reaction was terminated by 
the addition of 12.5% (w/v) trichloroacetic acid (0.5ml). After 
centrifugation at 2,500rpm for 10 minutes in a Beckman J6 centrifuge an 
aliquot of the supernatant (2.0ml) was used for diazotization in a clean 
test tube. Tubes were allowed to stand for 3 minutes after .addition of 
0.1% NaN02 (0.5ml). This was followed by 0.5% ammonium sulphamate (0.5ml) 
and finally 0.1% NED (0.5ral). The volume was made up to 10ml with 
distilled water and the mauve colour was determined 30 minutes later at 
545nm in a Gilford 250 spectrophotometer. Suitable blanks and standards
(0.25^tmoles) were carried through the same procedure.
\
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2.2.7 Studies on the effect of in vitro additions of steroids on drug 
enzyme activity in the liver
Steroids were dissolved in a suitable volume of dimethylformamide 
(DMF) (BDH Ltd.) and added to the drug enzyme incubation mixture such that 
the effects of 10"^ to 10"^M (final concentrations) could be observed. 
Steroids were added prior to the initiation of the enzyme reaction. The 
volume of DMF added to the incubation mixture represented 0.56% of the 
total volume. Control incubates received DMF alone.
Drug enzyme assays were performed as described elsewhere (see 2.2.6).
2.2.8 Measurement of cytochrome P450
Cytochrome P450, the terminal mixed-function oxidase, was measured by 
making use of its ligand binding properties. Carbon monoxide combines with 
the reduced form of cytochrome P450 to form a single peak at 450nm when 
compared with untreated microsomes. The method used was described by 
Sladek and Mannering (1966).
Microsomal suspension (25%) was diluted threefold with 0.1M phosphate 
buffer pH 7.4. Diluted suspension (5ml) was divided equally between two 
lcm glass cuvettes. A baseline of equal light absorbance between 400 and 
500nm was established using a Pye Unicam SP1800 recording spectrophotometer 
in the duel beam mode. The contents of both cuvettes were reduced by the 
addition of solid sodium dithionite (l-2mg) and carbon monoxide was bubbled 
through the contents of the sample cuvette for 20 seconds.- A difference 
spectrum was obtained between 400 and 500nm. The absorbance change at the 
absorbance maximum (approx.450nm) was measured relative to that at 490nm, 
and the concentration of cytochrome P450 was calculated using an extinction 
coefficient of 91mM“^ cnH (Omura and Sato,1964a).
2.2.9 Measurement of cytochrome b5
Cytochrome b5 was measured as the difference spectrum of NADH reduced 
microsomes against oxidised microsomes. The method of Schenkman et al. 
(1967) was used. Microsomal suspension (25%) was diluted threefold with 
0.1M phosphate buffer pH 7.4. Diluted microsomal suspension (5ml) was
divided equally between two 1cm glass cuvettes.
A base line of equal light absorbance was established between 390nm 
and 450nm in a Pye Unicam SP 1800 recording spectrophotometer in the dual 
beam mode. Into the sample cuvette 0.1ml NADH (lmg/ml) was added and a 
difference spectrum was obtained between 390nm and 450nm. The 
concentration of cytochrome b5 was determined by measuring the difference 
in absorbance between 410 and 426nm (ie.trough and peak) using an 
extinction coefficient of 185mM”^ cm*^  •
2.2.10 NADPH-cytochrome c reductase
This enzyme is thought to be the same as NADPH-cytochrome P450 
reductase. Direct measurement of cytochrome P450 reduction is difficult to 
carry out routinely so cytochrome c is used as an alternative electron 
acceptor. The reduction of cytochrome c was monitored 
spectrophotometrically by using a modified version of the method of 
Williams and Kamin (1962). Use is made of the difference in absorption 
between oxidised and reduced cytochrome c at 550nm.
Reagents
(1) 0.05M Potassium phosphate buffer (pH 7.6) containing ImM KCN
(2) O.lmM Cytochrome c (Boehringer Mannheim GmbH)
(3) 30mM NADPH in 0.05 phosphate buffer 
Method
Into two cuvettes the following were added:
Test Reference
Phosphate buffer 1.7ml 1.8ml
Cytochrome c (O.lmM) 1.0ml 1.0ml
Microsomal suspension (25%) 0.2ml 0.2ml
NADPH (30mM) 0.1ml
Total Volume= 3.0ml 3.0ml
o
The cuvettes were preincubated at 25 for 5 minutes. After drawing a 
baseline the reaction was commenced by the addition of NADPH and followed 
at 550nm in a Pye Unicam SP 1800 recording spectrophotometer. The initial 
velocity was taken as the measure of cytochrome c reduction. An extinction 
coefficient of 18.5mM^ cm*^  was used to calculate the rate of reduction.
2.2.11 Ligand induced binding spectra
Binding spectra were elicited as described by Schenkman et al.(1967). 
Microsomes (5ml of a suspension containing 2mg protein/ml in 66mM Tris-HCl, 
(pH 7.4) were divided equally between two cuvettes and placed in a 
thermostated cuvette holder at 37° in a Varian Cary 219 split beam 
spectrophotometer. A baseline of equal light absorbance between 350 and 
500nm was established. The ligand was added to the sample cuvette in yui 
quantities of a solution in buffer (Aniline) or N,N-dimethyl formamide 
(DMF) (Ethylmorphine, Progesterone and 17<tf-hydroxyprogesterone) using a 
Hamilton lOyml syringe (Hamilton Bonaduz AG, Switzerland). An equal volume 
of solvent was added to the reference cuvette and the contents of both 
cuvettes were mixed by gentle inversion. A difference spectrum between 350 
and 500 nm was recorded.
2*2.12 Haemoprotein spin state analysis
The spin state of microsomal cytochrome P450 was determined by a 
modified method of Sligar (1976).
A sample of microsomal suspension was diluted to lnmol cytochrome P450 
per ml in 50mM phosphate buffer, pH 7.25 containing 20% (w/v) glycerol and 
lOmM EDTA. This was placed in a cuvette in a Perkin-Elmer 356 dual 
wavelength spectrophotometer with the monochromators fixed at 390 and 
420nm. A thermistor temperature probe (type FM, Edale Instruments, 
Cambridge, England) was placed carefully in the cuvette such that the tip 
was immersed but the light path was not obscured and connected to a 
temperature read-out device with a full scale expansion of 0°to 50° (Model 
C, Edale Instruments, Cambridge, England). The temperature of the cuvette 
was raised from approximately 14° to 40° by a heated water bath connected 
to the cuvette housing and the increase in AA 390 miunus 420 was recorded 
simultaneously with the corresponding cuvette temperature.
The absorbance values of cytochrome P450 corresponding to 100% 
low-spin material and 100% high-spin material were used as free floating 
parameters in conjunction with the observed AA 390-420 values in a one 
parameter fit procedure described by the equation:
K= Aj_g -A ,assuming Aj_(5 ~A[_5 = 126mM ^  cm ^
A - AHS 
(Cinti et aL, 1979).
K is the spin equilibrium constant (defined as the ratio of high-spin 
to low-spin cytochrome P450). A^^is the delta absorbance of 100% low-spin
cytochrome P450, A|_jgis the delta absorbance of 100% high-spin material and 
A is the observed A A 390-420 at any given temperature. The spin 
equilibrium constant was fitted to a van't Hoff plot by reiterative 
analysis (Cinti et_aL,1979), on line to the University of Surrey Computing 
Centre.
2.2.13 Determination of total lipid and phospholipids
2.2.13.1 Extraction of lipids
Lipids were extracted from liver homogenate (25%) or microsomal 
suspension (50%) according to the method of Folch et al. (1957).
Reagents
(1) Chloroform/Methanol (2/1)
(2) Pure solvents upper phase: Chloroform/Methanol/Water (3/48/47)
(3) 0.88% (w/v) KC1 
Method
An aliquot (0.25ml) of liver sample was pipetted (in duplicate) into.a 
clean 8ml soveril tube. To this was added 4.25ml chloroform/methanol. The 
tube was stoppered and the contents shaken on a rotary shaker for 10 
minutes. The mixture was filtered through a filter paper (Whatman No.l; 
7.0cm), moistened with Chloroform/Methanol into a second soveril tube. The 
remaining contents of the first tube were re-extracted, with a further 
addition of Chloroform/Methanol (3.0ml), for 10 minutes and then filtered
through the same filter paper to give a total volume of 7.5ml in the second 
soveril tube. An aliquot (1.5ml) of 0.88% (w/v) KC1 was added and the tube 
shaken for 5 minutes, followed by centrifugation at 2,000rpm on an MSE 
Bench centrifuge for 5 minutes. The upper phase was removed using a 
pasteur pipette attached to a vacuum source. Care was taken to ensure that 
the lower phase was not disturbed. The lower phase was washed three times 
by the careful addition of small quantities of 'pure solvents upper phase'. 
These were removed and the lower phase and remaining upper phase combined 
by the addition of methanol.
The resulting solution was dried down under in a water bath at 30°. 
The lipids were redissolved in ice cold chloroform (1.0ml) and the tube was 
kept tightly stoppered on ice. The lipid extract was used for the 
determination of total lipid and phospholipid and was stored for up to two- 
weeks at -20°. The efficiency of lipid extraction by this method was found 
to be >95%.
2.2.13.2 Determination of hepatic total lipids
Total lipids were determined using a Boehringer-Mannheim GmbH 
Diagnostics Test Kit (Cat.No.124303) for Total Serum Lipids which was 
modified to enable liver lipids to be measured.
This assay is based on the reaction of lipids with sulphuric and 
phosphoric acids and vanillin to form a pink coloured complex. This 
reaction will detect triglycerides, phospholipids and cholesterol.
Reagents
(1) Colour reagents: phosphoric acid (14mol/l) and vanillin (13mmol/l)
(2) Lipid standard: total lipids 1,OOOmg/100ml
(3) Sulphuric acid (concentrated)
Method
Aliquots (0.1ml) of liver homogenate lipid extract (from 2.3.13.1) 
were pipetted into clean tubes. Chloroform was removed under N£ at 37° and 
distilled water (50 l^L) was added. The following tubes were prepared:
blank standard sample
(in 50jdL distilled water)
Lipid standard - 0.05ml -
Sulphuric acid - 2.0ml 2.0ml
The tubes were mixed well, plugged with cotton wool and placed in a boiling 
water bath for 10 minutes. The tubes were cooled in cold water and the 
following was pipetted into clean test tubes:
blank standard sample
from solutions above - 0.01ml 0.01ml
Sulphuric acid 0.10ml - -
Colour reagent 2.50ml 2.50ml 2.50ml
The tubes were mixed thoroughly and stood at 20-25p for 30 minutes. The 
pink colour was determined at 546nm in a Gilford 250 spectrophotometer.
2.2.13*3 Determination of total microsomal phospholipids
Phospholipids were determined using the method described in the 
Boehringer-Mannheim GmbH Diagnostica Test Kit (Cat.No. 124974). 
Phospholipids are oxidised to phosphate with perchloric acid and hydrogen 
peroxide. Phosphate forms a yellow coloured complex with molybdate and 
vanadate in the presence of nitric acid.
Reagents
(1) Vanadate solution: Ammonium vanadate (21mM) in 0.28M Nitric acid
(2) Molybdate solution: Ammonium molybdate (40mM) in 1.25M sulphuric acid
(3) Standard phosphor us: Disodium hydrogen phosphate (6.44mM)
(4) Perchloric acid (70%)
(5) Hydrogen peroxide (30%)
Method
Aliquots of microsomal lipid extract (from 2.2.13.1) (250^1) were pipetted 
into soveril tubes. Chloroform was removed under N£ at 37® and distilled 
water (lOO^ ul) added to the dried lipid extract. The following tubes were 
prepared:
blank
Perchloric acid 0.5ml
Standard phosphorous -
Hydrogen peroxide 0.2ml
The tubes were mixed and placed into an oil bath at 20-25w. The tubes were 
heated to 180-200° for approximately 20 minutes and then cooled to 20-25°. 
After cooling distilled water (2.0ml), Vanadate solution (1.0ml) and
i
molybdate solution (1.0ml) were added to all the tubes. After 10 minutes 
the absorbance was read at 405nm in a Gilford 250 spectrophotometer.
standard sample (in lOO^ ul 
distilled water) 
0. 5ml 0. 5ml
0. 1ml -
0.2ml 0.2ml
2.2.13.4 Separation and determination of component microsomal phospholipids
Individual phospholipids were separated by thin layer chromatography 
using a method modified from that of Skipsky et al. (1962).
Reagents
(1) Solvent system: chloroform (50) : methanol (25) : glacial acetic
acid (7) : water (3)
(2) Iodine crystals (resublimed: obtained from BDH Chemical Ltd., Poole,
Dorset)
(3) Phospholipid standards (2-10mg/ml in chloroform)
Standard Source
Phosphatidylcholine Bovine liver III-L
Phosphatidylethanolamine Bovine brain I
Phosphatidylinositol Soya bean
Phosphatidylserine Bovine brain I
L-<x-lysophosphatidylcholine Egg yolk I 
Sphingomyelin Bovine brain I
L-o(-phosphoric acid Egg lecithin I
All standards were obtained from Sigma Chemical Co.(London) and were >98% 
pure. Standards were stored at -20° in the dark.
Method
Aliquots (500^1) of microsomal lipid extract (from 2.2.13.1) were dispensed 
into flat-bottom glass vials (2x5/8M) and the volume reduced to 
approximately IOO^ lL under N 2 at room temperature. The extract was applied 
to a TLC plate (silica gel G 1500, acid fast, 0.25mm x 20cm x 20cm glass 
plates obtained from Schleicher and Schull, West Germa ny) with a 100yul 
microcap dispenser (Drummond Sci.Co., USA) and the chloroform removed under 
a cold stream of air from a hairdryer. The glass vial was washed twice
with chloroform (50^1). The samples were spotted as horizontal streaks 
approximately 1.0-1.5cm in width. This was found to give better resolution 
of the component phospholipids. The TLC plates were developed in a TLC 
tank saturated with the running solvent (chloroform (50) : methanol (25) : 
glacial acetic acid (7) : water (3)). The run was terminated when the 
solvent had travelled 15cm from the origin.
The spots were visualised by placing the TLC plate in a tank 
containing iodine crystals for 5-10 minutes. The iodine vapour in the tank 
detected most organic compounds, dissipated within 24 hours and did not 
interfere with subsequent phospholipid analysis. The fractions were 
identified by comparison with pure phospholipid markers.
Phospholipid standard Rf value
L-o(-lysophosphatidylcholine 0.10 
Sphingomyelin 0.30
Phosphatidylcholine 0.42
Phosphatidylinositol 0.44
Phosphatidylserine 0.56
Phosphatidylethanolamine 0.79
Phosphatidic acid 0.95
The phospholipid spots were scraped into soveril tubes to which 
distilled water (IOO^ jI) was added. The amount of each phospholipid was 
determined as described in 2.2.13.3. The presence of silica gel did not 
interfere with the phosphate determination. After colour development the 
tubes were centrifuged at 2,500rpm for 5 minutes in a Beckman J6 centrifuge 
and the supernatant removed for colour determination.The efficiency of 
recovery of known amounts of phospholipid separated using this method was 
>95%.
2*2.14 Gel electrophoresis of microsomal protein
The method of Laemmi (1970), developed in our laboratory by Fennell 
(1980), for sodium dodecyl sulphate (SDS)-polyacrylamide disc gel 
electrophoresis was used in the analysis of hepatic microsomal proteins. 
Reagents
(1) Gel stock: 30% (w/v) acrylamide containing 0.8% (w/v)
N,N-methylenebis-acrylamide (Biorad Biochemicals,USA)
(2) Buffer 1: 1.5M Tris-HCl (pH8 .8) containing 0.4% (w/v) SDS (Biorad
Biochemicals,USA)
(3) Buffer 2: 500mM Tris-HCl (pH 6 .8) containing 0.4% (w/v) SDS
(4) Buffer 3: 25mM Tris-HCl (pH 8.3) containing 192mM glycine and 0.1% 
(w/v) SDS
(5) Buffer 4: 62.5mM Tris-HCl (pH 6 .8) containing 2.3% (w/v) SDS, 15%
(w/v) glycerol, 5% (w/v) 2-mercaptoethanol and 0.001% (w/v) bromophenol 
blue (Biorad Chemicals,USA)
(6) Staining solution: isopropanol (25) : acetic acid (10). : water (65)
containing 0.05% (w/v) Coumassie Blue G250 (Biorad Biochemical,USA)
(7) Destaining solution: isopropanol (10) : acetic acid (10) : water
(80)
(8 ) 3% (w/v) glycerol
(9) N,N'-tetramethylenediamine (TEMED) (Biorad Biochemicals,USA)
(1 0) 10% (w/v) ammonium persulphate (prepared fresh)
(11) 1.5% (w/v) agar (Difco Laboratories,USA)
(12) Protein standards:
Protein Mol.wt. Source
Phosphorylase a 92,500 Rabbit muscle
(Boehringer Mannheim GmbH)
Bovine serum albumin 68,000 Grade IV
(Sigma Chemical Co.)
Catalase 60,000 Beef liver
(Sigma Chemical Co.)
Glutamate dehydrogenase 53,000 (Boehringer Mannheim GmbH)
Chicken egg albumin 43,000 Grade V
(Sigma Chemical Co.)
Creatinine phosphokinase 40,000 Rabbit muscle
(Sigma Chemical Co.)
Lactate dehydrogenase 36,000 Rabbit muscle, type IX
(Sigma Chemical Co.)
Cytochrome c 11,700 Horse heart, type VI
(Sigma Chemical Co.)
Protein standards were prepared as O.lmg/ml in Buffer 4.
Method
Electrophoresis was carried out at room temperature in a vertical slab 
gel apparatus made in the Biochemistry Department workshop. . The gel was 
contained in a glass and perspex cuvette of internal dimensions 
120mmxl00mmx1.5mm. The perspex component of the cuvette was washed in 
detergent, rinsed in tap water and then distilled water and dried with 
tissue. The glass plates of the gel cuvette were treated similarly and in 
addition rinsed in methanol and then acetone and left to dry. The cuvette 
was assembled and sealed with 1.5% (w/v) molten agar and then clamped in a 
vertical position.
The lower (running) gel was prepared by mixing Buffer 1 (10ml), gel 
stock (13.3ml) and water (16.6ml). Polymerization was initiated by the
addition of TEMED ammonium persulphate solution • The
solution was poured into the glass cuvette to a height of 80mm. In order 
to ensure a flat interface between the running gel and the stacking gel a 
layer of distilled water was introduced above the running gel mixture.
When polymerization was complete the water layer was removed.
The upper (stacking gel) was prepared by mixing Buffer 2 (2.5ml), gel 
stock (1.0ml) and water (6.5ml). Polymerization was initiated by the 
addition of TEMED (20^1) and ammonium persulphate solution (60^ il) and the 
mixed gel was added to the cuvette above the running gel. A perspex comb 
was introduced into the stacking gel before polymerization to form the 
sample wells. When the polymerization was complete the comb was removed 
and a small amount of Buffer 3 was introduced into the sample wells to keep 
them separate. The lower spacer was removed from the cuvette and the 
cuvette was then placed in the electrophoresis tank. Buffer 3 was added to 
the upper and lower reservoirs, and air bubbles trapped underneath the gel. 
were removed using a syringe.
Microsomal suspensions were diluted to a final concentration of lmg
protein/ml in sample buffer (4) and placed in a boiling water bath for 3
minutes. After cooling the samples were introduced into the sample wells 
with a 25jjl Hamilton glass syringe. The amount of protein applied was
10-20^ tg. A constant current of 20mA was applied until the bromophenol blue
entered the running gel whereupon it was increased to a constant current of .
40mA. When the bromophenol blue was within 5mm of the end of the gel the
electrophoresis was stopped and the cuvette removed from the tank. The
glass plates were separated and the gel removed for staining.
The gels were immersed overnight in the Coomassie blue stain. . The gel 
background was destained by immersing in progressive changes of destaining
solution over a period of 48 hours. The gels were stored in 3% glycerol at
4 ° once the background was cleared.
2.2.15 Hepatic DNA and RNA
Nucleic acid present in liver homogenate is solubilised by treatment 
with perchloric acid at 70°. DNA can be determined by its reaction with 
diphenylamine in acid solution (Dische reaction) giving a blue colour
(Burton,1956). RNA is determined colo rimetrically after reaction of its
ribose component with orcinol (Munro and Fleck,1966).
2.2.15.1 Solubilization of hepatic nucleic acids
To 2.55ml of liver homogenate (25%) 0.45ml of 3.3M perchloric acid was 
added. The samples were incubated at 70° for 30 minutes to solubilize 
nucleic acids. Samples were centrifuged and the supernatant ('hot PCA 
extract') was retained for DNA and RNA estimation.
2.2.15.2 DNA
Reagents
(1) 0.5M perchloric acid
(2) Burton reagent: Glacial acetic acid (500ml) + concentrated sulphuric
acid (7.5ml) + diphenylamine (7.5g). Reagents were mixed carefully and 
stored in a brown glass bottle at room temperature.
(3) 1.6% (w/v) acetaldehyde: stored at 4°
(4) Mixed Burton reagent: (prepared fresh) 20ml Burton reagent plus 0.1ml
1.6% (w/v) acetaldehyde
(5) DNA standard: lOO^g DNA/ml in 0.5M perchloric acid. This was heated
at 70° for 30 minutes and 0 to 1.0ml used for a standard curve. DNA was 
obtained from BDH Ltd.
Method
Duplicate 0.2ml aliquots of the 'hot PCA extract' were placed into 
test tubes and made up to 1.0ml with 0.5M PCA. Mixed Burton reagent. 
(2 .0ml) was added, the tubes covered with parafilm and left .standing at 
room temperature in the dark for 18-48 hours. Blanks and standards were 
treated similarly. The blue colour was measured at 600nm in a Gilford 250 
spectrophotometer. A standard curve was constructed and the DNA content of 
the 'hot PCA extracts' determined.
2.2.15.3 RNA
Reagents
(1) 20% (w/v) orcinol in 95% ethanol (prepared daily)
(2) 0.03% (w/v) FeClg in concentrated HC1
(3) Standard RNA: lOOyag RNA/ml in 0.05M NaOH (0-1.5ml used for the
standard curve). RNA was obtained from BDH Ltd.
(4) 0.05M NaOH 
Method
Duplicate 0.1ml aliquots of 'hot PCA extract' were placed into test 
tubes and made up to 1.5ml with distilled water. This was followed by 
0.03% FeClg (1.5ml) and 20% orcinol (0.1ml). The tubes were mixed 
thoroughly and placed in a vigorously boiling water bath for 30 minutes. A 
blank and set of standards were treated similarly. Glass marbles were 
placed on the top of the test tubes while boiling to prevent volume loss.
The tubes were cooled in an ice water slurry.
The red colour was read at 655nm in a Gilford 250 spectrophotometer.
A calibration curve was constructed and the RNA content of the 'hot' PCA 
extracts determined.
2.2.16 Determination of hepatocyte size
Hepatocyte size was determined following their isolation by the method 
of Fry et al.(1976).
Reagents
(1) Phosphate buffered saline 'A' (PBS'A'):
NaCl (8 .00g)
KC1 (0.20g)
KH2P0  ^ (0 .20g)
Na2HP0^ .12H20 (2.98g)
Phenol red (0.0lg)
The above were dissolved in 1 litre of distilled water.
(2) Hanks B.S.S. (-Ca++and -HC0“):
NaCl (8 .OOg)
KC1 (0.40g)
KH2P0  ^ (0.06g)
Na2HP0^.2H2 0 (0.06g)
Glucose (l.OOg)
Phenol red (O.Olg)
The above were dissolved in 1 litre of distilled water.
(3) Culture medium: Leibowitz L-15 medium supplemented with 10% foetal 
calf serum and penicillin/streptomycin (lOOi.u. and 100 g/ml respectively) .
(4) 250mM CaCl'2
(5) 0.5mM EGTA
(6) 2.8% (w/v) NaHCO^
(7) Collagenase (Sigma Type I)
(8) Hyaluronidase (Sigma Type II)
(9) 0.4% Trypan blue solution
Method
(1) The rat was killed, the abdomen swabbed with 70% alcohol and opened.
The liver pieces were excised and placed in a beaker containing PBS'A'
(2) Each liver was then briefly blotted on filter paper and placed on a 
fresh sheet of filter paper supported on a glass plate. A disposable 
microtome blade (British American Optical Co., Slough) was used to slice 
the liver. Each new blade was first degreased by wiping it.over with 
carbon tetrachloride followed by 70% alcohol and finally PBS'A'. The liver 
pieces were sliced to obtain slices approximately 0.5mm thick. The slices 
were placed in a petri dish containing 10ml PBS'A'.
(3) When all the pieces had been sliced, the slices plus PBS'A' were
transferred to a 250ml conical flask which was then shaken for 10 minutes
at 37° (approx. 100 oscillations per minute).
(4) The flask was removed from the water bath, left for a few seconds (to ' 
allow the slices to settle) and the medium carefully removed with a pasteur 
pipette. Fresh PBS'A' (10ml) was then added to the flask-which was 
reincubated as above.
(5) Step 4 was repeated once
(6) After these washes the slices were incubated as described above (10 
minutes shaking at 37°) in 10ml PBS'A' containing 0.5mM, EGTA
(7) Step 6 was repeated once
(8) While the slices were being subjected to EGTA treatment collagenase 
(5mg) and hyaluronidase (lOmg) were weighed into the same container. To . 
these enzymes 10ml Hanks B.S.S (-Ca++ and -HCO^ ) was added. When the 
enzyme was dissolved, 0.2ml of 250mM CaCl2 was added and sufficient 2.8% 
NaHCOg to bring the pH to approximately 7.5 (as shown by the phenol red 
indicator). The enzyme solution was then ready for use.
(9) When step 7 was completed the EGTA solution was carefully removed and 
replaced with enzyme solution. The flask was then shaken for 1 hour at
(10) At the end of this time the cloudy suspension was passed through a 
single layer of Bolting cloth ("Nybolt", 125yjm pore size. ' British agents: 
John Staniar and Co., Sherbourne Street, Manchester, M3 IFD) into a beaker. 
The slices remaining in the flask received 5ml fresh PBS'A' and the whole 
was gently swirled to loosen any extra cells. The solution and slices were 
then placed and the slices were gently agitated on the cloth with a Pasteur 
pipette to complete the cell dissociation.
(11) The cell filtrate was transferred to a 50ml glass centrifuge tube 
which was then spun at 50gQV for 1 minute.
(12) The supernatant was carefully removed and discarded and 10ml fresh 
PBS'A' was pipetted onto the pellet and once sucked up and down the pipette 
to disperse the cells.
(13) Steps 11 and 12 were repeated twice
(14) The cell pellet was finally resuspended in 10ml culture medium and 
after thorough mixing a 0.25 ml sample was mixed with 0.1ml of 0.4% trypan 
blue solution and the yield and viability determined with -an improved 
Neubauer counting chamber. The cell suspension was then ready for use.
Cell yield = cell count x 7/5 x 10^ cells per ml
%viability = No. of viable cells x 100 / Total No. of cells
(15) Hepatic size was determined under the microscope using a graticule 
eyepiece, calibrated so that 100 divisions was equivalent to 0.25mm (1 
division = 2*5ji)
2*2.17 Hepatic glycogen
The determination of hepatic glycogen was based on the method of 
•Keppler and Decker (1974). Liver homogenate was treated with perchloric 
acid and the protein removed by centrifugation. The resulting supernatant 
was incubated with amyloglucosidase releasing free glucose from the 
glycogen. Free glucose was converted to glucose-6-phosphate with 
hexokinase and ATP and thence to 6-phosphogluconate with
glucose-6-phosphate dehydrogenase. This latter conversion produced reduced 
NADP which was followed spectrophotometrically at 340 nm.
Reagents
(1) 0.6M Perchloric acid (PCA)
(2) 1.0M Potassium bicarbonate
(3) 0.3M Triethanolamine buffer pH 7.5 containing 4mM MgSO^
(4) 0.2M Acetate buffer pH 4.8
(5) Amyloglucosidase: 50mg/ml Agidex in acetate buffer (prepared daily)
(BDH Ltd.)
(6 ) 12mM NADP
(7) 15mM ATP
(8 ) Hexokinase / Glucose-6-phosphate dehydrogenase (Sigma Chemical Co.Ltd.) 
Method
An aliquot (0.5ml) of liver homogenate (10%) was thoroughly 
homogenised with 5 volumes of ice cold 0.6M perchloric acid. Immediately 
after homogenisation 0 .2ml of homogenate was pipetted into a test tube.
This was neutralised by the addition of 1M KHCOg (0.1ml). Amyloglucosidase 
suspension in buffer (2ml) was added and the tube incubated in a Mickle 
shaking water bath at 37° for 2 hours. The rate of shaking was kept
constant at 60 cycles per minute.
The reaction was stopped with PCA (1.0ml) and the precipitate removed 
by centrifugation at 2,500rpm for 15 minutes in an M.S.E. bench 
.centrifuge. An aliquot (0.2ml) was used for glucose determination.
A sample blank was prepared by omitting homogenate and replacing it 
with 0.6M PCA. An enzyme blank was prepared by centrifuging 0.5ml of 
homogenate (10%) with 5 volumes of ice cold 0.6M PCA. This was neutralised 
with solid KHCO3 , centrifuged and an aliquot of supernatant (0.2ml) taken 
for glucose determination.
The incubation mixture for the glucose determination consisted of: 
Triethanolamine buffer (2.5ml)
Sample (0.2ml)
12mM NADP (0.1ml)
15mM ATP (0.1ml)
The reaction was started by the addition of 10^ *1 of hexokinase /
glucose-6-phosphate dehydrogenase. The absorbance was read at 340nm at
o
time 0 and after 15 minutes incubation at 30 . A blank was prepared by 
replacing sample with buffer.
2*2.18 Progesterone release from silicone implants
Progesterone release, from silicone rubber implants (see 2.2.5.3), was 
determined according to the method of Symons et al. (1974).
Method
Silicone implants were removed from experimental animals on death, 
washed briefly with 0.9% (w/v) NaCl (isotonic saline) and then placed into 
conical flasks with 15ml isotonic saline. The flasks were shaken (100 
oscillations/minute) in a Mickle shaking water bath at 37°. Every 24 hours 
for 3 days the saline was replaced and the progesterone concentration in 
the old saline determined. Extinction values at 250nm were determined 
using quartz cuvettes in a Gilford 250 spectrophotometer and compared to 
those obtained with a range of progesterone standards in saline 
(0-100|jg/L). Saline samples were diluted as necessary to-bring the 
solution within the range of the progesterone curve.
Progesterone release from unused autoclaved silicone implants was also, 
determined. These were shaken at 37° for 21 days in saline which was 
changed at 24 hour periods.
2.2.19 Liver histology
•2.2.19.1 Tissue fixation, processing and section cutting 
Fixation
Pieces of tissue were fixed in 10% neutral buffered formalin for 
several days.
Formula for 10% neutral buffered formalin:
Formalin (40% formaldehyde) (100ml)
Sodium dihydrogen orthophosphate (Nal^PO^.21^0) (4.5g)
Anhydrous disodium hydrogen orthophosphate (Na2HP0^) (6.5g)
Distilled water (to 1 litre)
Processing
The tissue was embedded in paraffin wax by the following method:
A piece of liver 2-3mm in thickness was cut from each sample and 
placed in a metal processing container together with the appropriate 
reference number. The containers were placed in a tissue basket which was 
then fitted to a Histokinette automatic tissue processor. Tissues were 
transferred automatically from one beaker of fluid to the next and the 
processes of dehydration, clearing and impregnation with wax were carried 
out using the following processing schedule:
Dehydration
70% alcohol 1 hour
85% alcohol
95% alcohol
100% alcohol I
100% alcohol II
100% alcohol III
Clearing
Toluene I
Toluene II
Impregnation
Paraffin wax I at 58°
Paraffin wax II at 58(
1 hour 
1 hour 
1 hour 
1 hour 
1 hour
1 hour 
1 hour
1 hour 
1 hour
The melting point of the wax was 56 . After this process the tissue
containers were transferred to a vacuum embedding oven containing paraffin'
o
wax at a temperature of 58 for 1/2 hour. This acted as a third wax bath 
and the reduced pressure aided impregnation by ensuring that any remaining 
air bubbles and clearing agent were removed. The tissue was blocked out by 
removing it from the container using a pair of electrically heated forceps 
and placing it in a plastic mould filled with molten wax. The tissue was 
orientated so that the surface to be cut rested on the base of the mould.
A plastic block was placed in the mould with the reference number label.
Section cutting
Sections were cut from the blocks at a thickness of 7yu using an 
American Optical Spencer 820 Rotary microtome. The sections were floated 
on distilled water at a temperature of 50° until the creases disappeared. 
The sections were mounted on slides by half submerging a clean slide into 
the water near the section and withdrawing it, so bringing the flattened
section with it. The slides were placed initially on a drying hot plate 
and then left in an incubator at a room temperature of 37° overnight to 
dry •
Sections prepared in this way were stained with Haematoxylin and Eosin 
or by the Periodic acid-Schiff (P.A.S) technique.
2.2.19.2 Tissue staining with Haematoxylin and Eosin
Sections prepared in 2.2.19.1 were stained with Ehrlich's acid 
haematoxylin (obtained from R.A.Lamb Ltd) and eosin (colour index No.45380 
obtained from R.A.Lamb Ltd.).
Slides were placed in:
(1) Xylene to remove wax (2 minutes)
(2) Absolute alcohol (1 minute)
(3) 70% alcohol (1 minute)
(4) 50% alcohol (1 minute)
(5) Distilled water (rinse)
(6) Ehrlich's acid haematoxylin (15 minutes)
(7) Tap water (5 minutes)
(8) Differeniated in acid alcohol (1% HC1 in 70% alcohol) by agitating (5. 
seconds)
(9) Returned to tap water
(10) Examined under low power microscope to ensure the sections were 
sufficiently differentiated
(11) Tap water (15 minutes)
(12) Counterstained in 1% aqueous Eosin (2 minutes)
(13) Rinsed in tap water (1/2 minute)
(14) Dehydrated in 85% alcohol (1/2 minute)
(15) Dehydrated in 100% alcohol (1/2 minute)
(16) Dehydrated in 100% alcohol (1/2 minute)
.(17) Cleared in xylene (1/2 minute)
(18) Cleared in xylene (1/2 minute)
The sections were mounted in D.P.X. (B.D.H Ltd.) by placing a drop 
of the mountant on a clean coverslip and pressing gently so that the
mountant spread under the coverslip. Slides were examined at
magnifications of x40, xlOO and x400 using a Vickers M15c microscope.
Using this stain the nuclei appeared blue and the cytoplasm pink.
2.2.19.3 Periodic acid-Schiff (P.A.S) staining technique
This technique was used to stain for liver glycogen. The reaction was . 
based on the fact that certain tissue elements were oxidised by periodic 
acid producing aldehydes which were then demonstrated with Schiff reagent.
Periodic acid cleaves C-C bonds where these carbon atoms have adjacent 
hydroxyl (-0H) groups or adjacent hydroxyl and amino groups.
Glycogen can be distinguished because it is selectively digested by enzymes 
(diastase, amylase or 'saliva') into smaller water soluble molecules which 
can be removed by washing.
Method
Liver sections prepared in 2.2.19.1. were immersed in water and taken 
through the following procedure:
(1) Oxidised in 1% periodic acid (5 minutes)
(2) Washed in gently running water (5 minutes)
(3) Rinsed in distilled water
(4) Treated with Schiff reagent (Feulgen reagent obtained from R.A.Lamb 
Ltd.) (15 minutes)
(5) Washed in gently running water (10 minutes)
(6) Counterstained lightly with 1% light green (alcoholic) (colour index 
42095, obtained from R.A.Lamb Ltd.) (5-10 seconds)
(7) Dehydrated in 100% alcohol (1/2 minute)
(8 ) Dehydrated in 100% alcohol (1/2 minute)
(9) Cleared in xylene (1/2 minute)
(10) Cleared in xylene and mounted in D.P.X. (1/2 minute)
Result
P.A.S. positive substances : bright pink
Other tissue constituents : pale pink
The P.A.S. technique, when used to detect glycogen, included a diastase 
control.
Control slide
(1) Immersed in water
(2) Incubated at 37° in 0.1% diastase (obtained from R.A.Lamb Ltd.) (30 
minutes)
(3) Washed in running water (5 minutes)
Control and experimental slides were taken through the P.A.S. procedure 
simultaneously.
2.2.19.4 Oil Red 0 staining technique for lipids
This technique was based upon the fact that Oil Red 0 was more soluble 
in tissue lipids than in the solvent system used.
Reagents
(1) Staining solution: A saturated solution of oil red 0 (0.25-0.5%) in 
propan-2-ol was prepared as a stock solution. For use stock solution (6ml) 
was diluted with distilled water (4ml) and allowed to stand for 5-10 
minutes. The stain was filtered and used within 1-2 hours. Oil red 0 
(colour index 26125) was obtained from R.A.Lamb Ltd.
(2 ) 60% (v/v) alcohol
(3) Harris's Haematoxlin (obtained from R.A.Lamb Ltd.)
(4) Acid alcohol: 1% HC1 in 70% alcohol
(5) Borax: saturated aqueous sodium tetraborate
Method
Liver tissue was fixed (see 2.2.19.1), frozen and cut to lOyu on a 
Reichert sledge microtome. Sections were stained using the following 
procedure:
(1) Washed well in water
(2) Placed in stain in a sealed container for 10-15 minutes
(3) Rinsed in 60% alcohol to clear background
(4) Washed in tap water
(5) Nuclei stained lightly in Harris's haematoxylin (2 minutes)
(6) Washed in water
(7) Differentiated in acid alcohol (2 or 3 quick dips)
(8) Washed in water
(9) Blue-ed in borax for 10 seconds (colour intensity checked 
microscopically)
(10) Washed in tap water
(11) Mounted in glycerin jelly 
Results
Lipids stained bright red and nuclei stained blue.
2.2.19.5 Calculation of hepatic mitotic index
Liver sections stained with Haematoxylin and Eosin were, observed at 
magnification of x200 using a Vickers M15c microscope with a graticule 
eyepiece. The number of mitoses were counted in 40 grids (approximately
12.000 cells). The grid was moved across the whole section avoiding larg 
vessels. The mitotic index was expressed as the number of mitoses in
10.000 cells.
2.2.20 Progesterone radioimmunoassay (RIA)
r
Progesterone was determined by a radioimmunoassay developed by the 
Epsom Hospital Laboratories (West Park Hospital, Epsom, Surrey).
Reagents
(1) Assay buffer: pH 7.0:
0.1mol/l phosphate buffer
lg/1 gelatine powder (BDH Ltd.) 
lg/1 sodium azide (BDH Ltd.)
The ingredients were dissolved in distilled water (gentle warming in 45° 
water bath) and made up to 11 when cool. The assay buffer was stored at 
4°.
(2) Charcoal suspension: l«75g Norit A charcoal (Sigma Chemical Co. Ltd.)
was dissolved in 250ml assay buffer in a bottle containing a 'Teflon' 
coated stirring magnet. The contents were stirred for 2 hours and stored 
at 4°. A 24-hour equilibrium period was allowed after preparation before 
using the suspension for the first time. The suspension was. mixed well 
before use and stirred continuously while dispensing.
(3) Liquid scintillation solution: 5g PPO (2,5-diphenyloxazole), 0.5g 
DMPOPOP (l,4-di-2- (4-methyl-5-phenyl oxazolyl) benzene) amd 330ml of 
metapol (Durham Chemical Distributors) were made up to 1 litre with 
toluene.
(4) Petroleum spirit, 40-60° :(BDH Ltd., AR grade)
(5) Standards (in absolute ethanol): A stock solution of progesterone
(2mmol/l) was diluted in stages to 20nmol/L. A range of working standards
were prepared from this solution with concentrations 0, 1, 2, 4, 6, 10, 14,
o
20, 30 and 40nmol/l. All standards were stored at -20 .
3
(6) Tracer: (1, 2, 6, 7 - H) progesterone (specific activity 85
Figure 2.1 Progesterone radioimmunoassay standard curve
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The standard curve was produced using- a final antiserum dilution of 1/4000. 
The radioactive tracer final dilution was 1/4OO. The percentage of 
total counts bound (in the 0 pmol progesterone standard tube) was None
specific binding was<5$-
curies/mmol, obtained from The Radiochemical Centre, Amersham) was diluted 
to a radioactive concentration of 50mCi/L with the same solvent as already 
present. This was stored as a stock solution at -20° in its original 
container. A working solution (1/200 dilution of the stock solution) was 
prepared by drying down an aliquot of stock solution under N£ for a minimum 
time and redissolving immediately in assay buffer.
(7) Antiserum: (Guildhay Antisera HP/S/53-IIA, from the Division of
Clinical Biochemistry, University of Surrey, Guildford, England). Neat 
antiserum was stored at 4°. An aliquot of neat antiserum (lOOjul) was 
diluted to 5ml in assay buffer to give a dilution factor of 50. This stock 
solution was stored at 4°. The working antiserum solution (1/2000 dilution 
of the stock solution) was prepared freshly for each assay batch by 
diluting an aliquot of stock.
(8) Controls: Within bath and between batch duplication was checked with a
series of serum controls.
Method
(1) Water blanks were prepared by pipetting 20jjl distilled water (in 
duplicate) into clean 12x75mm glass tubes.
(2) An aliquot (20jul) of the serum sample was pipetted (in duplicate) into 
clean 12x75mm glass assay tubes. Dilutions of the original serum sample 
were sometimes required depending on the source of the sample.
(3) Petroleum spirit (2ml) was added to the tubes which were sealed with 
polythene caps.
(4) Progesterone was extracted for 15 minutes on an orbital shaker (Luckman 
Ltd.) at maximum speed. Care was taken to ensure that the contents of the 
tube did not come into contact with the polythene caps. After shaking the 
tubes were allowed to stand for 5 minutes.
(5) The organic layer was carefully decanted into another clean 12x75mm
Figure 2'. 2 Progesterone antiserum dilution curve
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Line A: Antiserum dilution curve with a 1/400 final dilution of tritiated 
progesterone in the absence of cold progesterone.
Line B : Antiserum dilution curve in the presence of cold progesterone 
(2 pmoles / assay tube)
glass tube (the aqueous layer remained adhering to the original tube 
without the need for freezing).
(6) The petroleum spirit was dried under N 2 at 45° in a fume cupboard for a 
minimum of time.
(7) Standards (lOOjxl) were pipetted (in duplicate) into clean 12x75mm glass 
tubes, giving a range of 0, 0.1, 0.2, 0.4, 0.6, 1.0, 1.4, 2.0, and 
3.0pmol/tube. These were dried under N£ at 45° for a minimum time.
(8) Duplicate 'total' 12x75mm glass assay tubes were prepared containing 
400jj1 assay buffer.
(9) Duplicate 'Norit Blank' 12x75mm glass assay tubes were prepared 
containing 200yul assay buffer.
(10) Working tracer solution (200yml) was added to all tubes.
(11) Working antiserum solution (200yul) was added to all tubes except the
'total' and 'Norit blank' tubes.
(12) All tubes were vortexed thoroughly.
(13) The tubes were then incubated for 30 minutes at 37° and then overnight
at 4°.
(14) To all assay tubes except the 'totals' 200^1 of stirred charcoal 
suspension was quickly added. The tubes were vortexed quickly.
(15) The tubes were left in ice-water for 10 minutes followed by 
centrifugation at 2500rpm for 5 minutes at 4°.
(16) The tubes were returned to the ice-water bath and 400yul of the 
supernatant transferred to polythene counting "mini vials" (G.D.Searle and 
Co.Ltd.).
(17) Liquid scintillation solution (4.2ml) was added, the tubes capped and 
shaken and placed inside glass counting vials. The tubes were allowed to 
equilibrate for 30 minutes before counting for 10 minutes. Counting was 
performed in an LKB Ultra beta liquid scintillation counter.
(18) Serum progesterone levels were determined from a calibrated curve
. f  *
(Figure 2.1). The calibration curve shows the percentage of zero counts 
bound (ie. the 0 pmol progesterone standard = 100% and other standards 
were expressed as a percentage of this) against pmol progesterone/assay 
tube. The progesterone concentration in the original specimen (nmol/1) 
50x amount found (pmol) for undiluted specimen. The avidity of the 
progesterone antiserum is shown in an antiserum dilution curve (Figure 
2 . 2).
Formal cross reaction of Antiserum HP/S/53-IIA with steroids
Formal cross reaction was measured at 'half displacement' of the 
progesterone tracer from its zero standard level (data supplied by 
P.Butler, Equine Research Station, Suffolk).
Steroid Formal Cross Reaction
Progesterone 100
11-Deoxycorticosterone 0.43%
Corticosterone 0.5%
Cortisol 0.003%
Testosterone 0.06%
17$ -oestradiol <<0.0006%
Prednisolone <<0.009%
2.2.21 Microsomal protein
Microsomal protein was determined according to the method of Lowry et 
al. (1951), modified by Miller< (1959).
Reagents
(1) Copper reagent:prepared fresh by mixing, in order, 10% (w/v) sodium 
carbonate in 0.5M NaOH (20ml), 2% (w/v) aqueous Sodium Potassium Tartrate 
(lml) and 1% (w/v) aqueous Copper Sulphate (1ml).
(2) Folin-Ciocalte u Phenol Reagent (BDH Ltd.): diluted 1:6 for use
(3) Bovine serum albumin (Sigma Chemical Co.Ltd.): 250yug/ml in water
(prepared fresh)
Method
Microsomal suspension was diluted in water to give a protein 
concentration of less than 250^ug/ml (normally a final dilution of 160). 
Diluted microsomal sample (lml) was added to Copper Reagent (lml) and left 
for 10 minutes at room temperature. This was followed by diluted 
Folin-Ciocalte u Phenol reagent (3mls). The mixture was mixed immediately 
and incubated for 10 minutes at 50°. The tubes were cooled in iced water 
and the blue colour read at 540nm in a Gilford 250 spectrophotometer. 
Soluble blanks and standards (0-250^ ug bovine serum albumin) were taken 
through the same procedure.
2.2.22 Hepatic non-drug metabolising enzyme assays
2.2.22.1 Glucose-6-phosphatase (EC. 3.1.3.9)
This determination was based on the method of Noordlie and Arion 
(1966), developed in our laboratory by Curtin (1981).
Reagents
(1) Tris-maleate buffer 0.05M pH 6.7
(2) 175mM Glucose-6-phosphate
(3) 10% (w/v) Trichloroacetic acid (TCA)
(4) Acid ammonium molybdate: 2.5% (w/v) in 2.5M H 2SO4
(5) ANS Reducer: 1-Amino, 2-Napthol, 4-Sulphonic acid (0.2g) plus sodium . 
metabisulphite (12.Og), dissolved in 70ml distilled water at 40°. This was 
made up to 100ml after adding Na2S0  ^.7H 2O (2.4g)
(6) Standard phosphate: 0.324mM 
Method
Tris-maleate buffer (0.6ml), glucose-6-phosphate (0.2ml) and distilled 
water (0.6ml) were preheated to 37° in clean test tubes. Aliquots (0.1ml) 
of liver homogenate (diluted 1 in 10) were added and the tubes incubated 
for 10 minutes. The reaction was terminated by the addition of 10% (w/v) 
TCA (1.0ml) and the tubes were cooled on ice. Following centrifugation for 
10 minutes at 2,000rpm (M.S.E Bench Centrifuge) aliquots of supernatant 
(0.5ml) were transferred to clean test tubes together with distilled water 
(3.9ml), ammonium molybdate (0.4ml) and ANS Reducer (0.2ml). The 
absorbance was read after 10 minutes at 700nm in a Gilford 250 recording
spectrophotometer. Absorbances were compared with the absorbance of 
phosphate standards (2.0ml phosphate standard + 2.4ml distilled water + 
0.4ml ammonium molybdate + 0.2ml ANS reducer). A zero time blank was 
included for each sample.
2.2.22.2 Glucose-6-phosphate dehydrogenase (EC. 1.1.1.49)
The determination of Glucose-6-phosphate dehydrogenase was based on 
the method of Langden (1966), developed in our laboratory by Curtin (1981). 
The reduction of NADPH was followed at 340nm.•
Glucose-6-phosphate + NADP —  > *- 6-phosphogluconate + NADPH
Reagents
(1) 0.2M Tris-HCl pH 7.5
(2) 175mM Glucose-6-phosphate
(3) 75mM MgCl2
(4) lOmM NADP 
Method
The following was pipetted into clean 1cm micro cuvettes:
Sample Blank
Tris buffer 0.2M pH 7.5 200^1 220^1
175mM G6 P lOyul lOyul
75mM MgCl2 lOOyul 100yul
lOmM NADP 20yul
Sample: 10-20yul 
soluble fraction
in water 0.67ml 0.67ml
Total Volume 1. 0ml 1 • 0ml
The cuvette was placed in a Gilford 250 recording spectrophotometer
and the reaction was started by the addition of soluble fraction (10-20^ 1 ) 
and followed at 340nm for 5 minutes. Enzyme activity was calculated from
3
the gradient of the slope using an extinction coefficient of 6 .22x 10 
1/mol/cm for NADP.
2.2.22.3 NADP-specific malate dehydrogenase, "Malic enzyme” (EC 1.1.1.40)
The determination of malic enzyme activity was based on the method of 
Hsu and Lardy (1969) developed in our laboratory by Curtin (1981).
L-malate + NADP w Pyruvate + CO2 + NADPH
Reagents
(1) Triethanolamine buffer 0.2M pH 7.5
(2) lOmM Malate: neutralised to pH 7.4 with KOH
(3) 120mM MnCl2
(4) lOmM NADP 
Method
The following was pipetted into clean 1cm micro cuvettes:
pre-heated to 30°. The cuvette was allowed to warm to 30° for 5 minutes
Sample Blank
TEA buffer 0.2M pH 7.5 250/Jl 300^1
lOmM Malate 50jul
50/Jil 50/»l
50/41 50/vl
120mM MnCl2
lOmM NADP
Sample:
lOjal soluble fraction
in water 0 .6ml 0 .6ml
Total Volume 1.0ml 1.0ml
The cuvettes were placed in a Gilford 250 recording spectrophotometer
and allowed to warm to 30° for 5 minutes. The reaction was initiated by
the addition of soluble fraction (lOyul) and followed at 340nm for 5
minutes. Enzyme activity was calculated from the gradient of the slope
3
using an extinction coefficient of 6.22x10 1/mol/cm for NADP.
2.2.22.4 Glucokinase (EC 2.7.1.2) and Hexokinase (EC 2.7.1.1)
The determination of glucokinase/hexokinase was based on the method of 
Sharma et al.(1963) developed in our laboratory by Curtin (1981). Glucose 
is phosphorylated with ATP to glucose-6-phosphate. This is oxidised with 
NADP to 6-phosphogluconate and this is further oxidised with NADP to 3-keto 
6-phosphogluconate. Thus two moles of NADP are reduced for every mole of 
glucose phosphorylated. Both glucokinase and hexokinase can be determined 
since hexokinase is active at very low glucose concentrations.
Reagents
(1) Glycylglycine buffer 0.25M pH 7.5
(2) 75mM MgCl2
(3) 1.0M KC1
(4) 750mM glucose
(5) 3.75 mM glucose
(6) lOmM NADP
(7) lOOmM ATP
(8 ) Glucose-6-phosi>ate dehydrogenase (40i.u./ml) 
Method
The following was pipetted into four clean 1cm micro cuvettes: 
Total Hexokinase Glucose Control
„ dehydrogenase
(ml) (ml) (ml) (ml)
Glycylglycine 0.15 0.15 0.15 0.15
MgCl2 0.10 0.10 0.10 0.10
KC1 0.10 0.10 0.10 0.10
750mM glucose 0.10 — 0.10 —
3«75mM glucose — 0.10 — —
NADP 0.05 0.05 — —
ATP 0.05 0.05 — —
G6PDH 0.01 0.01 0.01 0.01
Sample: soluble
fraction (lOjul)
in water 0.19 0.19 0.24 0.34
Total Volume 0.75ml 0.75ml 0.75ml 0.75ml
The cuvettes were preincubated for 5 minutes at 30° in a Gilford 250
recording spectrophotometer. The reaction was initiated by the addition of
soluble fraction (10^ *1) and the reaction followed at 340nm. An extinction
3coefficient of 6.22x10 1/mol/cm for NADP was used.
2.2.22.5 Glutamate dehydrogenase (EC 1.4*1.2)
Glutamate dehydrogenase activity was assayed by the method of Herzfeld 
(1972), developed by Curtin (1981) in our laboratory.
2-oxoglutarate + NADH glutamate + NAD
Reagents
(1) 0.25M sucrose
(2) 1.75M ammonium chloride
(4) 1.0M phosphate buffer pH 7.5
(5) 3mM NADH 
Method
Liver homogenate (10%) was diluted in 0.25M sucrose 
to a final dilution of 1%. This was sonicated for 3x10 seconds using 
a sonicating probe (Type 1130/1A, Dawe Instruments Ltd., London). The 
following was pipetted into clean 1cm microcuvettes:
Sample Blank
Phosphate buffer 100/d 100/d
2-oxoglutarate 50/d 50/d
NH^Cl 200/d 200/d
NADH 50/d —
Distilled water 0.59ml 0.64ml
Sample:
(1% sonicated
homogenate) 10/..1 10/d
Total 1.00ml 1.00ml
The cuvettes were preincubated at 30° for 5 minutes in a Gilford 250 
spectrophotometer. The reaction was initiated by the addition of liver
3
sample (lOyul) and followed at 340nm. An extinction coefficient of 6.22x10 
1/mol/cm for NAD was used.
2.2.22.6 Aspartate aminotransferase (EC 2.6.1.1)
Aspartate aminotransferase activity was assayed by the method of 
Wergedal and Harper (1964) as developed in our laboratory by Curtin (1981).
Aspartate
aminotransferase
Aspartate + 2oxoglutarate ------------ ►  Oxaloacetate + glutamate
Malate dehydrogenase 
Oxaloacetate + NADH ------------------- ►  Malate +NAD
Reagents
(1) 0.25M sucrose
(2) 1M Tris-HCl, pH 7.6
(3) 60mM 2-oxoglutarate
(4) 0.8M L-aspartate
(5) 4mM NADH
(6) Malate dehydrogenase 5,000i.u./ml (Boehringer Mannheim GmbH)
Method
Liver homogenate (10%) was diluted 1 in 10 in 0.25M sucrose*
This was sonicated for 3x10 seconds using a sonicating probe
(Type 1130/1A, Dawe Instruments Ltd., London). The following was pipetted 
into clean 1cm microcuvettes:
Sample Blank
Tris-HCl pH 7.6 100/d. lOO/il
2-oxoglutarate 110/jl llO/il
L-aspartate lOOyul lOO/il
NADH 50/ul
Distilled water 0.62ml 0.67ml
Sample:
1% sonicated homogenate 10/j1 10/d.
Total 1.00ml 1.00ml
The cuvettes were preincubated at 30° for 5 minutes in a Gilford 250
recording spectrophotometer. The reaction was initiated by the addition of
3
sample (10/d.) and followed at 340nm. An extinction coefficient of 6.22x10 
1/mol/cm for NAD was used.
CHAPTER 3 HEPATIC DRUG METABOLISM DURING PREGNANCY AND POST-PARTUM
IN THE RAT
3.1 Introduction
Pregnancy induced changes in hepatic drug metabolism in the rat are 
well documented (see Chapter 1, 1.2.5). What is lacking is a clear 
explanation of the nature of the changes. These can only be evaluated by a 
characterisation of the mixed-function oxidase system during gestation.
This chapter will be concerned with the analysis of microsomal drug enzyme 
activity throughout pregnancy and the relationship between factors known to 
affect drug metabolism such as cytochrome P450 and microsomal 
phospholipids. In addition the relationship between liver weight changes 
and hepatic drug metabolism will be discussed.
The effect of pretreatment with inducing agents such as phenobarbitone 
and 3-methylcholanthrene has been examined as it may be helpful in 
understanding the processes involved in determining mixed-function oxidase 
activity in pregnancy. Similarly, a dietary supplement of choline may 
serve as a useful tool by which the relationship between microsomal drug 
metabolism and phospholipids could be evaluated. This has also been 
examined.
3.2 Experimental
(a) Body weight, liver weight, hepatic drug enzyme activities (Chapter 2, 
2.2.6), cytochrome P450 (Chapter 2, 2.2.8), cytochrome b5 (Chapter 2,
2.2.9) and microsomal protein (Chapter 2, 2.2.21) were determined in 
non-pregnant, pregnant (7, 15, 17 and 20 days) and post-partum (1 and 5 
days). NADPH-cytochrome c reductase activity (Chapter 2, 2.2.10) was 
determined in non-pregnant and pregnant (20 days) rats.
(b) Hepatic microsomal total phospholipids, phosphatidylcholine and 
phosphatidylethanolamine have been determined (Chapter 2, 2.2.13) in groups 
of non-pregnant, pregnant (15 and 20 days) and post-partum (1 and 7 days) 
rats.
(c) Hepatic DNA, RNA, lipid, glycogen, hepatic size and hepatic non-drug 
metabolising enzyme activities have been determined (Chapter 2) in the 
livers from non-pregnant and pregnant (20 days) rats. Liver sections from.
lo
these groups were analysed histogically (Chapter 2, 2.2.19).
(d) The effect of a choline supplemented diet on hepatic microsomal drug 
enzyme activity, cytochrome P450, cytochrome b5, protein and. phospholipids 
was determined in pregnant (20 days) and non-pregnant rats. Rats were fed 
on a 1% choline chloride diet for 19 days (Chapter 2, 2.2.5.5) and the 
results were compared with those obtained from pregnant (20 days) and 
non-pregnant rats maintained on a normal diet.
(e) The effect of inducing agents on hepatic drug metabolism in pregnant 
(20 days) and non-pregnant rats was investigated. Rats were injected i.p. 
with phenobarbitone (80mg/kg) or 3-methylcholanthrene (20mg/kg) for three 
days and killed 24 hours later (Chapter 2, 2.2.5). Control non-pregnant 
rats received saline or corn oil alone.
3.3 Results
3.3.1 Maternal body weight and liver weight changes during pregnancy and 
post-partum
During pregnancy, maternal liver weight and body weight increased 
significantly above non-pregnant control levels (Figure 3.1). This 
increase was greatest on day 20 of gestation when liver weight and body 
weight were elevated by 37% and 44% respectively. Following parturition 
there was a significant decrease in liver and body weight. In the 
post-partum rat (1 and 5 days) liver and body weights though declining were 
still significantly elevated above non-pregnant control levels.
3.3.2 Maternal hepatic drug metabolism during pregnancy
During pregnancy there was a progressive decrease in the activities of 
ethylmorphine N-demethylase, aniline js-hydroxylase and j)-nitrobenzoic acid 
reductase per gram liver (Figure 3.2). The largest decrease was found on 
day 20 of pregnancy (74%,73% and 53% of non-pregnant levels respectively). 
Enzyme activities were still significantly depressed 1 day
post-partum but had returned to non-pregnant control levels by 5 days 
post-partum. Microsomal levels of cytochrome P450 were not significantly 
different from non-pregnant control levels when expressed per milligram 
microsomal protein (Figure 3.4). Cytochrome b5 was significantly decreased
in the 7-day pregnant rat but unchanged at other time points (Figure 3.4).
When expressed per total liver (Figure 3.3), drug enzyme activities in 
the pregnant and post-partum rat were unchanged or increased above 
non-pregnant control levels with the exception of jD-nitrobenzoic acid 
reductase activity which was significantly reduced on day 20 of pregnancy 
and 1 day post-partum (Figure 3.3) Total hepatic cytochrome P450 and b5 
levels were significantly increased above non-pregnant control levels at 
all time points in pregnancy and post-partum (Figure 3.4).
Microsomal protein was significantly elevated above non-pregnant 
control levels on days 7 and 17 of pregnancy but unchanged at other time 
points (Table 3.1). NADPH-cytochrome c reductase activity was unchanged in 
the 20 day pregnant rat (46.3±2.5 S.E.M (n=4)yumoles cytochrome c reduced / 
gliver/ h ) compared to the non-pregnant rat (38.8±2.5 S.E.M. (n=4)yUmoles 
cytochrome c reduced / gliver / h ).
3.3.3 Maternal hepatic microsomal phospholipids during pregnancy and 
post-partum
Total phospholipids and phosphatidylcholine were significantly 
decreased and phosphatidylethanolamine significantly increased in the 15 
and 20 day pregnant and 1 day post-partum rat (Figure 3.5) compared with 
the non-pregnant control levels. These changes were greatest on day 20 of 
pregnancy when they represented 82%, 77% and 130% on non-pregnant control 
levels respectively. Microsomal phospholipids had returned to non-pregnant 
control levels by 7 days post-partum. The ratio of phosphatidylcholine to
phosphatidylethanolamine was significantly decreased during pregnancy and 1 
day post-partum but was unchanged at 7 days post-partum compared with 
non-pregnant control levels*
3*3*4 Liver biochemistry and histology in non-pregnant and pregnant 
(20 days) rats.
Hepatic DNA, RNA, lipid, glycogen, enzyme function and hepatocyte size 
were determined in pregnant (20 days) and non-pregnant rats (Table 3.2 and 
Figures 3.6, 3.7, 3.8). Hepatic DNA, RNA, total lipid, glycogen and 
hepatocyte size were unchanged on day 20 of pregnancy compared with 
non-pregnant control levels. These results were confirmed histologically 
by the similar appearance of the livers from the two groups using the three 
staining techniques: haematoxylin and eosin (Figure 3.6), periodic
acid-schiff (Figure3.7) and Oil red 0 (Figure 3.8). Mitotic activity was 
assessed histologically in non-pregnant and pregnant rats (Figure 3.9). A 
significant increase in the mitotic index was seen in early pregnancy.
This fell progressively to control levels by day 20 of gestation.
A number of non-drug metabolising enzymes were assayed in the livers 
from pregnant and non-pregnant animals (Table 3.2). Microsomal 
glucose-6-phosphatase activity was significantly decreased (to 61% of 
control values) in late pregnancy and aspartate aminotransferase 
(determined in the sonicated homogenate) significantly elevated to 131% of 
non-pregnant control levels.
3.3.5 The effect of a 1% choline diet on hepatic microsomal
monooxygenase activity and phospholipids in pregnant and non-pregnant rats.
A 1% choline diet had no effect on body weight, liver weight or 
general appearance of either the pregnant or non-pregnant rats. The 
activities of aniline ^ -hydroxylase, ethylmorphine N-demethylase and 
£-nitrobenzoic acid reductase are shown in Figure 3.10. Microsomal 
phospholipid levels are shown in Figure 3.11.
Pregnancy resulted in a significant decrease in total phospholipids 
and phosphatidylcholine and an elevation in phosphatidylethanolamine as 
discussed earlier (section 3.2.3). A dietary supplementation of choline 
increased the total phospholipid and phosphatidylcholine levels in pregnant 
rats to the level found in non-pregnant control animals while significantly 
decreasing the level of phosphatidylethanolamine. Similarly, non-pregnant 
rats receiving a choline supplemented diet showed significantly increased 
levels of phosphatidylcholine and decreased phosphatidylethanolamine but 
total phospholipid levels remained unchanged. This treatment resulted in a 
significant increase in the ratio between phosphatidylcholine and 
phosphatidylethanolamine from 3.0 and 1.8 in non-pregnant and pregnant rats 
to 4.9 and 6.2 in their choline fed counterparts.
Microsomal cytochrome P450, cytochrome b5 and microsomal protein 
levels are shown in Figure 3.12. All were unaffected by a dietary choline 
supplement.
3.3.6 The effect of inducing agents on hepatic microsomal drug metabolism
in pregnant (20 day) and non-pregnant rats
The effect of in vivo pretreatment with phenobarbitone and
3-methylcholanthrene on in vitro hepatic microsomal drug enzyme activity in 
the pregnant (20 days) and non-pregnant rat has been expressed per unit 
liver weight (Figure 3.13). Microsomal levels of cytochrome P450, 
cytochrome b5 and protein are shown in Figure 3.14. Phenobarbitone and
3-methylcholanthrene did not affect the liver or body weight of the 
animals•
Phenobarbitone pretreatment of pregnant and non-pregnant rats resulted 
in a statistically significant increase in aniline ^ -hydroxylase and 
ethylmorphine N-demethylase. The activity of j)-nitrobenzoic acid reductase 
was significantly increased in non-pregnant but not pregnant rats. 
Phenobarbitone pretreatment resulted in a significant increase in 
microsomal protein concentrations in both pregnant and non-pregnant 
animals. The level of cytochrome P450 was increased by phenobarbitone 
pretreatment in non-pregnant and pregnant rats. In addition cytochrome 
P450 levels in the phenobarbitone treated non-pregnant rats were 
significantly elevated above the levels found in phenobarbitone treated 
pregnant animals. Cytochrome b5 levels were unaffected by phenobarbitone 
treatment.
Pretreatment with 3-methylcholanthrene resulted in a significant 
increase in aniline j>-hydroxylase and ethylmorphine N-demethylase activity 
in pregnant and non-pregnant animals. The activity of £-nitrobenzoic acid 
reductase was unchanged. Microsomal cytochrome P450 was significantly
increased by 3-methylcholanthrene pretreatment in pregnant and non-pregjuant 
rats. Microsomal protein and cytochrome b5 remained unchanged.
The pregnancy associated decrease in hepatic drug enzyme activity was 
abolished by pretreatment with phenobarbitone and 3-methylcholanthrene. 
There were no significant differences in enzyme activities between 
non-pregnant and pregnant animals following inducer pretreatment.
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post-partum in the Wistar-albino rat.
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Figure 3.2 Hepatic microsomal mixed-function oxidase activity during
pregnancy and post-partum in the rat expressed per gram liver.
Values represent mean + SEM (n=4 or 8) for pregnant/post-partum
(•---•) and non-pregnant (•--- •) animals. Significant differences
(students ’t * test) between non-pregnant and pregnant/post-partum 
animals are shown as * p<0.05» ** p<0.01, *** p <0.001.
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Figure 3.3 Hepatic microsomal mixed-function oxidase activity during
pregnancy and post-partum in the rat expressed per total liver
Data from Figure 3*2 has been expressed as enzyme activity per total 
liver. Values represent mean + SEM (n=4 or 8) for pregnant/post-partum
(•---•) and non-pregnant (•---•) animals. Significant differences (students
•t’ test) between non-pregnant and pregnant/post-partum animals are 
shown as * p < 0.05> ** p<0.01, *** p <0.001.
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Figure 3»4 Hepatic microsomal cytochrome P450 a-nd b5 during pregnancy
and post-partum in the rat expressed per milligram protein (a) or per 
total liver (b).
Hepatic cytochrome P450 ( • ) and b5 ( A ) in pregnant/post-partum (----- )
and non-pregnant (----- ) rats has been expressed per milligram microsomal
protein (a) or per total liver (b).
Significant differences (students ‘t 1 test) between non-pregnant and 
pregnant/post-partum animals are shown as * p < 0.05» ** p<0.01,
*** p <  0.001 (cytochrome P450) and + p<0.05> ++ p<0.01, +++ p <  0.001 
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Figure 3.5 Microsomal phospholipid levels during pregnancy and
post-partum in the rat.
Values represent mean ±  SEM (n=4) for pregnant/post-partum 
and non-pregnant animals. Significant differences
17"
(students ' t 1 test) between non-pregnant and pregnant/post-partum 
animals are shown as * p < 0 .0 5 » ** p < 0 .0 1 , ** p< 0 .0 0 1 .
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Figure 3*6 Liver from non-pregnant (a ) and pregnant (20 days) (b ) rats
stained with Haematoxylin and Eosin. (Magnification x100)
Figure 3*7 Liver from non-pregnant (a ) and pregnant (20days) (B) rats
stained with Periodic acid-Schiff. (Magnification x100)
Figure 3*3 Liver from non-pregnant (a ) and pregnant (20 days) (b ) rats
stained with Oil Red 0. (Magnification x100)
(A)
Figure 3.9 Hepatic parenchymal mitotic indices in pregnant and
non-pregnant rats.
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Mitotic indices are expressed as the number of cells in division per 
counts of 10,000 cells. Values represent mean + SEM; n=3 (8 days 
pregnant), n=4 (non-pregnant, 17 and 20 days pregnant) and n=1 (14 days 
pregnant). Significant differences (students 't * test) between non­
pregnant and pregnant rats are shown as * p < 0.05» ** p<0.01, *** p<0.001.
ire 3.10 The effect of a choline supplemented diet (1$) on
atic microsomal mixed-function oxidase activity in pregnant 
days) and non-pregnant rats.
Normal diet
Non-pregnant (control)
Pregnant
ifo Choline diet
V Non-pregnant.
Pregnant
ues represent mean + SEM (n=4 except for pregnant animals fed on a 
line diet where n=3). Significant differences (students ft' test) 
ween control and test groups are shown as * p < 0.05> ** p<0.01,
p< 0.001.
ju
mo
le
s 
pr
od
uc
t 
fo
rm
ed
 
/g
 
li
ve
r 
/
h
Ethylmorphine (N-demethylation)10
9
8
7
6
T
5 T
4
~r T
*#
Aniline (ja-hydroxylation)
0.8 -
I X ~r T T _____
n-Nitrobenzoic acid (reduction)2 . 2  -I
Ixl
JC___AL
*** *** **#

Figure 3*11 The effect of a choline supplemented diet (1$) on hepatic 
microsomal phospholipids in pregnant (20 days) and non-pregnant rats.
Each point represents mean + SEM (n=4 except for pregnant rats on a 
choline diet where n=3) for total phospholipids, phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and the PGsPE ratio. Significant differences 
(students !t f test) between control and test animals are shown as
* p < 0.05, ** p<0.01, *** p <  0.001.
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Figure 3.12 The effect of a choline supplemented diet (1 tfo) on
hepatic microsomal cytochrome P45O, b5 and protein in pregnant
(20 days) and non-pregnant rats.
Normal diet
Non-pregnant (control)
Pregnant
1 ‘fo Choline diet
Non-pregnant
Values represent mean + SEM (n=4 except for pregnant animals fed on 
a choline diet where n=3). There were no significant differences 
between control and test groups.
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Figure 3.13 The effect of in vivo pretreatment with phenobarbitone
and 3-sethylcholanthrene on in vitro hepatic microsomal mixed-function 
oxidase activity in pregnant (20 days) and non-pregnant rats.
Animals were pretreated for three days prior to death with 
phenobarbitone (80mg/kg) or 3-methylcholanthrene (20 mg/kg).
Untreated non-pregnant control
Inducer pretreated non-pregnant
Inducer pretreated pregnant (20 days)
Values represent mean +. SEM (n=4). Significant differences (students 
1t 1 test) between control and pretreated animals are shown as 
* P<0.05, ** p<0.01, *** p<0.001.
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Figure 3.14 The effect of in vivo pretreatment with phenobarbitone
and 3-methylcholanthrene on in vitro hepatic microsomal cytochrome P450,
b5 and protein in pregnant (20 days) and non-pregnant rats.
Animals were pretreated for three days prior to death with pheno­
barbitone (80mg/kg) or 3-methylcholanthrene (20mg/kg).
Untreated non-pregnant control
Inducer pretreated non-pregnant
Inducer pretreated pregnant (20 days)
Values represent mean + SEM (n=4)* Significant differences (students ’t 1 
test) between control and pretreated animals are shown as * p<0.05> 
**p<0.01, *** p< 0.001. Significant differences between pretreated 
non-pregnant and pregnant animals are shown as + p < 0 .0 5 > ++ p<0.01,
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Table 3.1 Microsomal protein levels in non-pregnant, pregnant and 
post-partum rats
Days after conception
Microsomal protein (mg g liver) 
Non-pregnant Pregnant
7 20.1 +/-1.0 25.2 +/-0.8*
15 19.2 +/-1.1 21.8 +/-1.3
17 17.9 +/-1.0 25.4 +/-1.4*
20 22.5 +/-0.8 22.7 +/-1.0
Post-partum
22 (1 day post-partum) 21.8 +/-0.75 21.0 +/-1.1
26 (5 days post-partum) 22.7 +/-1.20 24.3 +/-0.9
Results are means +/- SEM (n=4 or 8). Significant differences (Students 
't' test) are shown as * p<0.05, ** p<0.01, ***p<0.001 between non-pregnant 
and pregnant rats.
Table 3.2 Liver biochemistry in pregnant (20 days) and non-pregnat ratjs
Non-pregnant Pregnant
DNA (mg/g liver ) 1.22.+/-0.04 1.23 +/-0.08
RNA (mg/g liver ) 32.6 +/-4.0 29.8 +/-2.2
Total lipid (mg/g liver ) 28.5 +/-3.7 26.9 +/-3.8
Glycogen (mg/g liver ) 16*2 +/—4.0 6.8 +/-2.5
Hepatocyte size (jj) 24.0 +/-0.2 25.8 +/-0.2
n-212 n=210
Glucose-6-phosphatase 
(IU/g liver )
13.3 +/-0.5 8.1 +/-0.3 ***
Glutamate dehydrogenase 
(IU/g liver )
49.4 +/-1.6 37.8 +/-5.3
Aspartate aminotransferase 
(IU/g liver )
93.4 +/-2.0 122.3 +/-6.2 **
1 .7ft 4-/-n.?J --- U_9O_+/-0.«-34---v J-LlLUrwX! 1 f"l w \ , —
(IU/g liver )
Hexokinase 
(IU/g liver )
0.25 +/-0.04 0.33 +/-0.04
Glucose 6 phosphate dehydrogenase 
(IU/g liver )
4.23 +/-0.53 2.98 +/-0.44
Malic enzyme 
(IU/g liver)
2.56 +/-0.21 2.52 +/-0.72
Values expressed are mean +/- SEM (n=4 unless otherwise stated). 
Significant differences (students 't' test) between non-pregnant and 
pregnant rats are shown as * p<0.05, ** p<0.01, *** p<0.001.
3.4 Discussion
Several workers have previously noted changes in hepatic drug 
metabolism during pregnancy (see Chapter 1). Most studies have been 
carried out at one or two time points and have not attempted to examine 
changes over the whole period of gestation. In the present work, three 
hepatic microsomal transformations Were measured at six time points during 
gestation and post-partum.
Mixed-function oxidase activity during pregnancy has been shown to 
depend upon the parameter to which activity was related (Figures 3.2 and 
3.3). Maternal liver weight was elevated by up to 40% during pregnancy 
(Figure 3.1), and enzyme activity expressed per unit liver weight (Figure 
3.2) was found to progressively decrease during pregnancy. This change was 
maximal at day 20 of gestation and 1 day post-partum but had returned to 
non-pregnant control levels by 5 days post-partum. The total capacity of 
the liver and thus the overall capability of the animal to metabolise drugs 
remained unchanged or even increased (Figure 3.3). This has been noted 
previously (Neale and Parke,1973; Schlede and Borowski,1974) though other 
investigators have reported that total hepatic mixed-function oxidase 
activity is decreased in late gestation (Dean and Stock,1975).
Pregnancy-induced alterations in mixed-function oxidase activity have 
been attributed to a decrease in the concentration of hepatic cytochrome 
P450 (Guarino et al., 1969a; Neale and Parke, 1973; Dean and Stock, 1975).
The present investigation does not support this hypothesis as the 
concentration of cytochrome P450 was unchanged during pregnancy and the 
total hepatic content of the haemoprotein was significantly elevated above
levels found in non-pregnant control rats (Figure 3*4)* This agrees with 
the findings of Gut et al. (1976) and Schlede and Borowski (1974). Contrary 
to the results presented (Figure 3.4) a number of investigators have 
reported a decrease in the concentration of hepatic cytochrome P450 during 
pregnancy (Guarino et aL, 1969a; Neale and Parke,1973; Dean and 
Stock,1975; Feuer and Kardish,1975; Tabei and Heinrichs,1976; Mukhtar et 
jaL, 1978). The reason for these contradictory findings is not clear though 
in the case of Tabei and Heinrichs (1976) and Mukhtar et al. (1978) the data 
presented actually reveals that the concentration of cytochrome P450 is 
unchanged in late gestation. The decrease in cytochrome P450 levels in 
late pregnancy reported by Guarino et al. (1969a) is also possibly erroneous
since control levels were abnormally high at this time point. In the case
u
of Neale and Parke (1973) some of their data show decreased and some 
unchanged microsomal concentrations of cytochrome P450 in pregnant compared 
to non-pregnant rats.
 :— The—pxesent work—a4so shows that—the decrease in hepat-i-e------- ;------
mixed-function oxidase activity during pregnancy was not related to 
NADPH-cytochrome c reductase activity or microsomal protein levels (Table
3.1).
Many workers have determined in vivo hexobarbital sleeping times 
during pregnancy. The significance of these as an indicator of in vitro 
hepatic mixed-function oxidase activity is questionable, particularly since 
the overall capacity of the liver to metabolise drugs is largely unchanged 
in pregnancy (Figure 3.3). Gut et al. (1976) suggested that the fate of 
hexobarbital administered in vivo is not determined by a change in 
microsomal enzyme activity, but rather by a changed drug distribution in 
which the foetuses act as a storage site of unmetabolised drug.
A discussion of the alterations in hepatic mixed-function oxidase 
activity during pregnancy must consider whether the increase in liver size 
found is due to hyperplasia (increase in cell number) or hypertrophy 
(increase in cell size). In addition, pregnancy-induced alterations in 
liver composition (eg. lipid and glycogen content) may also be important 
in quantifying any change in mixed-function oxidase activity per unit liver 
weight. Indicators of hepatic hypertrophy and/or hyperplasia have been 
discussed by Schulte-Hermann (1974). Hypertrophy is indicated by a 
decrease in DNA concentration, an increase in hepatic size and an increased 
proportion of cytoplasmic to nuclear area. Hyperplasia, in contrast, is 
marked by an increase in total hepatic DNA but unchanged DNA concentration, 
an elevation in the rate of DNA synthesis or in mitotic activity. An 
agreement of biochemical and histological findings is of particular 
importance since none of the individual procedures can prove the existence 
of parenchymal hyperplasia or hypertrophy or permit an estimate of the 
quantitative contributions of these cellular changes to the overall liver 
enlargement-.  ----------------------------------------   — -— ---
The appearance of the maternal liver in late pregnancy was similar to 
that of the non-pregnant rat (Figure 3.6). There was no evidence of lipid 
or glycogen accumulation or depletion histologically (Figures 3.7 and 3.8) 
or biochemically during pregnancy (Table 3.2), which is in agreement with 
the findings of Herrera et al. (1969), who reported in addition that hepatic 
concentrations of water and protein were unchanged in late gestation. In 
contrast to these results Campbell and Kosterlitz (1949) suggested that a 
large proportion of hepatic weight increase in the pregnant rat could be 
accounted for by a fractional increase in the content of water, 
phospholipids, protein and RNA. Reports of hepatic lipid concentrations 
during pregnancy have been contradictory. The concentration of
triglyceride has been reported to be increased (Smith and Walsh,1978) or 
decreased (Montes et al.,1978) while phospholipid is decreased (Dhami et 
al., 1979) or unchanged (Smith and Walsh, 1975; Hererra, 1969) •
Liver RNA concentrations were unchanged in late gestation (Table 3.2) 
confirming earlier work by Ekholm et al. (1972). Contrary to this finding 
increased hepatic concentrations of RNA during gestation have been reported 
(Campbell et_aL,1974; Campbell and Kosterlitz,1949)•
The lack of change in hepatic morphology, DNA concentrations and 
hepatocyte size during pregnancy (Table 3.2) together with evidence of 
raised mitotic activity (Figure 3.9; Campbell et aL, 1974; Desser-Weist 
and Desser, 1977) are indicative of parenchymal hyperplasia. A similar 
conclusion was reached by Penzes (1961) and Campbell et al. (1974) and is 
supported by the work of Kelly (1951) who found an increase in hepatic 
nucleic acid turnover during pregnancy. After parturition, the significant 
dec.r-e.ase in hepatic weight—appea-rs to-be due—t-o-parenchymal death-and—lysi-s- 
(Campbell et al., 1974). Maternal liver weight was still significantly 
elevated in the 5 day post-partum non-lactating rat (Figure 3.1) and has 
been reported to decline to control levels by one month after parturition 
(Poo et al., 1939; Schwenck and Joachim, 1961). The increase in liver size 
during pregnancy appears to be predominantly a consequence of parenchymal 
hyperplasia. This implies that mixed-function oxidase activity during 
pregnancy is decreased as a consequence of a decrease in hepatocellular 
capacity to metabolise drugs and represents a real rather than an apparent 
change in microsomal function.
It has been suggested that pregnancy imposes a selective effect on the 
hepatic endoplasmic reticulum (Feuer and Kardish,1975). In the present
study a number of microsomal and non-microsomal non-drug metabolising 
enzymes were measured in pregnant (20 days) and non-pregnant rats (Table
3.2). It is difficult to conclude from these results that there is a 
selective effect of pregnancy on the microsomal enzymes as described by 
Feuer and Kardish (1975).
Any interpretation is complicated since an enzyme activity may alter 
as a response to either the metabolic requirements of pregnancy £r to a 
change in the structure and function of a cellular component. Many 
non-microsomal enzymes have been shown to have an altered activity during 
pregnancy (Campbell et aL, 1972; Song and Kappas,1968; Parvez et al., 1975).
Pregnancy-induced changes in mixed-function oxidase activity appear to 
be part of a general alteration in microsomal function. A number of other 
microsomal enzymes are decreased in activity during gestation. These 
include glucuronyltransferase (see Chapter 1, 1.2.5), glucose-6-phosphatase
(Table 3.2, Feuer and Kardish,1975) and phosphatidylethanolamine___________
S-methyltransferase (Feuer and Kardish,1975).
Alterations in enzyme activity in the endoplasmic reticulum during 
pregnancy may be associated with changes in membrane phospholipids. The . 
importance of microsomal phospholipids to mixed-function oxidase activity 
has been discussed (see Chapter 1, 1.1.7). The results presented in Figure 
3.5 show marked changes in microsomal phospholipid composition paralleling 
changes determined in drug metabolism during pregnancy and post-partum 
(Figure 3.2). Phospholipids are important in substrate binding 
(Narasimhula,1977) and electron transfer to cytochrome P450 (Duppel and 
Ullrich,1976). The lipid bilayer is probably responsible for holding the 
haemoprotein and NADPH-cytochrome P450 reductase in a functional complex.
Guengerich and Coon (1975) have shown that phosphatidylcholine, the 
predominant membrane phospholipid, lowered Ks and Km for benzphetamine and 
inceased AAmax and Vmax for its metabolism. In addition, the substrate 
induced conformational change of cytochrome P450 may be regulated by 
phospholipids (Tsong and Yang,1978). These authors investigated the 
molecular basis of the spectral and spin-state changes of cytochrome P450 
by a temperature jump technique. It was found that the relaxation times of 
cytochrome P450 (which reflects conformational changes of the enzyme after 
substrate binding) were greater in microsomal fragments than after 
haemoprotein purification. This was attributed to the presence of 
phospholipid which significantly increased the rate of substrate induced 
conformational changes of the haemoprotein spin-state. It was suggested 
that phospholipid provides an environment for haemoprotein conformational 
changes to occur. This requirement for phospholipids has been reported 
before (Eletr et aL, 1973; Fiehn and Hasselbach,1970).
A link between microsomal phospholipids and mixed-function oxidase 
activity has been clearly established although the mechanism, of interaction 
is more obscure. Alterations in drug metabolism during pregnancy are 
possibly as a consequence of the changes occuring in the microsomal 
membrane phospholipids at this time. The ratio of phosphatidylcholine to 
phosphatidylethanolamine is significantly decreased in gestation and 1 day 
post-partum (Figure 3,4) and this may be of particular importance since 
Strobel et al. (1970) found that phosphatidylethanolamine had an inhibitory 
effect on the phosphatidylcholine enhanced hydroxylation of benzphetamine. 
Microsomal phospholipids may also be important modulators of the ferric 
spin-state of cytochrome P450, a point which will be discussed in greater 
detail in Chapter 5.
In addition to their effect on mixed-function oxidase activity a 
number of studies have suggested a functional relationship between 
microsomal phospholipids and the enzymes glucose-6-phosphatase 
Nordlie,1974; Garland and Cori,1972; Dyatlovitskaya et al.,1979) and 
UDP-glucuronyltransferase (Vessey and Zakim,1971; Graham and Wood,1974).
In guinea pig microsomes for example, Eletr et al. (1973) correlated breaks 
in the Arrhenius plots for glucose-6-phosphatase and
UDP-glucuronyltransferase with changes in the fluidity of the microsomal 
membrane at 19° and 32°, thus indicating a functional dependence of these 
enzymes on the physical state of the membrane phospholipids.
Microsomal phospholipid levels in late pregnancy in the rat have been 
reported by Feuer and Kardish (1975). These authors found a significant 
decrease in total phospholipids and, contrary to the results of Figure 3.5, 
a decrease in both phosphatidylcholine and phosphatidylethanolamine. The 
reason for this difference is unknown. The work of this group was extended 
by Dhami et al. (1979a) who reported that microsomal phospholipid-fatty 
acids were decreased in late pregnancy, the unsaturated fatty acids being 
decreased to a greater extent than the saturated. Fatty acid changes were 
related to membrane fluidity which was suggested to influence 
mixed-function oxidase activity. The data presented by these authors 
actually reveals that the ratio of saturated to unsaturated fatty acids ' 
does not alter in late gestation.
Phosphatidylcholine is synthesised in the endoplasmic reticulum, 
through two main pathways; (a) by direct utilisation of preformed choline 
via phosphorylcholine and cytidyl diphosphate choline (Kennedy and 
Weiss, 1956) and (b) by a stepwise methylation of phosphatidylethanolamine 
using the methyl groups from S-adenosylmethionine (Bremer et aL, 1960). The
importance of this latter pathway has been assessed and may account for^  20% 
of phosphatidylcholine production in rat liver (Sundler and Akesson ,1975). 
The contribution of this pathway to phosphatidylcholine biosynthesis may be 
increased during choline deficiency since the activity of 
phosphatidylethanolamine -methyltransferase(s) is elevated (Schneider and 
Vance,1978; Lombardi,1971). Female rats use the indirect pathway more 
than adult male rats (Bjornstad and Bremer,1966) as do choline deficient 
males, both groups having a lower content of drug metabolising enzymes as 
compared to adult males or choline-supplemented animals (Belina et aL, 1975; 
Chen et al., 1972; Cooper and Feuer,1973; Glenn and Austin,1971; Mezey et 
al., 1975; Saito et al.,1975). Given that the methylation pathway becomes 
more active during the administration of a choline deficient diet, it has 
been postulated that this pathway has a potential for increasing the 
choline supply during times of need (Thompson,1973). Reasoning that 
females use the methylation pathway more than males it was hypothesised 
that females have a physiological deficiency of choline (Pani et aL, 1978). 
The changes in microsomal phospholipids seen during pregnancy (Figure 3.5) 
resemble those seen in a state of choline deficiency: that of decreased
phosphatidylcholine and elevated phosphatidylethanolamine (Tokmakjian and 
Haines,1979)• Excess choline can inhibit ethanolamine phosphorylation in 
isolated liver preparations (Weinhold and Rathy,1974) and it is possible 
that this action of choline could result in a decline in the liver 
phosphatidylethanolamine level. Conversely, a deficiency of choline as a 
source of methyl groups which are responsible for the regeneration of 
S-adenosylmethionine could result in elevated phosphatidylethanolamine and 
decreased phosphatidylcholine (Tokmakjian and Haines,1979). Pregnancy is 
associated with increased fat mobilisation (Montes et al., 1978; Smith and 
Walsh, 1975; Herrera et al., 1969). Therefore it is not unreasonable to 
postulate that a relative choline deficiency in the female rat may be
accentuated during pregnancy. If this is so it is not a serious condition 
as there was no histological evidence of fatty degeneration in the liver 
(Figure 3.7) which has been found to be associated with a choline deficient 
diet (Koch et_aL,1979; Lombardi,1971). The effect of choline deficiency 
during pregnancy might be accentuated by the 10-15% decrease in 
phosphatidylethanolamine S-methyltransferase activity in late gestation 
reported by Feuer and Kardish (1975). A dietary supplement of choline 
throughout pregnancy produced an increase in microsomal total phospholipids 
and phosphatidylcholine at day 20 of gestation to the level found in 
non-pregnant rats fed on a normal diet (Figure 3.11).
Phosphatidylethanolamine levels in these rats were significantly decreased 
below control levels which resulted in an elevated phosphatidylcholine to 
phosphatidylethanolamine ratio. These changes were associated with an 
increase in mixed-function oxidase activity above the level found in 
pregnant rats fed on a normal diet (Figure 3.10). A choline supplemented . 
diet given to non-pregnant rats increased microsomal phosphatidylcholine, 
the phosphatidylcholine to phosphatidylethanolamine ratio and 
mixed-function oxidase activity and decreased phosphatidylethanolamine 
(Figures 3.10 and 3.11). These effects in non-pregnant animals to confirm 
the work of Pani et al. (1978) who found similar changes in female but not 
male rats. The results presented in Figure 3.10 and Figure 3.11 emphasise 
the important relationship between microsomal phospholipid levels and 
mixed-function oxidase activity. The dietary supplement of choline did not. 
affect the levels of microsomal cytochrome P450 in either pregnant or 
non-pregnant rats (Figure 3.12). Thus choline induced changes in 
mixed-function oxidase activity are not related to the level of cytochrome
It is not possible to conclude that pregnancy is associated with an 
enhanced deficiency of choline. This, however, is worthy of further 
consideration particularly since Weinhold (1969) reported that pregnancy 
was associated with an increased incorporation of [methyl-^C]-choline into 
phospholipids in liver slices.
Pregnancy-associated changes in mixed-function oxidase activity can be 
influenced by inducing agents as well as choline. The results in Figure 
3.13 and Figure 3.14 confirm previous reports that the inhibitory effect of 
pregnancy on drug metabolism can be decreased or eliminated by pretreatment 
with phenobarbitone or 3-methylcholanthrene (Neale and Parke,1973; Kato et 
aL, 1968a; King et_a_L, 1963). At variance with these results, Schlede and 
Borowski (1974) found that phenobarbitone pretreatment induced 
mixed-function oxidase activity to a much greater extent in non-pregnant 
than pregnant (14 and 21 days) rats.
Changes in the concentration of cytochrome P450 following pretreatment 
with inducing agents do not necessarily follow the change in mixed-function 
oxidase activity. Thus cytochrome P450 is significantly elevated by 
phenobarbitone pretreatment in non-pregnant but not pregnant rats (Figure 
3.14).
t
The effect of inducing agents on microsomal phospholipids in the 
pregnant rat has not been investigated. In the male rat, however, 
induction of drug metabolising enzymes in the liver by phenobarbitone 
injection is accompanied by a proliferation of the endoplasmic reticulum 
(Remmer and Merker,1963) and increased synthesis of membrane phospholipids 
(Orrenius et al., 1965). Phenobarbitone also causes a redistribution of the 
phospholipid species in the membrane by stimulating the methylation of
phosphatidylethanolamine to phosphatidylcholine (Young et aL, 1971) via^an 
increase in phosphatidylethanolamine S-methyltransferase activity (Davison 
and Wills,1974). Cooper and Feuer (1972) reported that phenobarbitone 
pretreatment significantly increased microsomal protein and phospholipids 
in parallel with the induction of drug metabolising enzymes. At variance 
with this finding it has been reported that phenobarbitone pretreatment 
does not affect microsomal phospholipid concentration and increases 
phospholipid turnover rate (Davison and Wills,1974). Pretreatment with 
3-methylcholanthrene has been reported to depress both the turnover rate 
and the rate of formation of phospholipids (Davison and Wills,1974).
In conclusion, the results presented show that pregnancy in the rat is 
associated with marked alterations in hepatic mixed-function oxidase 
activity which appear to be related to microsomal membrane phospholipids. 
The extent of these changes clearly depends upon the way in which enzyme . 
activity is expressed although there is a decrease in hepatocellular 
ability to metabolise drugs during gestation. The hepatic concentration of 
cytochrome P450 is unchanged during pregnancy. The role of. choline and the 
effect of monooxygenase inducing agents has been discussed.
CHAPTER 4 THE INFLUENCE OF ENDOGENOUS STEROIDS ON HEPATIC DRUG
METABOLISM DURING PREGNANCY IN THE RAT
4.1 Introduction
Steroid hormones are mainly deactivated in the liver. Several enzyme 
systems are involved in their biotransformation which after dehydration, 
reduction, hydroxylation and conjugation ultimately results in the 
production of more polar metabolites. Cytochrome P450 in liver microsomes 
has been recognised as the terminal "oxygen activating" enzyme that 
hydroxylates several steroids in the presence of NADPH, the microsomal 
electron transport system and oxygen (Kuntzman et aL, 1964; Conney,1967; 
Conney et aL, 1969; Hrycay et aL, 1976).
Pregnancy is associated with a rise in the circulating levels of 
progesterone and oestrogens (Davis and Ryan,1972) and it has been suggested 
that this is responsible for the decrease in maternal hepatic drug 
metabolism (Creaven and Parke,1965; Guarino et aL, 1969a; Feuer and 
Liscio,1969; Soyka and Deckert,1974; Feuer and Kardish,1975;
Feuer,1979). Steroids may produce this effect via competitive inhibition 
of drug metabolism (Guarino et al., 1969a; Creaven and Parke, 1965), a 
combination of competitive and uncompetitive inhibition (Soyka and 
Deckert,1974) or by an effect on microsomal membrane structure and function 
(Feuer and Kardish,1975; Feuer,1979). These hypotheses are based on the 
results of experiments which can be conveniently divided into in vitro and 
in vivo. The in vitro effects were determined following the addition of
steroid to the drug enzyme incubation medium prior to initiation of the 
enzyme reaction. The in vivo effects were assessed by determining drug 
metabolism following a period of animal pretreatment with the steroid.
A large proportion of the studies have involved the use of male rats. 
The important role of sex steroids in the manifestation of the sex 
difference in drug metabolism in the rat has been discussed (see Chapter 1, 
1.2.10) and in view of this it would be erroneous to assume that any 
steroid induced effects in the male rat could be extrapolated to the female 
rat. Indeed, Fahim and Hall (1970) have reported that progesterone 
pretreatment induced mixed-function oxidase activity in female rats while 
an opposite effect was seen in male rats. Similarly, Defrawy et al. (1974) 
have shown that oestradiol pretreatment of male rats resulted in a decrease 
in hepatic monooxygenase activity though no effect was seen in females.
Progesterone (Juchau and Fouts,1966; Tephly and Mannering,1968;
Soyka and Long,1972; Tuttenberg et al,1974; Soyka and Deckert,1974) and 
its metabolites (Soyka and Long,1973; Soyka and Deckert,1974) have been 
reported to have an in vitro inhibitory effect on hepatic microsomal drug
“5metabolism in male rats. Progesterone, at a concentration of 10 M, in the
assay system produced up to 50% inhibition in drug enzyme activity as
determined by a number of drug substrates, although the degree of enzyme
inhibition was generally lower than this, being in the range of 0-17% for
seven of the nine enzymes measured (Juchau and Fouts,1966). A number of
progesterone metabolites have been reported to be more potent inhibitors of
drug metabolism than progesterone itself although in no instance was the
percentage inhibition of j>-nitroanisole O-demethylase greater than 25% at 
-5
10 M steroid in male rats (Soyka and Long,1972). Pregnanolone and 
pregnanedione exhibited uncompetitive kinetics in contrast to progesterone,
a competitive inhibitor. In a later study Soyka investigated the in vitro
effect of a range of progestogens, oestrogens, androgens and
corticosteroids on hepatic jj-nitroanisole demethylation in male rats (Soyka
and Deckert,1974). Of the natural steroids tested pregnanolone and
progesterone were the most potent inhibitors of drug enzyme activity (36%
„c
and 38% inhibition respectively at 10 M steroid). Oestradiol and cortisol
were inactive as enzyme inhibitors while oestrone produced only 12%
-5inhibition of enzyme activity at 10 M. Soyka and Deckert compared the 
inhibitory effects of steroids on j)-nitroanisole demethylation in male and 
female rats. Of interest was the finding that the degree of inhibition 
produced by pregnanolone, progesterone, androsterone and oestradiol was 
markedly less in female than male rats. This again emphasises the 
importance of sex in determining steroid induced changes in drug metabolism 
in the rat. During pregnancy (17-20 days) Soyka and Deckert (1974) 
observed that the inhibitory effect of steroids was uniformly increased 
above non-pregnant levels.
The in vivo effects of progestogens and oestrogens on hepatic drug 
metabolism in tha rat have been the subject of a limited number of 
investigations concerned primarily with contraceptive steroids. Chronic 
treatment of female rats with contraceptive steroids did not inhibit but 
increased the activity of liver microsomal enzymes (Jori et aL, 1968) . 
Progesterone itself had no effect on enzyme activity. Similar findings 
were reported by Juchau and Fouts (1966) and Rumke and Noordhoek (1969). 
Contrary to these results Freudenthal and Amerson (1974) failed to show any 
inductive effect of synthetic progestogens in male rats but found a weak 
inhibition of microsomal drug metabolism. This conclusion, based on the 
determination of cytochrome P450 levels and other compounds of the. 
microsomal electron transport chain has been criticised by Briatico et al.
(1976) who reported that pretreatment with contraceptive steroids resulted 
in elevated mixed-function oxidase activity without a corresponding 
increase in cytochrome P450 levels. This effect seemed to be mediated by 
the progestogenic compounds while oestrogens had only a very slight effect. 
Fahim et al. (1971) reported that pretreatment of male and female rats with 
oestradiol produced a significant decrease in j>-chloro-N-methyl-aniline 
demethylation, the effect being more pronounced in male rats. Steroids 
such as methyltestosterone, cortisone and spironolactone stimulated drug 
metabolism in female rats without a corresponding increase in the 
microsomal content of cytochrome P450 (Hamrick et al., 1973). Carter et al. 
(1974) found a significant increase in ethylmorphine N-demethylase activity 
in female rats following chronic treatment with a norethynodrel-mestranol 
mixture for up to six weeks and Jori et al. (1976) reported increased 
hepatic mixed-function oxidase activity in female rats following 
contraceptive steroid pretreatment. Sweeny and Cole (1980) found a 
significant decrease in mixed-function oxidase activity following ethynyl 
oestradiol pretreatment in male rats for 4 to 8 weeks.
The only detailed study in which the relationship between progesterone 
metabolites and pregnancy induced changes in drug metabolism has been 
investigated was undertaken by Feuer and colleagues (Feuer and 
Kardish,1975; Feuer,1979). Female rats were treated with seven daily 
injections (lOmg/kg) of a number of 'hydroxylated' and 'reduced' 
progesterone metabolites. Reduced metabolites, such as
5o*-pregnane-3$.ol-20-one and 5<X-pregnane 30, 20^-diol caused a decrease in 
mixed-function oxidase activity, cytochrome P450 and microsomal 
phospholipids similar to the changes found in late gestation by these 
authors (Feuer and Kardish,1975). Hydroxylated metabolites 
(16c<-hydroxyprogesterone) produced opposite effects. The authors have
previously determined that during pregnancy progesterone metabolism is 
shifted toward a greater production of reduced metabolites (Kardish and 
Feuer,1972). It was argued that the pregnancy induced changes in drug 
metabolism were as a consequence of an altered microsomal membrane function 
which itself was caused by a change in the proportion of reduced to 
hydroxylated progesterone metabolites. Feuer and Kardish have not, 
however, investigated the effect of progesterone on drug metabolism in the 
rat and, furthermore, do not present serum profiles of the various 
progesterone metabolites throughout gestation.
A number of general conclusions can be drawn from the data reviewed:
(1)The in vitro inhibitory effect of a number of sex steroids on 
mixed-function oxidase activity has been established in male rats. The 
inhibition was usually less than 20%, even at high steroid concentrations 
(10 to 10 ^M) . The degree of inhibition by progesterone and oestradiol 
was less in female than in male rats.
(2) The in-vivo effect of progestogens and oestrogens on hepatic 
mixed-function oxidase activity appears to be sex-dependent. Steroid 
pretreatment of male rats was associated with a decrease or no change in 
drug enzyme activity while similar treatment in female rats produced an 
increase or no change. Pretreatment of female rats with progesterone 
metabolites has been shown, by one group of workers, to create effects on 
drug metabolism similar to those seen during pregnancy.
Thus the case for a steroid-mediated alteration in drug metabolism 
during pregnancy is inconclusive. A detailed investigation into the in 
vitro and in vivo effects of progesterone and oestrogens on female
mixed-function oxidase activity was undertaken to evaluate their role 
during pregnancy. The in vivo investigations were both acute and chronic. 
Chronic studies involved the administration of progesterone by 
intra-peritoneal (i.p) injections and by steroid-containing silicone rubber 
implants. It was hoped that silicone implants would maintain a constant 
elevated level of serum progesterone which could not be achieved by 
intra-peritoneal injections.
4.2 Experimental
(a) Progesterone levels in the serum and liver (10,000g supernatant and 
100,000g microsomal fraction) from pregnant (20 days) and non-pregnant rats 
were determined by radioimmunoassay (Chapter 2, 2.2.20).
(b) The in-vitro effect of a number of steroids on drug enzyme activity in
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rat liver was studied (Chapter 2, 2.2.7). Each steroid (10 -10 M) was
dissolved in dimethylformamide (<0.6% assay volume) and added to the assay 
prior to reaction initiation. Appropriate controls were run.
(c) The chronic effect of progesterone and oestradiol on hepatic drug 
enzyme activity (Chapter 2, 2.2.6), cytochrome P450 (Chapter 2, 2.2.2.8) 
and microsomal protein (Chapter 2, 2.2.21) was determined. Groups of 
non-pregnant rats were injected i.p. with progesterone (lOmg/kg daily for 
12 days) or oestradiol (lOmg/kg daily for 10 days) in corn oil and killed. 
24 hours later (Chapter 2, 2.2.5.3 and 2.2.5.4). Serum progesterone levels 
were determined by radioimmunoassay. Results were compared with control 
rats receiving com oil alone.
(d) The effect of an acute dose of progesterone (40mg/kg i.p.), in corn oil 
one hour before death, on hepatic drug metabolism, microsomal phospholipids 
(Chapter 2, 2.2.13.2) and serum progesterone levels in non-pregnant rats
was investigated. Results were compared with control rats receiving corn 
oil alone (Chapter 2, 2.2.5.3).
(e) Silicone rubber implants containing progesterone (32mg) were surgically 
placed under the skin on the flank of the right leg of non-pregnant rats. 
Controls were sham operated. Animals were killed 7, 14 and 21 days after 
implantation (see Chapter 2, 2.2.5.3) and hepatic drug metabolism, 
microsomal phospholipids and serum progesterone levels determined.
4.3 Results
4.3.1 Hepatic and serum progesterone levels in pregnant and non-pregnant 
rats
Progesterone levels were determined by radioimmunoassay in liver 
fractions and serum from non-pregnant and pregnant (20 days) rats (Table 
4.1). The concentration of progesterone in the hepatic 10,000g supernatent 
and 100,000g microsomal suspension was not significantly different between 
pregnant and non-pregnant animals. Serum progesterone concentrations were 
significantly elevated on day 20 of pregnancy to five times the level found 
in non-pregnant rats.
4.3.2 The in vitro effects of steroids on hepatic drug metabolism in female
non-pregnant rats
Figure 4.1 shows the effect of four progestagens (progesterone,
pregnanedione, 17<x-hydroxyprogesterone and pregnanolone) on the in.vitro
activity of ethylmorphine N-demethylase, aniline ^-hydroxylase and
jD-nitrobenzoic acid reductase. Progestogen concentrations greater than 
-510 M were required to produce an inhibition in the activities of aniline 
j)-hydroxylase and _p-nitrobenzoic acid reductase. Ethylmorphine 
N-demethylase was inhibited be progestagen concentrations lower than 10 JM. 
A progressive inhibition of ethylmorphine N-demethylase activity was seen 
over the concentration range used, pregnanedione being the most effective 
inhibitor.
In Figure 4.2. the in vitro effect of testosterone, oestradiol,
oestriol and cortisol on drug enzyme activity is shown. Oestradiol did not
inhibit drug enzyme activity at any concentration while the other steroids
inhibited all three drug enzymes to between 55% and 90% of control levels
-5at concentrations exceeding 10 M.
4.3.3 The effect of chronic injection (i.p) of progesterone on
hepatic microsomal drug metabolism in non-pregnant female rats
Groups of non-pregnant rats were injected with progesterone (lOmg/kg) 
i.p in corn oil for 12 days and killed on the 13th day. Hepatic drug 
metabolism and serum progesterone levels were compared to control rats
receiving corn oil alone (Table 4.2). Chronic dosing with progesterone 
resulted in a significant increase of 30% in ethylmorphine N-demethylase 
activity. Liver, weight, body weight, aniline ^ -hydroxylase activity, 
]3-nitrobenzoic acid reductase activity, cytochrome P450, microsomal protein 
and serum progesterone levels were not significantly altered.
4.3.4 The effect of chronic oestradiol injection (i.p) on hepatic 
microsomal drug metabolism in non-pregnant female rats
Groups of non-pregnant rats were injected with oestradiol (lOmg/kg) 
i.p. in corn oil for 10 days and killed on the 11th day. Control rats 
received com oil alone. This treatment had no effect on body weight,liver 
weight, drug enzyme activity, cytochrome P450 or microsomal protein levels 
(Table 4.3).
4.3.5 The acute effect of progesterone on hepatic microsomal drug 
metabolism and phospholipids in non-pregnant female rats
Groups of non-pregnant rats were dosed with progesterone (40mg/kg) 
i.p. in corn oil one hour before death. Control animals received com oil 
alone. This pretreatment raised the serum progesterone concentration to 
twenty-five times the control level but had no effect on microsomal drug 
enzyme activity, phospholipids or cytochrome P450 (Table 4.4).
4.3.6 The effect of progesterone containing implants on hepatic
drug metabolism and phospholipids in non-pregnant female fats
The release of progesterone from the silicone implants following 
removal from the animals on death was measured and compared with the 
release from unused implants (Table 4.5). The solubilty of progesterone in 
saline has been reported to be 48^umol/L (Heap et aL, 1970). It can be seen 
from Table 4.5 that implants removed from rats 7, 14 and 21 days after 
implantation released progesterone to saturate a saline solution (15mls) 
over three successive 24 hour periods. A similar release was determined in 
unused implants over 20 days. This data indicates that the implants were 
probably releasing progesterone at a constant rate during the period of 
implantation within the animal.
Serum progesterone levels were significantly elevated in the implanted 
animals to twice the level found in control rats (Figure 4.3). This was 
associated with significant increases in body weight 14 and 21 days after 
implantation and liver weight 21 days after implantation . (Figure 4.5).
The activity of ethylmorphine N-demethylase was significantly elevated 
at 7, 14 and 21 days after implantation. The activity of j)-nitrobenzoic 
acid reductase was also significantly increased 21 days after implantaion 
(Figure 4.3). Aniline pj-hydroxylase, cytochrome P450 and microsomal 
phospholipid levels were unchanged from control levels in the implanted 
rats (Figures 4.3 amd 4.4).
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Figure 4*3 Effect of progesterone implants on hepatic drug metabolism 
in the female rat
Drug metabolism, liver weight and serum progesterone levels in control 
(•—— •) and implant rats (o----o).
Significant differences (students 't * test) between control and treated 
rats are shown as * p<0.05> ** p<0.01, *** p< 0.001*
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Table 4.1 Progesterone levels in liver fractions and serum from
non-pregnant and pregnant (20 days) rats
Liver fraction Non-pregnant Pregnant (20 days)
Progesterone pmoles /g liver
10,000g supernatant 31.8 +/-7.0 41.6 +/-7.3
100,000g resuspended
microsomal pellet 10.2 +/-3.2 14.6 +/-1.9
Progesterone nmoles /L
Serum 48.8 +/-12.5 239.0 +/-25.0 ***
Each point represents the mean +/- SEM (n=4). Significant differences 
(students 't' test) are shown as *** p<0.001.
Table 4.2 The effect of progesterone (lOmg /kg) i.p. for 12 days on
hepatic microsomal drug metabolism in the female rat
Control . Treated
Body weight (g) Initial 235.3 +/-5.6 235.3 +/-4.2
Final 247.2 +/-5.7 246.9 +/-6.6
Liver weight (g) 8.4 +/-0.2 9.3 +/-0.4
Aniline jv-hydroxylase 
(pnoles /g liver /h)
1.00 +/-0.08 1.04 +/-0.07
£-Nitrobenzoic acid reductase 
(pmoles /g liver /h)
1.78 +/-0.04 1.73 +/-0.03
Ethylmorphine N-demethylase 
(pmoles /g liver /h)
9.2 +/-0.65 21.1 +/-0.7 * '
Cytochrome P450
(nmoles /mg microsomal protein)
0.71 +/-0.07 0.75 +/-0.08
Microsomal protein (mg /g liver) 19.3 +/-0.8 - 19.2 +/-1.08
Serum progesterone (nmol /L) 55.1 -H/-6.3 58.3 +/-2.5
Values represent mean +/- SEM (n=4). Significant differences (students 't' 
test) between control and treated animals are shown as * p<0.05, ** p<0..01,
*** p<0.001.
Table 4.3 The effect of oestradiol (lOmg/kg) i.p. . for 10 days on hepatic
microsomal drug metabolism in the female rat
Control Treated
Body weight (g) Initial 233.8 +/-6.2 235.8 +/-4.0
Final 256.8 +/-3.7 258 +/-5.5
Liver weight (g) 10.2 +/-0.4 10.4 +/-0.3
Aniline ^-hydroxylase 
(pmoles /g liver /h)
1.35 +/-0.05 1.37 +/-0.03
jj.-Nitrobenzoic acid reductase 
(pmoles /g liver /h)
1.77 +/-0.06 1.77 +/-0.04
Ethylmorphine N-demethylase 
(pmoles /g liver /h)
7.94 +/-0.25 8.79 +/-0.23
Cytochrome P450
(nmoles /mg microsomal protein)
0.63 +/-0.03 0.72 +/-0.5
Microsomal protein (mg /g liver) 19.6 +/-1.0 20.4 +/-1.0
Values represent mean +/- SEM (n=4). No significant differences were found 
between control and treated groups.
Table 4.4 The acute effect of progesterone (40mg /kg) i.p. 1 hour before
death on hepatic microsomal drug metabolism in the female rat
Control Treated
Aniline jv-hydroxylase 
(pmoles /g liver /hour)
1.35 +/-0.08 1.47 +/-0.03
Ethylmorphine N-demethylase 
(pmoles /g liver /hour)
9.6 +/-0.9 11.4 +/-0.3
j>-Nitrobenzoic acid reductase 
(pmoles /g liver /hour)
1.71 +/-0.11 1.96 +/-0.09.
Cytochrome P450
(nmoles /mg microsomal protein)
0.63 +/-0.04 0.70 +/-0.01
Microsomal phospholipids (pmoles /g liver):
Total 14.20 +/-0.20 14.3 +/-0.30
Phosphatidylcholine 7.95 +/- 0.32 8.15 +/-0.13
Phosphatidylethanolamine 3.05 +/-0.35 3.13 +/-0.20
Serum* progesterone (nmol/L) 83.4 4-/-3.0 2070.0 +/-573.0 *
Values represent mean +/- SEM (n=4). Significant differences (students 't' 
test) between control and treated animals are shown as * p<0.05, ** p<0.01,
*** p<0.001.
Table 4.5 The daily release of progesterone into saline medium from 
implants
Period of implantation 
in the rat
Day Progesterone 
(pmoles /L)
None 1 46.6 +/-1.5
5 46.8 +/-1.8
10 46.4 +/-0.9
15 44.9 +/-1.3
20 47.8 +/-1.9
7 days 1 47.4 +/-2.1
2 46.6 +/-1.2
3 46.4 +/-0.8
14 days 1 48.-1 +/-1.1
2 45.8 +/-1.1
3 45.4 +/-1.5
21 days 1 46.4 +/-1.9
2 47.6 +/-1.3
3 49.0 +/-1.8
The daily passage of progesterone into saline (15mls) at 37° from silicone 
implants was determined (see Chapter 2, 2.2.18). Values represent mean +/-
4.4 Discussion
Progesterone has been studied in detail in this chapter because 
changes in its blood concentration during gestation correlate with the 
changes occuring in hepatic drug metabolism. Serum levels of progesterone 
are elevated early in pregnancy and remain high until parturition when they 
fall to a nadir (Weist,1970; Davies and Ryan,1972; Sanyal,1978). 
Quantitatively serum progesterone concentrations during gestation are up to 
five hundred times higher than corresponding concentrations of oestradiol 
and oestrone (Fuchs,1974)• In addition, serum levels of oestrogens 
(Shaikh,1971; Davies and Yen,1971; Fuchs,1978), corticosteroids (Ogle and 
Kitay,1977) and androgens (Gibori et aL, 1979) remain low until late 
gestation in the rat.
The hypothesis that pregnancy-induced changes in drug metabolism are 
regulated via an increase in circulating steroid levels (Creaven and 
Parke, 1965; Guarino et aL, 1969a; Feuer and Liscio,1969; Soyka and 
Deckert,1974; Feuer and Kardish,1975; Feuer,1979) is not supported by the 
results presented in this chapter. Despite its high serum levels, 
progesterone concentration is not significantly increased in the liver 
during late pregnancy (Table 4.1). The in vitro investigations showed that 
only in the presence of unphysiologically high concentrations of 
progesterone was there any inhibitory effect on mixed-function oxidase 
activity (Figure 4.1). Similarly other steroids tested showed little or no 
inhibitory effect on drug enzyme activity even at high concentrations 
(Figures 4.1 and 4.2).
The effect on hepatic mixed-function oxidase activity of in vivo 
pretreatment of intact rats with progesterone depended upon the method of 
administration of the steroid. A large acute i.p. dose, while elevating 
the serum progesterone concentration to twenty-five times the control 
level, had no effect on hepatic microsomal mixed-function oxidase activity 
or phospholipids (Table 4.4). Chronic pretreatment, on the other hand, 
resulted in a significant increase in ethylmorphine N-demethylase (Table 
4.2, Figure 4.3) and jD-nitrobenzoic acid reductase (Figure 4.3) activity. 
These changes were not associated with alterations in microsomal cytochrome 
P450 (Table 4.2, Figure 4.3) or phospholipids (Figure 4.4).
Of interest was the finding that the serum progesterone level in the 
rats treated with silicone implants was significantly increased above the 
control level (Figure 4.3). In contrast to this serum progesterone levels’ 
in rats 24 hours after i.p. steroid administration were unchanged from 
those found in untreated rats (Table 4.2). These findings suggest that 
continuously raised levels of steroid can be achieved with- the use of 
silicone implants but not by daily i.p. injection.
Chronic progesterone treatment with silicone implants was associated 
with a significant increase in body and liver weight (Figures 4.3 and 4.5) 
supporting the hypothesis that this steroid is responsible, at least in 
part, for the pregnancy-induced changes in liver weight (Song and 
Kappas,1968; Desser-Weist and Desser,1977).
Chronic oestradiol pretreatraent (Table 4.3) had no effect on 
mixed-function oxidase activity or cytochrome P450.
The in vivo effects of corticosteroids and androgens on mixed-function 
oxidase activity have not been investigated here. Serum levels of these 
steroids remain low until late gestaion as discussed earlier, and they 
appear to have little in vitro inhibitory effect on drug enzyme activity 
(Figure 4.2). Investigations in vivo have shown an increase in drug enzyme 
activity following their-administration. Administration of corticosteroids 
was able to restore drug enzyme activity in adrenalectomised rats to normal 
levels (Gillette,1963; Kato and Gillette,1965b) and Bousquet et al. (1965) 
demonstrated an increased in vivo metabolism of hexobarbital after the 
injection of ACTH or corticosterone.
Steroids, particularly progesterone and oestradiol, are unable to 
produce pregnancy-associated effects on hepatic drug metabolism and are 
unlikely to be responsible for mediating the observed changes at this 
time. This conclusion is supported by an additional observation that serum 
progesterone levels have fallen to a nadir one day post-partum (Weist,1970) 
when microsomal mixed-function oxidase activity and phospholipid levels are 
still significantly altered (Chapter 3, Figures 3.2, 3.3, 3.5). It is 
possible that the lack of effect of steroids on drug metabolism is due to 
their interaction with different forms of cytochrome P450 since this 
haemoprotein has been shown to exist in multiple forms (Guengerich,1979) 
with different though overlapping substrate affinities (Haugen et al., 1975; 
Huang et_aL, 1976; Guengerich,1977).
CHAPTER 5 CHANGES IN CYTOCHROME P450 DURING PREGNANCY:
MULTIPLE FORMS, SUBSTRATE BINDING SPECTRA AND SPIN EQUILIBRIUM
5.1 Introduction
The absolute concentration of cytochrome P450 has been shown to be 
unchanged during gestation and early post-partum in the rat (Chapter 3)• 
The relationship of cytochrome P450 to mixed-function oxidase activity 
during pregnancy was investigated further by analysis of the 
electrophoretic pattern of microsomal protein with particular reference to 
cytochrome P450 by SDS (sodium dodecyl sulphate)-polyacrylamide gel 
electrophoresis. Cytochrome P450-substrate interactions were followed 
spectrophotometrically by the measurement of substrate binding spectra.
The haera spin-state of cytochrome P450 was also determined by measuring 
thermally-induced spin-state transitions of the haemoprotein. A short 
discussion of the theoretical aspects of these techniques is presented.
5.1.1 SDS-polyacrylamide gel electrophoresis
The use of polyacrylamide gel in the electrophoretic separation of 
macromolecules has a number of advantages over other supporting media such 
as paper and cellulose acetate.
(1) The gels may be produced with a wide range of pore sizes.
(2) They can be formed in precision bore tubes and hence give reproducible 
results.
(3) They may be used with a wide range of buffers.
(4) Their degree of adsorption and electro-osmosis is low.
(5) They give rapid separation.
(6) They do not absorb ultra violet light at 270nm and hence proteins
separated on them may be estimated at this wavelength.
(7) They enable macromolecules to be stained and the amount of material 
present determined by densitometry.
Polyacrylamide gel is prepared by co-polymerizing acrylamide 
(CH2=CH.CO.NH2 ) and N,N'-methylenebisacrylaraide (CH2 (NH.CO.CHNCI^^) with 
a suitable free radical catalyst accelerator such as ammonium persulphate 
combined with N,N,N',N'-tetramethyleneethylenediamine (TEMED). The 
porosity of the gel is determined by the relative proportion of acrylamide 
monomer and cross linking reagent. Gel may be prepared containing 3-30% 
(w/v) total acrylamide corresponding to pore sizes of 0.2 and 0.5nm . 
respectively. The lower percentage gels have a larger pore.size and 
thereby offer less resistence to the passage of large molecules.
The use of sodium dodecyl sulphate as a detergent in electrophoresis 
systems was developed by Shapiro et al.(1967) and extended by Weber and 
Osborn (1969). Membrane disruption and protein denaturation and 
solubilization occur after treatment with SDS and a sulphydryl reducing 
agent. The resulting polypeptide chains can be separated on the basis of 
molecular weight alone, though this depends on three assumptions 
(Maddy, 1976):
(1) That the binding of SDS to a polypeptide disrupts all but the 
covalent interactions within chains and between chains and that the 
interactions between proteins and lipids are destroyed. It has been 
reported that not all membrane proteins are solubilized by SDS (Maddy,1976) 
and furthermore that some lipid may be associated with proteins becoming 
dissolved in the SDS (Dunn et aL, 1975).
(2) That the binding of the detergent per unit length of polypeptide 
is constant and sufficient to abolish charge differences between 
polypeptides. Variations in SDS binding to different proteins (Maddy,1976; 
Grefarth and Reynolds,1974) and to different extents in any one protein 
(Robinson and Tanford,1975) have been reported.
(3) That conformational changes between polypeptides are destroyed 
such that frictional drag during passage through the gel is a function of . 
molecular weight alone.
The resolution of different proteins may be improved by. the use of 
discontinuous (disc) electrophoresis, in which an upper large pore stacking 
gel is used to concentrate the sample prior to its entry into the lower 
running gel. In this system the pH of the buffer in the upper resevoir is 
lower than the buffer saturating the stacking gel and this allows the 
sample to be concentrated between highly mobile leading ions (Cl") and less 
mobile trailing ions (glycinate).
Electrophoresis systems containing SDS for the resolution of membrane 
proteins are of great use when the resolution of the maximum number of 
polypeptide bands is the main objective. Since SDS treatment largely 
destroys enzyme activity this method is of limited use when the retention
of enzyme activity is desired.
Further details on the principles and practice of electrophoresis are 
to be found in Williams and Wilson (1975).
5.1.2 Substrate induced cytochrome P450 binding spectra and, haemoprotein 
spin-state
Narasimhulu et al (1965) observed the formation of a spectral 
transition in the Soret region of cytochrome P450 upon addition of a 
steroid to a suspension of adrenal corticol microsomes. Less than one year 
later two types of spectral change were described when drugs were added to 
liver microsomes (Remmer et aL,1966; Schenkman et aL, 1967; Imai and 
Sato,1966). The first spectral change, termed 'type 1' was characterised 
by an absorption maximum at 385-390nm and a minimum at 420nm; the second 
spectral change, 'type 2', was shown to possess an absorption maxima at 
425-435nm and minima at 390-400nm (Schenkman et aL, 1967). The third 
spectral transition, initially called 'modified type 2' displayed a mirror 
image of the 'type 1' spectral change and was subsequently described as 
'reverse type 1' (Schenkman et al.,1973). All three spectral transitions 
are.induced following substrate addition to a liver microsomal suspension 
and may be followed by spectrophotometry or more conveniently by difference 
spectrophometry. The spectral binding affinity (Ks) and the maximum 
binding capacity (AAmax) can be calculated from a double reciprocal plot of 
absorbance change against substrate concentration analogous to the 
calculation of the kinetic constants Km and Vmax from a Lineweaver-Burke 
plot.
Mason and co-workers (1965) described an electron paramagnetic
resonance (EPR) spectrum in liver microsomes which resembled low-spin
ferrihaemoproteins and suggested that the EPR signal was related to
cytochrome P450. Cammer et al. (1966) reported similar findings and in
addition showed that both 'type 1' and 'type 2' substrates affected the
low-spin gx and gz components of the first derivative EPR spectrum in
opposite directions. For example, in the presence of aniline ('type 2'
substrate) the gx signal was shifted to lower field; the opposite occurred
in the presence of hexobarbital, a 'type 1' substrate (Cammer et aL, 1966).
A conversion of the low-spin ferric haemoprotein to the high-spin form
following addition of camphor was reported in the Pseudomonas pudita
cytochrome P450 system by Tsai et al. (1970) and Peterson (1971). The spin
•t
state of ferric cytochrome P450 can thus be modulated by subsrate addition, 
shifting from low- to high-spin with 'type 1' compounds, high to low-spin 
with 'reverse type 1' compounds or forming a new low-spin species with 
'type 2' compounds. Similar spin state changes occurred with adrenal 
cortex mitochondrial cytochrome P450 (Whysner et al., 1970). In addition 
both Hilderbrandt et al. (1968) and Jefcoate and Gaylor (1969) reported that 
in liver microsomes from 3-methylcholanthrene treated animals there was an 
EPR signal at about g=6 indicative of high-spin P450. Kumaki et al.(1978) 
have subsequently attempted to correlate the observed spectral changes 
('type 1', 'type 2' and 'reverse type 1') with the absolute spin state of 
the iron.
The low-spin to high-spin transition associated with a 'type 1' 
substrate is thought to arise from obstruction of the binding of the iron 
sixth ligand which is probably a water molecule (White and Coon,1980).
With the release of the water ligand the iron moves out of the plane of the 
porphyrin towards the fifth (thiolate) ligand. This ligand obstruction
phenomenon is probably also manifested in the variation of carbon monoxide 
bonding geometry with and withopt substrate as detected in the infrared 
spectrum of ferrous carbonyl P-450cam by O'Keeffe et al. (1978)# Upon a 
change of the coordination sphere from approximately octahedral 
(hexacoordinate) to square pyramidal (pentacoordinate) the energetic 
ordering of the ferric d-orbital changes and the electron pairing pattern 
shifts from low-spin (s=l/2) to high-spin (s=5/2). The high-spin iron has 
a larger radius and can no longer fit inside the central hole of the 
porphrin (White and Coon,1980). It is now apparent that the high-spin form 
of all types of cytochrome P450 is pentacoordinate and that the equilibria 
between low and high-spin forms is a manifestation of the binding 
equilibria of the sixth ligand (White and Coon, 1980; Ebel et al., 1978; 
Orme-Johnson et aL, 1979).
Recently Sligar (1976) showed that cytochrome P450cam in the presence 
or absence of substrate contained a mixture of high-spin and low-spin haem 
iron which was temperature sensitive. In related studies Rein et al. (1979) 
reported the presence of a substrate-induced high-spin/low-spin equilibrium 
which was temperature dependent. At the same time Pierson and Cinti (1977) 
found that the microsomal 'type 1' and 'reverse type 1' spectral changes 
could be attained by an alteration of temperature without the addition of 
substrate. Furthermore it was shown by both Rein et al. (1977) and Pierson 
and Cinti (1977) that the substrate-induced types '1' and '2' spectral 
changes were affected by temperature.
A relatively simple method for determining the spin state of 
cytochrome P450 based on thermally induced spin state transitions has been 
developed by Sligar (1976). The results obtained by this method are in 
agreement with the haemoprotein spin state determinations by high
temperature Mossbauer and electron paramagnetic resonance spectroscopy 
results (Sligar,1976). A method slightly modified from that of Sligar 
(1976) has been used to determine the absolute spin state of microsomal 
cytochrome P450 in pregnant and non-pregnant animals. A detailed 
description of the analysis is presented.
In the simplest two-state model at any physiological temperature the 
ferric P450 molecule can be considered to exist as a mixture of high-spin 
(total spin,s=5/2) or low-spin (s=l/2) forms corresponding to the ordering 
of the five d- orbital electrons. To each of the high- and low-spin forms 
there corresponds a unique optical spectrum. Thus, at any wavelength the 
total absorbance A, =E|_j2[F-450|_|£] +E^g[P450 ^ g] where E|_jgand Ej_g refer to 
the extinction coefficients and [P450|_^ ]^ and [P450^g] to the concentrations 
of high- and low-spin forms respectively. In addition, at all wavelengths * 
there exists a maximum (Amax) and a minimum (Amin) value of absorbance 
which corresponds to the limiting cases when the P450 molecule is in either 
the complete low-spin or complete high-spin state. When cytochrome P450 
exists as a mixture of spin states the absorbance will fall between the 
limiting values Amax and Amin with the distance from the upper and lower 
limits being directly proportional to the high- and low-spin fractions.
For example at 420nm the fraction of low-spin material is given by the 
ratio (A-Amin)/(Amax-Amin) while the proportion of high-spin is 
(Amax-A)/(Amax-Amin). Defining an equilibrium constant for the process 
P450^ " » P450h s  by K= [P450|_j^ ] / [P450^g] yields the following expression for 
K:
K=Amax-A/A-Amin
If this process is then assumed to follow standard Vant Hoff behaviour the
following can then be written:
ir A A/A A • AG/RT AS/R-AH/RT K = Amax-A/A-Amm = e = e e
In K = In Amax-A/A-Amin = AS/R — AH/RT
which completely describes the variation in spin state equilibrium constant 
with temperature. In the analysis, changes in the wavelength couple 390 
minus 420nm were recorded. These represent the wavelengths used to 
determine the low-spin to high-spin transition of a 'type 1' spectrum.
Since the values Amax and Amin cannot be known a priori by any experimental 
means they are used as parameters in a regression fit to the variation in 
observed absorbance value as a function of temperature. Using the 
correlation coefficient as a convergence parameter for the least squares 
straight line fit of In[(Amax-A)/(A-Amin)] vs. 1/RT one can determine the 
values Amax and Amin which give the best fit to the observed absorbances as 
well as the slope AH and the intercept AS/R. The computer analysis was 
simplified by assuming an extinction coefficient for the wavelength couple' 
390 minus 420nm of 126mM ^ cm ^ (Cinti et al., 1979; Gibson et aL, 1980a).
5.2 Experimental
(a) Microsomal proteins from non-pregnant and pregnant (20 days) rats were 
separated by SDS-polyacrylamide gel electrophoresis as described in Chapter 
2 (2.2.14). Microsomal protein (lO^ jg or 20^ ug) was applied to the stacking 
gel together with a series of standard proteins of known weight.
(b) Substrate-induced difference spectra for microsomal cytochrome P450 
from non-pregnant and pregnant (15 and 20 days) rats have been determined 
(Chapter 2, 2.2.11). The following substrates were used; aniline, 
ethylmorphine, progesterone and 17#-hydroxyprogesterone. Spectral binding
affinities (Ks) and the maximum spectral change (AAmax) were calculated 
from the difference spectra.
(c) Thermally induced spin state transitions were determined in 
non-pregnant and pregnant (20 days) rats. The data was fitted to a Vant 
Hoff plot by the method described (Chapter 2, 2.2.12). Haemoprotein 
spin-state, AH, AS and AG were calculated from this plot.
5.3 Results
5.3.1 SDS-polyacrylamide gel electrophoresis of microsomal 
proteins from non-pregnant and pregnant (20 days) rats
The body and liver weights of the rats together with microsomal 
protein and cytochrome P450 are shown in Table 5.1. Body weight and liver 
weight were significantly increased in the pregnant animals (Table 5.1) and 
were similar to the increases reported in Chapter 3 (Figure 3.1).
Microsomal levels of protein and cytochrome P450 were unchanged.
The electrophoretic patterns of the microsomal proteins from 
non-pregnant and pregnant animals are shown in Figures 5.1 and 5.2. No 
difference was seen in the pattern of microsomal proteins between 
non-pregnant and pregnant animals. A change in the type(s) of cytochrome 
P450 present would be expected to occur in the molecular weight region
45,000 - 60,000 (Guengerich,1979)• In Figure 5.1 this region is heavily 
stained and it is difficult to distinguish individual protein bands. This 
problem is overcome in Figure 5.2 by the application of less protein (10/jg) 
to the gel. However no difference in protein bands was observed in this
region between pregnant and non-pregnant rats.
5.3.2 Spectral binding affinities (Ks) and the maximum spectral change
(AAmax) for four substrates in non-pregnant and pregnant rats
Substrate-induced difference spectra for microsomal cytochrome P450 
have been determined. Ethylmorphine (type 1 substrate) produced a 
difference spectra with an absorption maxima at 385nm and minima at 415nm. 
Aniline (type 2 substrate) produced an absorption maxima at 430nm and 
minima at 390-395nm. Progesterone and 17«-hydroxyprogesterone (reverse 
type 1 substrates) produced absorption maxima at 415-420nm and minima at 
385nm (Figure 5.3). The spectral binding affinities (Ks) and the maximum- 
absorbance changes (AAmax) are shown in Tables 5.2 and 5.3 respectively. 
These parameters were calculated from the difference between the absorbance 
maxima and minima for each substrate. The spectral binding affinity 
represents the substrate concentration at which the absorbance change is 
half maximal.
During pregnancy the spectral binding affinities (Ks) for the four 
substrates used did not change from the values determined in control 
non-pregnant rats (Table 5.2). The Ks values for the four different 
substrates used vary considerably. The concentration of progesterone and 
17ot-hydroxyprogesertone required to produce a half maximal absorbance 
change is up to one thousand times less than the equivalent concentration 
of ethylmorphine or aniline* In Table 5.3 the AAmax values have been 
calculated from the same data used for Table 5.2. A significant decrease 
in the AAmax for aniline in the 20 day pregnant rat was found. The AAmax
for ethylmorphine, progesterone and 17c(-hydroxyprogesterone was unchanged 
during gestation. The AAmax for ethylmorphine was less than half of the 
value for the other three substrates. This is reflected in the maximum 
absorbance changes shown in Figure 5.1.
5.3.3 Microsomal cytochrome P450 spin-state equilibria in microsomes 
from non-pregnant and pregnant (20 days) animals
The equilibrium spin-state of microsomal cytochrome P450 was 
determined in non-pregnant and pregnant (20 days) rats. Body weights and 
liver weights for the pregnant (20 days) and non-pregnant rats together 
with the concentrations of microsomal protein and cytochrome P450 are shown 
in Table 5.1. Thermally induced absorbance changes between 390 and 420nm 
were fitted to Vant Hoff equation and this is shown in Figure 5.4. This 
analysis allows the values of AS, AH, AG and K to be calculated (Table 
5.4).
The equilibrium constant (K) was significantly lower in the pregnant 
compared with the non-pregnant animals over the temperature range used 
(Figure 5.4). The proportion of high-spin cytochrome P450 present was 
calculated from K and these are shown in Table 5.4 at 20° and 37°.
Pregnancy was associated with a significant decrease in the high-spin form 
of cytochrome P450 and an increase in low-spin cytochrome P450. Associated 
with this change were significant alterations in AH, AS and AG during 
pregnancy.
Figure 5*1 SBS-polyacrylamide gel electrophoresis of microsomal
proteins from non-pregnant and pregnant (20 days) rats
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Protein standards;
A Phosphorylase a Mol.wt. 92,500 
B Bovine serum albumin Mol.wt. 68,000 
C Catalase Mol.wt. 60,000 
B Glutamate dehydrogenase Mol.wt. 53»000 
E Chicken egg albumin Mol.wt. 43,000 
F Creatinine phosphokinase Mol.wt. 40,000 
G Lactate dehydrogenase Mol.wt. 36,000 
H Cytochrome c Mol.wt. 11,700
Microsomal protein (20yug) from non-pregnant (C1-C4) and pregnant 
(P1-P4) rats was separated together with a standard protein mixture 
(0.5yug standard mixture: STB (0.5) an(i 1.0^g standard mixture:
STB (0.5) )• Electrophoresis conditions are described in Chapter 2 
(2.2.14).
Figure 5*2 SBS-polyacrylamide gel electrophoresis of microsomal
proteins from non-pregnant and pregnant (20days) rats
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Protein standards
A Phosphorylase a Mol.wt 92,500 
B Bovine serum albumin Mol.wt. 68,000 
C Catalase Mol.wt. 60,000 
B Glutamate dehydrogenase Mol.wt. 53»000 
E Chicken egg albumin Mol.wt 48,000 
F Creatinine phosphokinase Mol.wt. 40,000 
G Lactate dehydrogenase Mol.wt. 36,000 
B Cytochrome c Mol.wt. 11,700
Microsomal protein (10/ug) from non-pregnant (C1-C4) and pregnant (P1-P4) 
rats was separated together with a standard protein mixture (0.5^»g 
standard mixture ; STB (0.5) and 1.0yug standard mixture STB (1.0) ). 
Electrophoresis conditions are described in Chapter 2 (2.2.14)*
Figure 5*3 Substrate induced cytochrome P450 difference spectra 
in the presence of saturated amounts of substrate.
0.008 A
460 nm420 /380 400 440.
1 Ethylmorphine (type '1 * substrate)
2 Progesterone (reverse type 11* substrate)
3 17^-hydroryprogesterone (reverse type *1' substrate)
4 Aniline (type '2* substrate)
Substrate induced difference spectra were obtained according to the 
method described (see Chapter 2, 2.2.11).
Figure 5*4 Thermally induced spin state transition in hepatic
microsomal cytochrome P450 from pregnant (20 days) and non-pregnant rats*
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Thermally induced spin state transitions were fitted to a Vant Hoff 
equation by the procedure described in Chapter 2 (2.2.12).
Each point represents the mean + SEM (n=4). Non-pregnant and 
pregnant values are significantly different at all points (p<0.0l).
Table 5.1 Body and liver weights, and microsomal contents of protein and 
cytochrome P450 from non-pregnant and pregnant (20 days)-rats used in 
electrophoretic analysis of microsomal proteins
Non-pregnant Pregnant
Body weight (g) 218.9 +/-3.0 288.6 +/-6.0 ***
Liver weight (g) 7.63 +/-0.32 11.86 +/-0.41 ***
Microsomal protein (mg /g liver) 18.0 +/-0.4 18.6 +/-0.8
Cytochrome P450
(nmoles /mg microsomal protein)
0.76 +/-0.08 0.78 +/-0.08
Values represent mean +/- SEM (n=4). Significant differences (students 't' 
test) are shown as * p<0.05, ** p<0.01, *** p<0.001.
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Table 5.3 Substrate induced maximum absorbance changes AAmax in
non-pregnant and pregnant rats
Substrate AAmax (xlO^) /nmole cytochrome P450
Non-pregnant 15 days pregnant 20 days pregnant
Ethylmorphine 5.5 +/-0.6 5.9 +/-0.2 5.4 +/-0.5
Aniline 17.3 +/-1.7 18.3 +/-3.6 11.8 +/-0.6 *
Progesterone 12.3 +/-1.7 13.6 +/-1.7 10.0 +/-1.3
17o(-Hydroxy- 
progesterone
15.1 +/-1.5 16.0 +/—2.6 13.4 +/-0.7
Each value represents the mean +/- SEM (n=4)• Significant differences 
(students 't' test) between non-pregnant and pregnant rats are shown as 
* p<0.05, ** p<0.01, *** p<0.001.
Table 5.4 Spin content and thermodynamic analysis of microsomal cytochrome
P450 from non-pregnant and pregnant (20 days) rats
Non-pregnant Pregnant ( a)
%High spin P450
20° 61.3 +/-2.0 43.2 +/-1.6 **
37° 73.6 +/-1.7 54.5 +/-1.1 **
Equilibrium constant (K)
S,
20° 1.20 +/-0.05 0.76 +/-C.05 **
37° 2.82 +/-0.26 1.61 +/-0.12 **
AH ( kcal) 9*05 +/—0.05 7.83 +/-0.41
AS ( e.u) 31.3 +/-1.8 26.2 +/—1.4
AG ( kcal /mol) 37° -0.64 +/—0.05 —0.29 +/—0.05
a : based on the equilibrium constant K= (P450j_|g) / (P450^). Values
represent mean +/- SEM (n=4). Significant differences (students 't' test) 
are shown as * p<0.05, **-p<0.01, *** p<0.001.
5.4 Discussion
5.4.1 The value of SDS-polyacrylamide gel electrophoresis in detecting 
multiple forms of microsomal cytochrome P450 during gestation
Evidence for the existence of multiple forms of cytochrome P450 comes 
from electrophoretic mobility studies (Welton and Aust,1974; Haugen et 
aL, 1975; Ryan et al, 1975; Hashimoto and Imai,1975; Guengerich,1979). 
Using SDS-polyacrylamide gel electrophoresis Welton and Aust (1974) 
resolved three haemoproteins with molecular weights of 45,000, 50,000 and
53,000 in rat liver microsomes. The haemoprotein of 50,000 molecular 
weight predominated in control microsomes while phenobarbitone and 
3-methylcholanthrene pretreatment induced the 45,000 and 53,000 molecular 
weight bands respectively. These findings were confirmed by Alvares and 
Siekevitz (1973) who also reported that all three bands were induced by 
polychlorinated biphenyls. Haugen et al. (1976) demonstrated the potential 
of the same approach by analysing the responses of mouse liver microsomal 
membrane polypeptides to various xenobiotics including 
pregnenolone-16oc-carbonitrile (PCN). The induction of novel microsomal 
membrane polypeptides following 2-acetylaminofluorene (Cameron et al., 1976) 
ethanol (Ohnishi and Leiber,1977) and isosafrole (Dickins et aL, 1978) 
administration has been reported. Recently, Sharma et al.(1979) have 
described twelve different patterns of induction following the treatment of 
rats with phenobarbitone, 3-methylcholanthrene, polychlorinated biphenyls, 
acetylaminofluorene, safrole, PCN or ethanol either alone or in various 
combinations.
Caution is required in interpreting the results of SDS-polyacrylamide 
gel electrophoresis of microsomal proteins which have been stained for 
protein with Coomassie blue. This arises because various microsomal 
proteins which are not related to cytochrome P450 have molecular weights in 
the 45,000 to 60,000 region. These include expoxide hydrase (Bentley and 
0esch,1975; Lu et aL,1975), UDP-glucuronyl transferases (Bock et aL, 1977) 
and stearoyl COA desaturase (Strittmatter et al., 1974).
SDS-polyacrylamide gel electrophoresis of microsomal protein from 
pregnant and non-pregnant animals revealed no observable difference in the 
quantitative or qualitative pattern of polypeptides (Figures 5.1 and 5.2). 
This technique, although giving a good indication, is not definitive for 
detecting small changes in polypeptides, particularly haemoproteins. It is 
unlikely that small changes in microsomal proteins could be detected by 
this method. Furthermore evidence has been presented that different forms 
of cytochrome P450 can appear to have identical mobilities (Philpot and 
Arinc,1976; Thomas et al.,1976; Guengerich, 1977; Haugen et aL, 1977). A 
number of other methods should be used in conjunction with 
SDS-polyacrylamide gel electrophoresis to establish whether or not an 
altered spectrum of cytochrome P450 haemoproteins exists during gestation. 
These should include haemoprotein purification, immunochemical techniques, 
peptide mapping and amino acid compositional studies (Guengerich,1979).
The gels shown in Figure 5.1 and Figure 5.2 were stained for protein 
with Coomassie blue. A technique which involves staining for residual haem 
peroxidase activity has been used to locate haemoproteins on gels (Welton 
and Aust,1974; Haugen et al., 1975). This method is based on the 
observation that cytochrome P450 on conversion to cytochrome P420 by SDS 
retains peroxidase activity (Hrycay and O'Brien,1971,a,b). This method was
not used in this study because of the difficulties involved and limitations 
in its use (for a detailed discussion of these see Fennell (1980)).
5.4.2 The significance of haemoprotein spin state changes during pregnancy 
in the rat
During pregnancy a significant decrease was found in the microsomal 
content of high-spin cytochrome P450 in the absence of exogenous substrates 
(Table 5.4). The significance of this in mixed-function oxidase activity 
is probably associated with the rate limiting step in monooxygenation. A 
number of investigations have reported that the reduction of 
ferricytochrome P450 by NADPH-cytochrome P450 reductase is the rate 
limiting step for some drugs (Bjorkhem,1977). The kinetics of reduction by 
NADPH via the reductase can be conveniently studied by rapid mixing of 
anaerobic, carbon-monoxide saturated solutions of the reductase-P450. 
complex and of NADPH in a stopped-flow spectrophotometer. Using this 
technique Gigon et al. (1968) showed that ethylmorphine, hexobarbital, 
aminopyrine and imipramine, all of which cause 'type 1' spectral changes, 
markedly enhanced the rate of reduction of cytochrome P450. In contrast 
aniline, nicotinamide and 2,4-dichloro-6-phenylphenoxyethylamine which 
cause 'type 2' spectral changes, decreased the rate of haemoprotein 
reduction. The substrate-induced enhancement of cytochrome P450 reduction 
by NADPH was found to be closely related to the rate of hydroxylation. The 
rate of cytochrome P450 reduction in the presence of substrate minus the 
rate in the absence of substrate corresponded to the rate of hydroxylation 
under several different conditions. This observation has been subsequently 
confirmed (Gigon et_aL,1969; Diehl et al., 1970; Gillette and Sasame,1970;
Gillette,1971; Holtzman and Rumack,1973), though the rate limiting step 
appears to change following phenobarbitone induction (Miwa et al., 1978).
Studies on the activation energies of a number of reactions have shown 
-that for aminopyrine demethylation the activation energy of the overall 
enzyme reaction was very close to the energy of activation of the ' 
ferricytochrome P450 reductase reaction in the presence of.substrate, 
suggesting that this step is rate limiting (Schenkman,1971)• This, 
however, was found not to be the case for ethylmorphine N-demethylation 
(Schenkman,1971; Holtzman and Carr,1972).
Investigations on the inhibitory effect of deuterated waiter on 
monooxygenase activity have revealed that the degree of inhibition of 
ethylmorphine N-demethylase by deuterated water was correlated with the 
degree of inhibition of the substrate-induced reduction of cytochrome P450, 
suggesting that this step was rate limiting (Holtzmann and Carr,1970). 
Similar findings have been reported by Bjorkhem (1972). High ionic 
strength is known to stimulate the rate of reduction of cytochrome c by 
purified NADPH-cytochrome c reductase preparations (Philips and 
Langdon,1962)• In accordance with the suggestion that the reductase step 
is rate limiting Estabrook et al. (1971) found that the rate of 
N-demethylation of ethylmorphine was increased at high ionic strength of 
the. buffer medium. A similar effect was reported by Bjorkhem and Danielson 
(1973).
Microsomal hydroxylations can be supported in the absence of NADPH and
O2 by organic hydroperoxides. This effectively bypasses the
NADPH-cytochrome P450 reductase step. If this step is rate limiting a
faster rate of hydroxylation would be expected. This has been found to be
the case for the 6j5-, 7*- and 160  ^hydroxylations of androstenedione (Hrycay 
et al.,1976).
As mentioned earlier, the rate of electron transfer from 
NADPH-cytochrome P450 reductase to ferricytochrome P450 is altered by the 
presence of substrates: various 'type 1 ' substrates (which increase the
high-spin form of the cytochrome) increase the rate of reduction of 
ferricytochrome P450 and 'type 2' substrates (which increase the low-spin 
form) inhibit the reduction rate (Schenkman,1968; Gigon et__aL, 1968) •
Ristau et al. (1978) measured the dissociation constants for the low and 
high-spin substrate protein complexes and the high-spin/low-spin 
equilibrium constants in the presence and absence of substrate. The 
substrate benzphetamine binds nearly five times more tightly to the 
high-spin than to the low-spin enzyme and consequently in the presence of • 
benzphetamine the high-spin/low-spin equilibrium is "pulled" towards the 
high-spin.
The substrate-induced change in electron spin state is associated with 
a shift towards a more positive value in the equilibrium redox potential of. 
the cytochrome for both bacterial (Sligar and Gunsalus,1976; Sligar,1976) 
and hepatic (Sligar et al., 1979) systems. This shift in redox potential 
might increase the rate of electron flow from NADPH-cytochrome P450 
reductase to cytochrome P450. The rate constants for this process have 
been measured in bacterial systems and the substrate-induced change in 
redox potential of cytochrome P450 was reflected by a modulation of the 
forward rate constant for electron transfer into the haemoprotein 
(Sligar,1976).
A model emerges where, during substrate binding to cytochrome P450 and 
its subsequent reduction by NADPH-cytochrome P450 reductase, three 
interacting equilibria are present: (1) substrate binding, (2)
oxidation-reduction of the haem group, and (3) interconversion between high 
and low-spin P450 states. It would appear that the binding of 'type 1' 
substrates to hepatic cytochrome P450 could increase the rate of electron 
flow from NADPH-reductase to cytochrome P450 by modulating the spin 
equilibrium of the electron accepting cytochrome. As this redox transfer 
process is rate limiting for some substrates the haem iron spin equilibrium 
could be of major importance in the regulation of monooxygenase activity 
(Sligar et aL,1979). This suggests that the endogenous spin state of the 
haemoprotein in the microsomal membrane may have an important regulatory 
effect on the rate of drug metabolism. This is in agreement with the 
finding (Table 5.4) that in late pregnancy there was a significant 
reduction in the high-spin form of hepatic microsomal cytochrome P450 
compared with the non-pregnant state. This change was associated with a 
significant decrease in mixed-function oxidase activity, as discussed in 
Chapter 3. Haemoprotein spin state changes are accompanied by significant 
alterations in the enthalpy (AH), the entropy (AS) and the free energy (AG), 
of the system during gestation. The values for the thermodynamic 
parameters obtained from non-pregnant rats were similar to values reported 
by Cinti et al. (1979) in male rats (%high-spin at 37°=78.5, AH=’ 14.7 
kcal/mol and AG(20°)=-0.043 kcal/mol).
It would thus appear that the decreased content of high-spin 
cytochrome P450 in the endoplasmic reticulum during gestation might be an 
important factor in mediating alterations in mixed-function oxidase 
activity by modulation of the redox potential of the haemoprotein.
It is now important to consider how spin state changes in cytochrome 
P450 are controlled. Progesterone caused a 'reverse type 1' spectral 
change on interaction with cytochrome P450 (Figure 5.3) arid may shift the 
haemoprotein spin state equilibrium towards the low-spin state (Kumaki et 
al., 1980). The microsomal concentration of progesterone, however, was not 
significantly different in pregnant compared to non-pregnant rats (Chapter 
4,Table 4.1). Furthermore, it has been shown (Chapter 4) that high 
concentrations of progesterone and other steroids administered in vitro or 
in vivo have little effect on mixed-function oxidase activity.
Spin state changes might alternatively be controlled by alterations in 
microsomal lipids. Purified soluble cytochrome P450 from both bacteria 
(Sligar, 1976; Sligar and Gunsalus, 1976; Sligar et aL, 1979) and rat liver 
(Cinti et aL, 1979; Gibson et aL, 1980a; Sligar et aL, 1979) sources, in the 
absence of added substrate, have been found to exist pedominantly in 
low-spin configuration. In contrast, unpurified microsomal P450 in the 
absence of added substrate, contains large amounts of high-spin cytochrome 
P450 (>50% at 20°) (Cinti et al., 1979; Gibson et aL, 1980a). Gibson et al.
(1980a,b) showed that microsomal lipids were responsible for holding the 
haemoprotein in the high-spin form and Ruckpaul et al. (1980) have reported 
that the addition of phospholipids to purified cytochrome P450 resulted in 
an increase in the high-spin form of the haemoprotein. In contrast Gibson 
et al. (1980a,b) found that the free fatty-acid fraction was responsible for 
a low-spin to high-spin transition of the haem iron of cytochrome P450. 
Phospholipids caused, if anything, a slight high-spin to low-spin 
transition (Gibson et al., 1980a; Tsong and Yang, 1979). It is possible that 
the altered microsomal phospholipid composition which has been shown to 
occur during pregnancy (Chapter 3) is responsible for the decrease in the 
high-spin form of cytochrome P450 (Table 5.4). Phospholipids may therefore
cause a decrease in mixed-function oxidase activity in one or both of two 
ways. Firstly, changes in phospholipids may alter the membrane environment 
of the haemoprotein (discussed in Chapter 3) without affecting the spin 
equilibrium or, secondly, phospholipids may have a direct effect on the 
proportion of cytochrome P450 in the high-spin state.
In view of the observed changes found in haemoprotein spin state 
during pregnancy the lack of change in AAmax for ethylmorphine, 
progesterone and 17<*-hydroxyprogesterone (Table 5.3) is somewhat 
surprising. Kumaki et al. (1978) suggested that AAmax depended on the spin 
content of the haemoprotein; the greater the amount of endogenous 
high-spin P450 the lower was the AAmax produced by 'type 1' substrates 
added in vitro, arid the greater was the AAmax produced by 'reverse type 1' 
and 'type 2' compounds. Conversely, the lower the amount of endogenous 
high-spin P450 the greater was the AAmax produced by 'type 1' substrates 
added in vitro, and the lower was the AAmax produced by 'reverse type 1' 
and 'type 2' compounds. The decrease in AAmax for aniline during pregnancy 
(Table 5.3) might therefore be explained by the increase in the endogenous 
low-spin form of cytochrome P450. The lack of change in AAmax for the 
substrates ethylmorphine, progesterone and 17<*-hydroxyprogesterone is 
possibly because only a portion of the cytochrome P450 in microsomal 
preparation will undergo a low-spin to high-spin transition upon the 
addition of substrates (Ullrich and Duppel,1975; Ebel et aL, 1977). This, 
may be related to the presence of multiple forms of cytochrome P450 with 
different but overlapping affinities for different substrates (Estabrook et 
al., 1973; Werringloer and Estabrook, 1975; Ullrich and Kremers, 1977). Thus 
a small change in AAmax produced by a substrate binding to part of the 
total haemoprotein population might remain undetected.
The lack of marked alterations in Ks and AAmax during pregnancy 
(Tables 5.2 and 5.3) support the results obtained from SDS-polyacrylamide 
gel electrophoresis which indicated that the types of cytochrome P450 do 
not alter substantially during gestation.
Results from this chapter indicate that the most important factors 
controlling alterations in mixed-function oxidase activity during pregnancy 
are microsomal phospholipids and haemoprotein spin equilibrium.
CHAPTER 6 THE ROLE OF PLACENTAL LACTOGEN IN.DRUG METABOLISM DURING
PREGNANCY IN THE. RAT
6.1 Introduction
Pregnancy is associated with significant alterations in hepatic 
microsomal mixed-function oxidase activity which is related to changes in 
membrane phospholipids and haemoprotein spin state (Chapters 3 and 5). The 
high levels of circulating steroids, particularly progesterone, during 
pregnancy do not appear to be responsible for these changes (Chapter 4)•
The increase in liver size during gestation is due to parenchymal 
hyperplasia (Chapter 3). It has been established that microsomal drug 
metabolism is lower than normal in many conditions characterised by the 
rapid growth of liver cells (Fouts,1963; Wilson and Froham,1974), for 
example in the foetus and neonate (Fouts and Adamson,1959; Jondorf et 
al., 1959; Fouts and Hart, 1965), after partial hepatectomy (Fouts et 
aL, 1961) and in hepatic tumours (Adamson and Fouts,1961; Kato et 
al., 1968b). In all of these conditions the presence of increased growth 
promoting factors has been reported. An increase in growth promoting 
factors such as growth hormone might be responsible for the inhibitory 
effect of pregnancy on drug metabolism.
It is well established that pituitary growth hormone causes a decrease 
in drug metabolism in male rats (Wilson,1968a, 1969a,1971,1973a,b; Wilson 
and Spelsberg,1976; Kramer et al., 1975,1978). The administration of growth
hormone to male rats lowered the level of hepatic cytochrome P450 and 
decreased the rates of metabolism of various substrates
(Wilson,1971,1973a,b; Kramer et aL, 1975,1978). A similar effect was seen 
after implantation of a growth hormone producing tumour (Wilson,1968a,b), 
injection of a tumour homogenate (Wilson,1968c,1969b,c) or after growth 
hormone injections to castrated (Wilson, 1971; Kramer _et__al,, 1978),' 
hypophysectomised (Kramer et aL, 1975) or hypophysectomised •/ 
adrenalectomised (Wilson and Spelsberg,1976) male rats. Growth hormone had 
no effect on oxidative drug metabolism in castrated (Kramer et al.,1978) or 
normal (Kramer et al., 1975) female rats.
Growth hormone would appear to be an important factor in mediating the 
sex differences in. mixed-function oxidase activity in rats. The effect of 
gonadal hormones on hepatic drug and steroid metabolism in rats has been 
well characterised (see Chapter 1, 1.1.9; Kato,1974). In general
androgens increase the activity of cytochrome P450 containing oxidative 
enzymes but decrease the rate of reductive steroid metabolism whereas 
oestrogens exert the opposite effect. Colby et al.(1973) demonstrated that, 
the effects of both testosterone and oestradiol on hepatic corticosteroid 
metabolism were not demonstrable in hypophysectomised animals, suggesting 
mediation by or permissive effects of pituitary factors. Subsequently 
other investigators have reported a similar pituitary requirement for the 
development and maintenance of sex dependent patterns in hepatic steroid . 
metabolism (Denef,1974; Gustafsson and Stenberg, 1974; Lax et al., 1974; 
Kramer et aL,1975,1979). It has been proposed that the pituitary mediator 
of oestrogen effects on drug metabolism is growth hormone (Kramer et 
al., 1979) . The effects of exogenous (Wilson, 1969a, 1973a,b) or endogenous 
(Wilson and Frohman,1974) sources of growth hormone on microsomal drug 
metabolism have been found to be essentially identical to those of
oestradiol (Kramer and Colby,1976; Kramer et aL, 1978). The effects of the 
two hormones are not additive (Kramer et al., 1978) suggesting a similar 
mechanism of action. Furthermore oestrogen administration increases plasma 
growth hormone levels (Frantz and Rabkin,1965; Lloyd et aL, 1971).
A sex difference exists in the concentration of hepatic growth hormone 
receptors in the rat. Liver membrane preparations from mature female rats 
had three times the capacity to bind human growth hormone than similar 
preparations from male rats (Herington et aL, 1976a). The difference in 
receptor levels developed at puberty (Posner et aL, 1974a) at the same time 
as the development of the sex difference in drug metabolism (Kato,1974). 
Hepatic growth hormone receptors are induced by oestrogens (Posner et 
aL, 1974b; Kelly et al., 1975; Herington et al., 1976a,b) an effect inhibited 
by testosterone (Furuhashi and Fang,1979).
A role for growth hormone in producing the alterations in drug 
metabolism during pregnancy is unlikely since the plasma concentrations of 
this hormone are low in gestation in the rat (Schatch and Reichlin,1966)," 
sheep (Basset et aL, 1970), cow (Ingalls et al., 1973), human (Verma et 
aL, 1971) and monkey (Mintz et al., 1969). However, a hormone of placental 
origin which has structural and functional similarities to growth hormone 
is placental lactogen (Sherwood et aL, 1980).
In the human, placental lactogen has been extensively studied (for 
reviews see Chatterjee and Munro,1977; Villee,1979) since it was first 
recognised by Josimovich and Maclaren (1962). Studies on placental 
lactogen in species other than man are less extensive. A placental 
lactogen analogous to that found in the human has been described in the 
plasma of the rat, mouse, hamster, dog, guinea pig, rabbit, sheep, cow,
goat, chinchilla, baboon and rhesus monkey (Shiu et aL, 1973; Shome and 
Friesen,1971; Talmantes,1975; Kohmoto and Bern, 1970; Buttle et aL, 1972). 
The lactogen present in rat plasma has been identified as rat placental 
lactogen by radioreceptor assay (Kelly et al„1975).
The plasma level of placental lactogen in the various mammals studied 
begins to rise at or before mid pregnancy and either remains elevated until 
term (hamster,goat, sheep,monkey and human) or declines gradually reaching 
peak concentrations just after mid-pregnancy (guinea pig) or has two peaks 
of activity (mouse and rat) (Kelly et al., 1976). The serum of the maternal 
rat shows two peaks, one between days 11 and 13 and the second between days 
17 and 21 of gestation (Buttle et aL, 1972). In contrast to the widespread 
occurrence of placental lactogen in mammalian pregnancy, a peptide hormone 
analogous to human chorionic gonadotrophin has only been positively 
identified in the rhesus monkey, chimpanzee and baboon though its presence 
has been suggested in the rat and rabbit (Chatterjee and-Munro,1977).
Human placental lactogen appears to have three major effects during" 
pregnancy. These have been established in experimental animals and are all 
directed toward maternal metabolism. Firstly it is luteotrophic, as 
evidenced by its stimulation of progesterone and oestrogen secretion by the 
corpora lutea of the hypophysectomised pseudopregnant rat, an effect that 
is potentiated by the administration of human placental lactogen and human 
chorionic gonadotrophin together (Josimovich,1968). Thus human placental 
lactogen secretion during the second trimester of pregnancy may supplement 
the stimulant action on the corpus luteum of human chorionic gonadotrophin 
which is diminishing at this time. However, attempts to demonstrate such 
an action in pregnant women have not been successful (Stock et aL, 1971).
Secondly placental lactogen is so named because of its capacity to 
stimulate milk production in rabbit (Josimovich and Maclaren,1962; 
Josimovich and Brande,1964; Friesen,1966) and simian mammary gland 
(Beck,1972) and to stimulate the pigeon crop (Josimovich and Maclaren,1962) 
analogous to the action of pituitary prolactin. Human placental lactogen 
and prolactin compete for receptors on mammary gland cell membranes (Shiu 
et al.,1973) but their relative roles in mammary gland development are 
unknown. Human placental lactogen may be more important since it is
present at term in concentrations 35 times greater than prolactin (Hwang et^
./.
aL, 1971; Friesen,1971)• Leader (1975) has postulated that the primary 
action of human placental lactogen is to stimulate the development of the 
mammary gland during pregnancy without causing milk secretion. At birth 
withdrawal of human placental lactogen then results in milk secretion under 
the active stimulus of prolactin of pituitary origin.
Finally the actions of human placental lactogen on maternal metabolism 
analogous to the activities of pituitary growth hormone are implicit in the 
alternative names; chorionic growth hormone prolactin and chorionic 
somatomammotrophin. The lactogenic activity of human placental lactogen on 
a weight basis is similar to that of human growth hormone (Handwerger et 
al, 1972). The somat otrophic activity of human placental lactogen is less 
than 1% of human growth hormone though the circulating concentration of 
human placental lactogen is 1000 times that of growth hormone at term 
pregnancy (Sherwood et al., 1980).
In various tests on animals (Josimovich and Maclaren,1962; Florini et 
1966; Josimovich,1966; Friesen,1965;) human placental lactogen showed 
a distinct but smaller growth promoting activity than human growth hormone. 
Grumbach et al. (1968) suggested that a major function of human placental
lactogen is to so alter maternal metabolism that adequate supplies of 
glucose, amino acids and minerals are made available to the foetus during 
pregnancy. In the mother there are no gross changes in carbohydrate or 
lipid metabolism during the first trimester, but in the last trimester 
•there is a diminished responsiveness to insulin, impaired glucose tolerance 
and mobilisation of lipid stores (Picard et al, 1968; Fairweather,1971).
Prolonged infusion of human placental lactogen into normal or 
hypopituitary subjects resulted in increased free fatty acid levels and 
impaired tolerance for glucose despite an increase in plasma insulin levels 
following the glucose administration (Beck and Daughaday,1967; Samaan et 
aL, 1968). However, changes in blood sugar response are disputed by 
Josimovich and Mintz (1968) and the alterations in free fatty acid levels 
were not observed by Kalkhoff et al. (1969).
Studies with animals treated with human placental lactogen confirm the 
increased secretion of insulin (Martin and Friesen, 1969; -Lopez-Quijada and 
Blazquez,1971) and the release of free fatty acids from adipose tissue 
(Turtle and Kipnis, 1967; Genazzani et aL, 1969; Felber et aL, 1972; 
Mochizuki et aL, 1975). The benefits to the foetus of this mobilization of 
substrate are illustrated by experiments in which human placental lactogen 
was given to pregnant rats resulting in increased foetal weight, glycogen, 
protein and lipid content (Mochizuki et aL, 1973). No such response was 
observed when human placental lactogen was administered directly to the 
foetus.
Human placental lactogen is preferentially synthesised in the 
syncytiotrophoblast of the placenta on membrane-bound polyribosomes and 
greater amounts are synthesised by the 40 week than 20 week placenta
(Chatterjee et aL, 1976; Chatterjee and Munro, 1977). Friesen et al. (1969) 
concluded that human placental lactogen was the major protein synthesised 
by the placenta near term accounting for as much as 10% of the protein 
released from slices of human full term placenta.
Heterogeneity of human placental lactogen has been demonstrated 
(Belleville et al., 1975 Chatterjee et aL, 1977) which may reflect a precursor 
form (Cox et al.,1976). Szczesna and Boime (1976) have shown that m-RNA 
from full term placenta directs the synthesis of a protein that is larger 
(mol.wt.25,000) than human placental lactogen (mol.wt.22,000). Cleavage of 
this precursor molecule occurs on ribosome-bound nascent peptide chains.
The human placental lactogen molecule is a single chain polypeptide of 191 
amino acids containing two intramolecular disulphide bonds (Chatterjee and 
Munro,1977; Sherwood et aL, 1980). Structurally human placental lactogen • 
bears a marked resemblance to human growth hormone, about 80% of the amino 
acid residues being identical in the two molecules (Sherwood et aL, 1980). 
Observation of the internal sequence homologies among pituitary growth 
hormone, prolactin and placental lactogen suggests that these polypeptide
hormones may have evolved by genetic reduplication from a smaller ancestral,
peptide (Niall et al., 1971; Sherwood et al., 1980).
The regulatory factors in human placental lactogen synthesis are
unknown. In general the amount of human placental lactogen formed is 
related to placental size, but other factors such as ionic environment may 
also contribute (Choy and Watkins,1976)• Evidence that there may be 
control mechanisms specific for the synthesis or release of human placental 
lactogen is provided by the observation that placental slices incubated in 
vitro rapidly lose their ability to synthesise this hormone (Gaspard and 
Franchimont,1972). Human placental lactogen secretion may be regulated by
a placental factor analogous to the hypothalamic factor controlling growth 
hormone release from the pituitary gland. Other releasing factors have 
been described for the placenta (De Palatis et aL,1980; Gibbons et 
aL, 1975; Khodr and Siler-Khodr,1978).
Reports have appeared on the purification and characterisation of rat 
placental lactogen (Kelly et al., 1975; Robertson and Friesep, 1975; Linkie 
and Niswender,1973). It has been reported to have mammotropic 
(Matthies,1967; Kinzey,1968; Cohen and Gala,1969; Shani et aL, 1970; 
Anderson,1975), luteotrophic (Matthies,1967; Linkie and 
Niswender,1971,1973; Anderson,1975) and sommatotrophic (Contopolous and 
Simpson,1957) activity.
Human and rat placental lactogens show an immunological similarity. 
Rabbit antisera to human placental lactogen cross reacts with rat placental 
extracts (Leake and Burt, 1969; Gusdon et al., 1970) and binds to the rat 
placenta in vivo (Gusdon et al., 1975). In addition passive or active
e
immunization of pregnant rats with human placental lactogen has deletrious 
effects on pregnancy and lactation (El Tomi et aL, 1970,1971) though 
neutralization of endogenous prolactin by anti- human placental lactogen 
antibodies might account for some of these effects.
In this chapter the effect of placental lactogen on hepatic
mixed-function oxidase activity, microsomal phospholipids and haemoprotein
spin state will be investigated in non-pregnant rats and the results
compared to the situation present during pregnancy. Non-pregnant rats will
e
be administered (i.p) with either homogenised placentae from prgnant rats 
(13 days) or purified human placental lactogen. These techniques have been 
used previously to investigate the physiological effects of placental
lactogen in rats (Blank et aL, 1977; Linkie and Niswender,1973).
6.2 Experimental
(a) The effect of in vivo pretreatment with rat placental homogenates on 
hepatic drug metabolism was investigated. Placentae from pregnant (13 
days) rats were homogenised in saline. Non-pregnant rats were injected 
(i.p) for six days with placental homogenates (2 placental equivalents / 
day) and killed on the seventh day (Chapter 2, 2.2.5.7). Control 
non-pregnant received saline alone. The effect of this treatment on 
hepatic drug enzyme activity (Chapter 2, 2.2.6), cytochrome P450 (Chapter 
2, 2.2.8), cytochrome b5 (Chapter 2, 2.2.9), microsomal phospholipids 
(Chapter 2, 2.2.13), microsomal protein (Chapter 2, 2.2.21) and 
haemoprotein spin state (Chapter 2, 2.2.12) was determined.
(b) The effect of in vivo pretreatement with human placental lactogen on in 
vitro hepatic drug metabolism, microsomal phospholipids and haemoprotein 
spin state was investigated. Non-pregnant female rats received human 
placental lactogen (0.22mg in saline-lactose solution /rat /day i.p) for 
six days and were killed on the seventh day. Control rats received 
saline-lactose solution alone (Chapter 2, 2.2.2.6).
6.3 Results
6.3.1 The effects of in vivo pretreatment with placental homogenates on
in vitro hepatic mixed-function oxidase activity, microsomal phospholipids 
and haemoprotein spin state in the female rat
In vivo pretreatment with rat placental homogenates had no effect on 
body weight, liver weight, microsomal protein, cytochrome P450 and 
cytochrome b5 compared with control rats (Table 6.1). The three drug 
metabolising enzymes aniline jo-hydroxylase, ethylmorphine N-demethylase and 
£-nitrobenzoic acid reductase were significantly decreased in treated rats- 
to 75-85% of control levels (Figure 6.1). Changes in mixed-function 
oxidase activity were accompanied by a significant decrease in microsomal 
phosphatidylcholine and the phosphatidylcholine to phosphatidylethanolamine 
ratio and an increase in phosphatidylethanolamine in treated compared with 
control rats (Figure 6.2). Total phospholipids were unchanged.
The relationship between the microsomal cytochrome P450 spin 
equilibrium constant (K) and temperature in treated and control rats is 
shown in a Van't Hoff plot (Figure 6.3). Thermodynamic and spin state data 
have been calculated from this plot and are shown in Table-6.2.
<.--v
Pretreatment of rats with placental homogenates produced a significant
decrease in the spin equilibrium constant (K) and high spin form of
o o
cytochrome P450 at 20 and 37 . Of the thermodynamic parameters AG was 
significantly decreased by pretreatment with placental homogenates while AH 
and AS were unchanged.
6.‘3.2 The effect of in vivo pretreatment with human placental lactogen
on in vitrohepatic mixed-function oxidase activity, microsomal 
phospholipids and haemoprotein spin state in the female rat
In vivo pretreatment with human placental lactogen had no effect on 
body weight, liver weight, microsomal protein, cytochrome P.450 and 
cytochrome b5 (Table 6.3). The three drug enzymes aniline jg_-hydroxylase, 
ethylmorphine N-demethylase and ]D-nitrobenzoic acid reductase were 
decreased in treated compared with control rats but this was only 
statistically significant in the case of aniline ja-hydroxylase (Figure
6.4).
Microsomal phosphatidylcholine was significantly decreased in the 
treated animals while total phospholipids, phosphatidylethanolamine and the 
phospatidylcholine to phosphatidylethanolamine ratio were- unchanged (Figure
6.5).
The relationship between the microsomal cytochrome P450 spin state 
equilibrium constant (K) and temperature in treated and control rats is 
shown in a Van't Hoff plot (Figure 6.6). Thermodynamic and spin state data 
have been calculated from this plot (Table 6.4). A significant decrease 
was seen in the spin equilibrium constant and in the percentage high-spin 
form of cytochrome P450 at 20° in treated compared with control rats. The 
thermodynamic parameters AS, AG and AH were unchanged by human placental 
lactogen pretreatment.
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Figure 6.3 Effect of in vivo pretreatment with rat .placental
homogenate on the thermally induced spin state transition of hepatic 
microsomal cytochrome P450 in female rats
0.8
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Thermally induced spin state transitions were fitted to a Vant Hoff equation 
by the procedure described in Chapter 2 (2.2.12). Each point represents 
the mean + SEM (n=4). Control and treated values are significantly 
different at all points (p< 0 .0 5 ).
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transition of cytochrome P450 in female rats
0.8
0.6
0.4
0.2
0.0 -
In K
- 0.2 -
-0.4 -
- 0.6
- 0.8 -
- 1.0
Control
Treated
1.6
1/RT kcal
“ I—
1.7
-1
1.8
Thermally induced spin state transitions were fitted to a Vant Hoff 
equation by the procedure described in Chapter 2 (2.2.12). Each 
point represents the mean + SEM (n=4)* ' Control and treated values 
were not significantly different at p< 0.05»
Table 6*1 The effect of in vivo pretreatment with rat placental homogenate 
on rat body weight, liver weight, hepatic microsomal protein, cytochrome 
P450 and cytochrome b5
Control Treated (a)
Body weight (g)
Initial 207.5 +/-3.3 202.0 +/-3.4
Final 216.3 +/-3.8 212.8 +/-4.2
Liver weight (g) 8.46 +/-0.50 8.70 +/-0.35
Microsomal protein 
(mg /g liver)
22.8 +/-1.3 20.7 +/-0.8
Cytochrome P450 
(nmoles /mg microsomal 
protein)
0.89 +/-0.03 0.74 +/-0.06
Cytochrome b5
(nmoles /mg microsomal
protein)
0.64 +/-0.01 0.77 +/-0.06
Values represent mean +/- SEM (n=4). No statistical differences were 
between control and treated rats.
found
(a) : Treated rats received 2 placental equivalents /day (i.p.) for six
days and were killed on the seventh.
Table 6.2 Effect of in vivo pretreatment with rat placental homogenate on
the spin content and thermodynamic parameters of microsomal cytochrome P450
in female rats
Control ‘ Treated (b)
%High-spin P450 
20° 57.5 +/-2.8 46.5 +/-0.7 *
37° 69.5 +/-2.5 61.5 +/-0.6 *
Spin equilibrium constant (K) (a) 
20° 1.39 +/-0.17 0.87 +/-0.05 * .
37° 2.36 +/-0.32 1.59 +/-0.05 *
AH ( kcal) 
AS ( e.u)
6.04 +/-0.31 
23.7 +/—1.2
6.63 +/—0.05 
23.7 +/-1.6
AG ( kcal /mol) at 37° -1.33 +/-0.20 - 0.74 +/-0.05 *
Values represent mean +/- SEM (n=4). Significant differences (students 't' 
test) are shown as * p<0«05, ** p<0.01, *** p<0.001. 
a : Based on the equilibrium constant K = (P450j_jg) /(P450^) 
b : Treated rats received 2 placental equivalents /rat /day (i.p.) for 6
Table 6.3 The effect of in vivo pretreatment with human placental lactogen 
on rat body weight, liver weight, hepatic microsomal protein, cytochrome 
P450 and cytochrome b5
Control Treated
Body weight (g) -
Initial 215.3 +/-4.S 213.3 +/-2.8
Final 227.5 -t-/—6.5 227.0 +/-4.8
Liver weight (g) 8.9 +/-0.6 8.96 +/-0.36
Microsomal protein (mg /liver) 20.7 +/-0.8 20.8 +/-0.6
Cytochrome P450 (nmoles /mg 
microsomal protein)
0.79 +/-0.05 0.79 +/-0.05
Cytochrome b5 (nmoles /mg 
microsomal protein)
0.60 +/-0.03 0.55 +/-0.04
Values represent mean +/- SEM (n=4). No significant differences were found 
between control and treated rats.
a : Treated rats received 0.22 mg human placental lactogen /rat /day
(i.p.) for six days and killed on the seventh.
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Table 6.4 Effect of in vivo pretreatment with human placental lactogen on 
the spin content and thermodynamic parameters of microsomal cytochrome P450 
in female rats
Control Treated b
%High-spin P450
N5 o o 45.6 +/-1.2 36.1 +/-3.6 *
37° 60.1 +/-2.05 50.3 +/-3.6
Spin equilibrium constant (K) a
ooCM 0.85 +/-0.04 0.58 +/-0.10 *
37° 1.53 +/-0.12 1.04 +/-0.16
AH ( kcal) 6.03 +/-0.45 6.15 +/-0.05
AS ( e.u.) 20.3 +/-1.5 19.8 +/-0.2
AG at 37° ( kcal /mol) , -0.26 +/-0.05 0.003 +/-0.100
Values represent mean +/- SEM (n=4). Significant differences (students 't'
test) are shown as * p<0.05, ** p<0.01, *** p<0.001.
a : Based on the equilibrium constant K = (P450j_j^ ) /(P450LS)
b : Treated rats received 0.22mg human placental lactogen /rat /day (i.p.)
for six days.
6.4 Discussion
Treatment of non-pregnant rats with rat placental homogenates produced 
decreases in hepatic mixed-function oxidase activity (Figure 6.1), changes 
in microsomal phospholipids (Figure 6.2) and haemoprotein spin state (Table 
6.2) similar to those seen during pregnancy (Chapters 3 and 5). Leveis of 
cytochrome P450, b5 and microsomal protein were unchanged analogous to the 
situation found during pregnancy (Table 6.1).
The content of LH, FSH, progesterone and prolactin in rat placenta (12 
to 16 days) is very low or undetectable (Linkie and Niswender,1973) and it 
is unlikely that the effect of placental injections on microsomal 
mixed-function oxidase activity and membrane compostion is due to these 
hormones. The presence of a factor with LH-like activity, analogous to 
human chorionic gonadotrophin, has been reported (Cheng,1975; Bambra and 
Gombe,1978) and it has been suggested that at least two luteotrophic 
factors may be present in crude placental homogenates: placental lactogen
and chorionic gonadotrophin (Blank et aL, 1977).
Rat placental lactogen is probably the most important constituent .of 
placentae that affects drug metabolism since the injection of purified 
human placental lactogen produced similar effects on mixed-function oxidase 
activity (Figure 6.4), microsomal phospholipids (Figure 6.5) and 
haemoprotein spin state (Table 6.4) to those seen after placental 
injections or during pregnancy. Drug enzyme activities were decreased by 
human placental lactogen pretreatment though this was only significant for 
aniline 2_-hydroxylase. A larger dose of human placental lactogen might- 
produce a more significant effect on mixed-function oxidase activity
(Wilson,1973a).
The mechanism by which rat placental lactogen may alter hepatic 
mixed-function oxidase activity and microsomal membrane composition is 
unknown. The structural and functional similarity between placental 
lactogen and growth hormone (Sherwood et al., 1980) suggests, however, that 
the action of placental lactogen may be similar to that of growth hormone. 
Growth hormone has been reported to have at least three actions on 
microsomal drug metabolism: an effect on (1) transcription (2) the rate of
reduction of ferricytochrome P450 and (3) on membrane phospholipids. These 
are possibly mediated via hepatic growth hormone receptors. A discussion 
of the mechanisms of growth hormone action and the relationship of this to 
placental lactogen follows.
A physical interaction between a hormone molecule and a specific
binding site (receptor) on the surface membrane of target cells is the
initial step in the mechanism of action of protein and polypeptide hormones
(Roth,1973). For growth hormone however, a direct link between receptor
binding and biological response has not been demonstrated. Studies with 
12RaI-labelled human growth hormone have demonstrated the existence of 
specific binding sites in cultured human lymphocytes (Lesnaiak et 
al., 1973,1974) and in microsomal membranes prepared from livers of rabbits 
(Tsushima and Friesen, 1973; Herington et a 1., 1974; Gerasimo et al.,1979) 
and rats (Posner et al., 1974b; Herington et aL,1976a,b; Veith et aL, 1975) . 
Studies have been carried out on the physiological regulation of liver 
binding sites (Herington et aL, 1976a,b; Posner et aL, 1974a) their 
on togenesis (Kelly et aL, 1974) and species variation (Posner et aL, 1974b). 
Of interest to the present work was the finding that during pregnancy in 
the rat (Kelly et al., 1974; Herington et al., 1976a) and rabbit (Gerasimo et
al., 1979) the growth hormone receptor content (expressed as the binding 
capacity of hepatic membranes for human growth hormone) was approximately 
double that found in non-pregnant animals. In the rat these receptors 
interact mainly with lactogenic hormones such as placental lactogen, 
prolactin and primate growth hormone (Posner et al., 1974b). This finding 
was based on earlier reports of binding specificity (Posner et aL, 1974a; 
Herington et aL, 1976a) where there was a lack of competition by growth 
hormone from species other than man and a significant but variable 
competition by various prolactin preparations. The physiological 
regulation of growth hormone binding sites has been studied. Marked 
increases in binding sites were induced by oestrogen administration and 
high prolactin or growth hormone concentrations. Marked decreases were 
induced by hypophysectomy or testosterone administration (Herington et 
aL, 1975,1976a; Posner et aL,1974a). Progesterone and human placental 
lactogen did not effect the receptor levels (Herington et aL, 1976a).
It is well established that growth hormone markedly affects the 
protein synthesizing activity of its target cells (Korner,1965). When the 
hormone is administered in vivo, an enhancement of protein syntheseis is 
observed in vitro or in vivo with isolated ribosomal fractions. However 
when growth hormone is added in vitro to isolated fractions there is no 
effect on protein synthesis. These results support the hypothesis that 
growth hormone init ially acts in areas of the cell other than those where 
protein synthesis takes place. By using inhibitors of protein and RNA 
synthesis Russel et al (1970) demonstrated that growth hormone induced 
increases in ornithine decarboxylase activity in rat liver were dependent 
primarily on RNA synthesis. Further, this action of growth hormone on gene 
transcription occurred within 2 hours after the injection of growth hormone 
into adult or weanling rats. These results together with the finding that
growth hormone induced synthesis of total cell protein can be inhibited 
with appropriate actinomycin D treatment (Tata,1970) support the idea that 
growth hormone manifests its action on various enzymes through the 
alteration of gene transcription. Further studies have shown that growth 
hormone stimulation of RNA involves all species of RNA but most 
significantly ribosomal RNA (Talwar et al.,1964; Salaman et aL, 1972; Ip
and Brossard,1971; Tata,1970). Other studies have indicated that growth 
hormone treatment increases the activity of nucleolar polymerase 1 (which' 
synthesises ribosomal RNA) with no observable effects on nuclear polymerase 
II (synthesising DNA-like RNA) (Janne and Raina,1969; Smuckler and 
Tata,1971) or on DNA restriction in the chromatin (Guptar and Talwar,1968; 
Breuer and Florini,1966). Spelsberg and Wilson (1976) reported that there 
was no correlation between the transcriptional response to growth hormone 
and the activities of the mixed-function oxidase system. These authors 
concluded that the induction of RNA polymerase 1 activity and derepression 
of DNA by growth hormone probably represents the selective synthesis of 
protein involved in liver growth rather than drug metabolism.
Wilson (1973a) reported that the decrease in liver metabolism of the
'type 1' substrate hexobarbital following growth hormone treatment in male 
rats was related more closely to a decrease in the reduction of 
ferricytochrome P450 by NADPH-cytochrome P450 reductase than to the change 
in cytochrome P450 concentration. This finding is of interest in view of 
the importance of the haemoprotein spin equilibrium in determining the rate 
of ferricytochrome P450 reduction (Chapter 5). Thus alterations in 
microsomal mixed-function oxidase activity during gestation (Chapter 3) or 
following rat placentae (Figure 6.1) and human placental lactogen (Figure
6.4) administration may be related to the effect of placental lactogen on 
haemoprotein spin state (Table 6.4) and hence the rate of ferricytochrome
P450 reduction.
The important relationship between drug metabolism and microsomal 
phospholipids during pregnancy has been discussed (Chapter 3) •
Pretreatment of non-pregnant rats with rat placentae or human placental 
lactogen produced similar effects on microsomal phospholipids (Figures 6.2 
and 6.5). Growth hormone in vivo and in vitro produced a conformational 
change in the phospholipids of hepatic plasma membranes (Rubin et aL, 1973; 
Postel-Vinay et aL,1974)« In addition growth hormone affects phospholipid 
synthesis increasing the incorporation of J^P into liver phospholipids in 
vivo and phosphorylcholine into choline glycerophosphatides in the 
homogenates from the livers of growth hormone treated rats (Leal and 
Greenbaum,1961)• The incorporation of radioactivity from[methyl- 
^d-choline, ll,2-^C]-ethanolamine and [methyl-^C]-methionine into 
phospholipids was increased in liver slices from pregnant rats compared 
with slices from non-pregnant rats (Weinhold,1969)•
In conclusion, evidence has been presented which suggests that the 
alterations in microsomal mixed-function oxidase activity during pregnancy 
in the rat is due to the presence of high levels of circulating rat 
placental lactogen. This effect may be mediated via changes in microsomal 
phospholipids and haemoprotein spin state. In addition transcriptional 
changes may occur which result in a selective synthesis of proteins 
concerned with liver growth rather than drug metabolism. The biological 
activity of placental lactogen is possibly associated with its binding to 
the hepatic microsomal growth l^ormone receptor which is elevated during 
gestation.
CHAPTER 7 GENERAL DISCUSSION
Changes in hepatic drug metabolism during pregnancy in the rat have 
been characterised and the role of steroids and other hormonal factors 
investigated. The results presented suggest that elevated levels of 
circulating placental lactogen cause a significant decrease in maternal 
hepatic mixed-function oxidase activity when expressed per gram liver.
This effect is probably mediated via changes in microsomal phospholipids 
and/or the cytochrome P450 spin equilibrium. Changes in drug metabolism 
are not related to alterations in the concentration of cytochrome P450.
The rise in circulating steroids, particularly progesterone, during 
gestation does not appear to be an important modulator of mixed-function 
oxidase activity. It is possible, however, that the gradual rise in 
circulating oestrogens has an indirect action on drug metabolism by 
inducing hepatic growth hormone receptors. These receptors are possibly 
important mediators of placental lactogen action.
The pregnancy associated alterations in drug metabolism may represent 
part of a biological control mechanism which ensures that the maternal 
liver adapts during pregnancy, enabling the mother to cope with the 
metabolic requirements of the developing foetus. The growth of the liver 
is seen as a response to these requirements. A selective proliferation of 
systems other than those concerned, with the metabolism of drugs results in 
a progressive decrease in mixed-function oxidase activity when expressed 
per gram liver. The total capacity of the liver to metabolise drugs, 
however, remains unchanged or increased. This 'level' of drug metabolism 
is possibly all that is required to satisfy the requirements of pregnancy. 
Furthermore, an increase in drug metabolism in proportion to the increase
in liver weight could have a detrimental effect if it resulted in the 
increased metabolism and excretion (and hence decrease in blood levels) of 
monooxygenase substrates such as progesterone. High circulating levels of 
progesterone are required to maintain pregnancy. This view is possibly 
simplistic since pregnancy seems to be associated with a general alteration 
in microsomal membrane composition and metabolism.
Many areas of further investigation arise from the results of this 
thesis. Of particular interest is the postulated interaction between 
microsomal phospholipids and haemoprotein spin state which may have broader 
implications in the field of drug metabolism particularly if such 
interactions are hormonally controlled. The role of microsomal 
phospholipids could be investigated using a purified cytochrome P450 
system. Microsomal phospholipids purified from pregnant and non-pregnant 
rats could be added to cytochrome P450 and NADPH-cytochrome P450 reductase, 
from non-pregnant and pregnant rats respectively. Changes in 
mixed-function oxidase activity and haemoprotein spin state could then be 
determined. This 'cross-over' experiment might establish more clearly the 
role of membrane phospholipids in drug metabolism. In addition the 
influence of pregnancy and membrane phospholipids on the rate of 
ferricytochrome P450 reduction and on the forward and reverse rate 
constants for the low-spin to high-spin transition should be investigated. 
The importance of subtle changes in microsomal membrane composition and 
haemoprotein spin state on alternative pathways of xenobiotic metabolism is 
unknown. The role of cytochrome P450 in the metabolic activation of 
environmental toxicants and carcinogens such as aflatoxin Bl,
2-acetamidofluorene and dimethylnitrosamine is well established
(Parke,1980). The role of the microsomal membrane and haemoprotein spin
state in these activation reactions is less clear. One may speculate that
alterations in the microsomal membrane environment and/or the haem spin 
equilibrium could result in the metabolic activation of a previously 
harmless drug resulting in toxic changes or cancer. Such alterations may 
be produced by changes in nutritional status or abnormally high levels of 
circulating hormones. The activities of many of the enzymes which 
metabolise drugs have been shown to be dependent on nutritional status 
(Parke,1978). Studies on laboratory animals have shown that starvation or 
dietary deficiencies in protein, lipids, vitamins and essential minerals 
generally lead to a progressive impairment of drug metabolism. When 
metabolism leads primarily to the deactivation of drugs and chemicals, 
starvation and dietary deficiency will result in increased pharmacological 
activity. Conversely, it would appear that when metabolism leads to 
activation, tissue necrosis and carcinogenesis, dietary deficiency or 
starvation should dacrecise toxicity.
Abnormally high levels of circulating placental lactogen, growth 
hormone and other polypeptide hormones have been reported to be produced by 
ectopic hormone producing neoplasias. Many other pathological states may 
result in a rise in circulating hormone levels (eg.growth hormone in 
acromegaly). A detailed characterisation of the effect of these hormones 
on hepatic drug metabolism is necessary in order to evaluate possible 
responses to applied drug therapy.
The low level of foetal drug metabolism has been discussed (Chapter 
1). It has been reported that in the human foetal circulation there are 
negligible levels of placental lactogen but elevated levels of growth 
hormone (Grumbach et aL, 1968). The growth hormone is of foetal origin and 
there is little placental transfer of either growth hormone or placental 
lactogen. The elevated levels of growth hormone may be responsible, at
least in part, for the depressed rate of foetal drug metabolism. The 
mechanism of this action might be similar to that in the adult (see Chapter 
5).
Purified rat placental lactogen is not available commercially though 
purification procedures have been described (Linkie and Niswender,1973; 
Kelly et aL, 1975) with rat placental lactogen. The effect of dosing on 
drug metabolism, phospholipids, haemoprotein spin state and ferricytochrome 
P450 reduction could then be studied. The potential role of the pituitary 
and ovaries in mediating the action of placental lactogen could be 
investigated by comparison with hypophysectomised and ovariectomised 
animals.
The significance of the findings in this thesis to the human is 
difficult to evaluate. Pharmacokinetic studies during pregnancy are 
equivocal and influenced by many physiological changes occurring at this 
time (see Chapter 1). Any evaluation is further hindered by a lack of data 
on species differences in hepatic drug metabolism during pregnancy. 
Mixed-function oxidase activity has been investigated predominantly in the 
rat and rabbit (see Chapter 1). Species differenc es in drug metabolism 
are well characterised (for review see Kato,1979) and it would be important 
to establish whether similar differences existed during gestation.
The work presented in this thesis has highlighted the importance of 
factors other than the concentration of cytochrome P450 in the regulation 
of hepatic mixed function oxidase activity. Furthermore an important 
connection has been established between polypeptide hormones and the 
hepatic mixed-function oxidase system. The pregnant rat would seem to 
offer a convenient system in which to study interactions between
circulating hormones, microsomal membrane composition and drug metabolism. 
A full investigation of this system would be an important requirement for 
detailed characterisation and understanding of the mixed-function oxidase 
system. *
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